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The existing medical model for managing rheumatoid arthritis (RA) focuses on 
minimising joint inflammation using suppressive treatments. However, patients have 
broader concerns spanning other symptoms like fatigue and pain and the way their 
health care is delivered. This thesis used qualitative and quantitative research 
methods to address three inter-related aspects of clinical care. Firstly, identifying 
critical challenges for providing patient-centred care. Secondly, defining outcomes 
important to patients like fatigue and pain and concomitant fibromyalgia. Finally, 
examining temporal changes in the RA management and evaluating aspects of 
clinical decision making. 
Firstly the thesis shows current care is not optimal. Key limitations include: being 
insufficiently patient-centred, failing to integrate management across the 
primary/secondary divide, over-emphasising drug treatment and overlooking "whole-
person" care. 
Secondly, care overlooks several crucially important areas to RA patients. Many 
patients had high levels of fatigue, associated with pain, disability and psychological 
factors. Their fatigue spanned several domains. Current fatigue questionnaires are 
heavily weighted towards psychological aspects, and a more balanced assessment is 
needed. Pain, a dominant RA symptom, is often not directly addressed. The research 
showed central sensitisation causes persistent pain in many RA patients; it may 
require different management approaches. The research also characterised patients 
with the fibromyalgic rheumatoid clinical phenotypes; their higher disease activity 
scores may not fully reflect disease activity. Despite changes in treatment over the 
years their disease activity scores have not improved significantly, unlike RA 
patients in general. Different treatment strategies are needed to improve their 
outcomes.  
Finally although patients with high disease activity usually have their treatment 
changed when reviewed in rheumatology clinics, patients with moderate disease 
activity often have insufficient treatment changes; patients' age has a significant 
influence on treatment decisions. Strategies are needed to better target moderate 
disease activity and overcome the limiting effect of age on treatment decisions. 
3 
 
TABLE OF CONTENTS 
ABSTRACT 2 
LIST OF ABBREVIATIONS 11 
ACKNOWLEDGEMENTS 14 
PUBLICATIONS 15 
Abstracts Presented At Meetings 15 
Full Papers 16 
CHAPTER 1. INTRODUCTION 17 
1.1. An Overview Of Rheumatoid Arthritis 18 
1.1.1. History 18 
1.1.2. Diagnostic Criteria 19 
1.1.3. Epidemiology 21 
1.1.4. Pathogenesis 24 
1.1.5. Outcome Predictors 26 
1.1.5.1. Genetics 26 
1.1.5.2. Sex and Hormonal Factors 26 
1.1.5.3. Infection 27 
1.1.6. Clinical Features 27 
1.1.6.1. Clinical Presentation and Subtypes 28 
1.1.6.2. Disease Course 29 
1.1.6.3. Joint Involvement 29 
1.1.6.4. Systemic Involvement 30 
1.1.7. Impact of Rheumatoid Arthritis on Society and the Individual 30 
1.1.7.1. Disability 31 
1.1.7.2. Work Disability 32 
1.1.8. Treatment 33 
1.1.9. Non-Pharmacological Interventions 34 
1.1.9.1. Occupational Therapy 34 
1.1.9.2. Physiotherapy 34 
1.1.9.3. Podiatry 35 
1.1.9.4. Surgery 35 
1.1.10. Pharmacological Interventions 35 
1.1.10.1. Analgesics 36 
1.1.10.2. Corticosteroids 36 
1.1.10.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 36 
1.1.10.4. Biologic Therapies 38 
1.1.10.5. Tumour Necrosis Factor-Alpha (TNF-α) 39 
1.1.10.6. Other Biological Therapies 42 
1.2. Disease Assessments In Rheumatoid Arthritis 42 
1.2.1. Joint Swelling and Tenderness 42 
1.2.2. Patient and Physician Global Assessment 46 
1.2.3. Laboratory Measures 46 
1.2.4. Using Multiple Measures to Assess Disease Activity 48 
1.2.4.1. Core Data Set 48 
1.2.4.2. Composite Measures of Disease Activity 49 
1.2.4.3. Radiological Assessments 51 
4 
 
1.3. Quality Of Life in Rheumatoid Arthritis 53 
1.3.1. Pain 54 
1.3.2. Fatigue 55 
1.3.2.1. Measuring Fatigue in Rheumatoid Arthritis 56 
1.3.3. Fibromyalgic Rheumatoid Arthritis 57 
1.3.4. Psychological Impacts 58 
1.3.5. Disability 60 
1.3.5.1. Health Assessment Questionnaire 60 
1.3.5.2. Arthritis Impact Measurement Scales 62 
1.3.6. Generic Measures of Quality of Life 62 
1.3.6.1. SF-36 62 
1.3.6.2. Nottingham Health Profile 63 
1.3.6.3. EuroQol and Others 64 
1.4. Quality Of Care in Rheumatoid Arthritis 65 
1.4.1. Standards of Care 66 
1.4.2. Measuring Patient Satisfaction 67 
1.4.3. The Use of Qualitative Research 69 
1.5. Rationale for Research 70 
1.6. Aims and Objectives 71 
1.6.1. Plan of Investigation 72 
1.6.1.1. Assessing Current Performance 72 
1.6.1.2. Measuring Satisfaction. 73 
1.6.1.3. Establishing a Local ARMA Framework 73 
1.6.1.4. Focusing On Fatigue and Pain 73 
CHAPTER 2. PATIENTS AND METHODS 75 
2.1. Patients 76 
2.1.1. General 76 
2.1.2. Obtaining Patients Views 76 
2.1.2.1. Patient Focus Groups 76 
2.1.2.2. Health Care Professionals Focus Group 76 
2.1.3. Standards of Care and Satisfaction Survey 77 
2.1.4. Fatigue in RA: Patients in Clinical Association Studies 77 
2.1.5. Fatigue in RA: Patients in Treatment Effects Studies 77 
2.1.5.1. Early RA 77 
2.1.5.2. Established RA 78 
2.1.6. Fatigue Measurements Study 78 
2.1.7. Initial Fibromyalgic RA and Pain Threshold Study 78 
2.1.8. Replicate Fibromyalgic RA Study (Established RA) 79 
2.1.9. Fibromyalgic Early RA Study 79 
2.1.10. Temporal Changes Study 79 
2.1.11. Treatment Changes Study 80 
2.2. Ethical Considerations And Consent 84 
2.2.1. Ethics Committee Approval 84 
2.2.2. Informed Consent 84 
2.3. Assessments And Analyses 84 
2.3.1. Qualitative Research in Focus Groups 84 
2.3.2. Standards of Care 85 
2.3.3. Satisfaction Questionnaires 87 
2.3.4. Defining the Associations of Fatigue 88 
5 
 
2.3.4.1. Fatigue Measurements Study 88 
2.3.4.2. FACIT-F 88 
2.3.4.3. Other Fatigue Scores 89 
2.3.4.4. Clinical Association Studies 89 
2.3.4.5. Treatment Effects Studies 89 
2.3.4.6. Fatigue Measurement Study 90 
2.3.4.7. Factor Analysis 90 
2.3.5. Fibromyalgic Rheumatoid Arthritis 91 
2.3.5.1. Initial Study 91 
2.3.5.2. Replicate Study (Established RA) 92 
2.3.5.3. Early RA Study 92 
2.3.6. Understanding Treatment Decisions in RA 92 
2.3.6.1. Temporal Changes Study 93 
2.3.6.2. Treatment Changes Study 93 
CHAPTER 3. IDENTIFYING LIMITATIONS OF CURRENT CARE 95 
3.1. Introduction 96 
3.2. Outline Of Patients And Methods 97 
3.2.1. Focus Groups 97 
3.2.1.1. Patient Focus Groups 97 
3.2.1.2. Patient Focus Group Process 97 
3.2.1.3. Health Care Professionals Focus Group 98 
3.2.1.4. Health Care Professional Focus Group Process 98 
3.2.1.5. Focus Groups Data Analysis 99 
3.2.2. Perceived Barriers to Integrated Care in RA 99 
3.2.2.1. Perceived Barriers to Integrated Care in RA: Data Analysis 102 
3.2.3. Standards of Care and Satisfaction Survey 102 
3.2.3.1. Standards of Care Questionnaire 103 
3.2.3.2. Satisfaction Questionnaires 104 
3.3. Results 104 
3.3.1. Clinical-User Group 104 
3.3.2. Patient Support Group Survey 105 
3.3.3. Focus Group Results 106 
3.3.3.1. Analytic framework 106 
3.3.3.2. Theme 1: The Personal Impact of RA. 108 
3.3.3.3. Theme 2: Information Needs of RA Patients 111 
3.3.3.4. Theme 3: Health Care Delivery for RA Patients 114 
3.3.4. Perceived Barriers to Integrated Care in RA 117 
3.3.5. Standards of Care 123 
3.3.5.1. ARMA Standards 123 
3.3.5.2. Satisfaction with Care 128 
3.4. Discussion 129 
3.4.1. Standards of Care and Patient Satisfaction 129 
3.4.2. Focus Groups: Defining Patients Needs 131 
3.4.3. Perceived Barriers to Integrated Care in RA 133 
6 
 
CHAPTER 4. OVERLOOKED AREAS: FATIGUE 137 
4.1. Introduction 138 
4.2. Outline Of Patients And Methods 139 
4.2.1. Patients 139 
4.2.1.1. Clinical Association Studies 140 
4.2.2. Treatment Effects Studies 140 
4.2.2.1. Early RA 140 
4.2.2.2. Established RA 140 
4.2.2.3. Fatigue Measurements Study 141 
4.2.3. Assessments 141 
4.2.3.1. Clinical Association Studies 141 
4.2.4. Treatment Effects Studies 141 
4.2.4.1. Early RA 142 
4.2.4.2. Established RA 142 
4.2.4.3. Fatigue Measurements Study 142 
4.2.5. Analyses 143 
4.2.5.1. Clinical Association Studies 143 
4.2.6. Treatment Effects Studies 143 
4.2.6.1. Early RA 143 
4.2.6.2. Established RA 144 
4.2.6.3. Fatigue Measurement Study 144 
4.3. Results 145 
4.3.1. Fatigue and Its Clinical Associations 145 
4.3.1.1. Frequency and Distribution of Fatigue 145 
4.3.1.2. Correlations with Fatigue 145 
4.3.1.3. Multiple Regression 146 
4.3.2. Effects of Treatment on Fatigue in RA 150 
4.3.2.1. Early RA 150 
4.3.2.2. Established RA 153 
4.3.3. Fatigue Measurement Study 153 
4.3.3.1. Fatigue and Disability 153 
4.3.4. Fatigue Measurement Study 158 
4.4. Discussion 166 
4.4.1. Fatigue and Its Clinical Associations 166 
4.4.2. The Effect of Treatment on Fatigue in RA 167 
4.4.3. Fatigue and Disability 168 
4.4.4. Fatigue Questionnaires: What Is Actually Being Measured? 169 
CHAPTER 5. CLINICAL SUBTYPES: FIBROMYALGIC DISEASE 171 
5.1. Introduction 172 
5.1.1. Fibromyalgic Rheumatoid 172 
5.1.2. Pain Thresholds in RA and Their Associations 173 
5.2. Outline Of Patients And Methods 173 
5.2.1. Patients in Initial Fibromyalgic RA and Pain Threshold Study 173 
5.2.2. Patients in Replicate Fibromyalgic RA Study (Established RA) 174 
5.2.3. Patients in Fibromyalgic Early RA Study 175 
5.2.4. Assessments 175 
5.2.4.1. Initial Study 175 
5.2.4.2. Replicate Study (Established RA) 176 
5.2.4.3. Early RA Study 176 
7 
 
5.2.5. Analyses 176 
5.2.5.1. Initial Study 176 
5.2.5.2. Replicate Study (Established RA) 177 
5.2.5.3. Early RA Study 178 
5.3. Results 178 
5.3.1. Tender Point Counts and Subtypes of Rheumatoid Arthritis Patients 178 
5.3.1.1. Prevalence of Fibromyalgic RA 179 
5.3.1.2. Identifying Fibromyalgic RA Using Tender Joint Counts 179 
5.3.1.3. Clinical Impact of Fibromyalgic RA 180 
5.3.1.4. Fibromyalgic RA and Active Disease 181 
5.3.2. Comparison of Different Groups of Rheumatoid Arthritis Patients 181 
5.3.2.1. Early Rheumatoid Arthritis 181 
5.3.2.2. Treatment Effects 185 
5.3.2.3. Established Rheumatoid Arthritis 185 
5.3.2.4. Early Rheumatoid Arthritis (ERAN) 186 
5.3.3. Pain Thresholds and its Associations 188 
5.3.3.1. Distribution of Pain Thresholds 188 
5.3.3.2. Relationship to Disease Activity and Associated Clinical Variables 190 
5.3.3.3. Regression Analysis 191 
5.4. Discussion 194 
CHAPTER 6. UNDERSTANDING TREATMENT DECISIONS 198 
6.1. Introduction 199 
6.2. Outline Of Patients And Methods 200 
6.2.1. Patients 200 
6.2.1.1. Temporal Changes Study 200 
6.2.1.2. Treatment Changes Study 200 
6.2.2. Assessments 201 
6.2.2.1. Temporal Changes Study 201 
6.2.2.2. Treatment Changes Study 201 
6.2.3. Analyses 201 
6.2.3.1. Temporal Changes Study 201 
6.2.3.2. Treatment Changes Study 202 
6.3. Results 203 
6.3.1. Temporal Changes Study 203 
6.3.2. Treatment Changes Study 210 
6.3.2.1. The Effect of DAS28 on Treatment Decisions 210 
6.3.2.2. The Effect of Fibromyalgic RA on Treatment Changes 212 
6.3.2.3. What Influences Changes in Treatment? 213 
6.3.2.4. The Effect of Age on Treatment Decisions 215 
6.4. Discussion 219 
6.4.1. Temporal Changes Study 219 
6.4.2. Treatment Changes Study 220 
8 
 
CHAPTER 7. DISCUSSION 223 
7.1. Summary Of Findings 224 
7.1.1. Key Issues 224 
7.1.2. Current Care 225 
7.1.2.1. Standards of Care 225 
7.1.2.2. Patients Needs 226 
7.1.2.3. Barriers to Integrated Care 226 
7.1.3. Patient Centred Outcomes 228 
7.1.3.1. Fatigue and Its Clinical Associations 228 
7.1.3.2. Treatment and Fatigue 229 
7.1.3.3. Fatigue and Disability 230 
7.1.3.4. Fatigue Questionnaires 230 
7.1.3.5. Fibromyalgic RA 231 
7.1.3.6. Pain in RA 233 
7.1.4. Treatment Changes 234 
7.1.4.1. Temporal Changes in RA 234 
7.1.4.2. Treatment Decisions 235 
7.2. Strengths And Weaknesses 236 
7.2.1. Strengths 236 
7.2.2. Weaknesses 236 
7.3. Future Research 237 
7.3.1. Better Treatment of Fatigue and Pain 238 
7.3.2. Adherence to Guidance and Developing Clinical Pathways 240 






LIST OF TABLES 
Table 1:1 1987 ACR Criteria for the Classification of Rheumatoid Arthritis ........... 19 
Table 1:2 2010 ACR/EULAR Classification Criteria For Rheumatoid Arthritis ...... 20 
Table 1:3 Incidence Studies of Rheumatoid Arthritis ................................................ 22 
Table 1:4 Prevalence Studies Of Rheumatoid Arthritis ............................................. 23 
Table 1:5 DMARDS and Their Mechanisms of Action ............................................ 37 
Table 1:6 OMERACT and EULAR Core Data Set for RA ....................................... 49 
Table 1:7 Composite Disease Activity Scores ........................................................... 50 
Table 1:8 ACR Response Criteria and the DAS28 .................................................... 51 
Table 1:9 Larsen Grading System for Erosions ......................................................... 53 
Table 2:1 Main Themes of ARMA Standards of Care Audit .................................... 87 
Table 3:1 Patients in Focus Groups ........................................................................... 98 
Table 3:2. Individual Interview Patients and Carers ................................................ 102 
Table 3:3 Patient Support Group Survey ................................................................. 106 
Table 3:4 Summary of Key Themes ........................................................................ 120 
Table 4:1 Patients in Clinical Association Studies .................................................. 140 
Table 4:2 Linear Regression Analysis of Fatigue VAS (a)...................................... 147 
Table 4:3 Regression Analysis of Fatigue VAS (b) ................................................. 148 
Table 4:4 Factors Contributing To Fatigue .............................................................. 149 
Table 4:5 SF-36 in Early RA Patients ...................................................................... 151 
Table 4:6 HAQ and Fatigue Scores ......................................................................... 155 
Table 4:7 Linear Regression with HAQ as Dependent Variable ............................. 157 
Table 4:8 Fatigue Questionnaires Descriptive Analysis .......................................... 158 
Table 4:9 Spearman’s Correlations with Different Fatigue Questionnaires ............ 159 
Table 4:10 Factor Analysis Using Rotated Matrix .................................................. 161 
Table 4:11 Dimensions In Fatigue Questionnaires .................................................. 164 
Table 4:12 Proposed Questions for Final Fatigue Questionnaire ............................ 165 
Table 5:1 Patients in Initial and Replicate Studies .................................................. 174 
Table 5:2 Regression Analysis of Factors Influencing Tender Point Counts .......... 179 
Table 5:3 High Tender Point Counts and Tender Minus Swollen Joint Counts ...... 183 
Table 5:4 High “Tender Minus Swollen Joint Counts” In Early RA ....................... 185 
Table 5:5 High “Tender Minus Swollen Joint Counts” and Treatment Changes .... 186 
Table 5:6 High “Tender Minus Swollen Joint Counts” on Treatment Changes ...... 186 
Table 5:7 Pain Thresholds and Clinical and Demographic Variables ..................... 190 
Table 5:8 Regression Analysis of Factors Associated with Pain Threshold ............ 193 
Table 6:1 Patients Studied ........................................................................................ 203 
Table 6:2 Treatment Changes and DAS28 Categories ............................................ 212 
Table 6:3 Factors Influencing Treatment Changes with DAS28 ............................. 214 
Table 6:4 Factors Influencing Treatment Changes with DAS28 Components ........ 215 
Table 7:1 Outline Proposal for Fatigue Trial ........................................................... 239 




LIST OF FIGURES 
Figure 1:1 Joints Used For 28 Joint Counts ............................................................... 45 
Figure 1:2 Visual Analogue Assessments .................................................................. 46 
Figure 2:1 Summary Of Participants’ Included In The Study ................................... 81 
Figure 3:1 Early Involvement: Access to Professional Advice ............................... 124 
Figure 3:2 Early Involvement: Range of Care Provided .......................................... 124 
Figure 3:3 Integrated Management of Care: Treatments Offered ............................ 125 
Figure 3:4 Annual Assessments by Healthcare Professionals ................................. 126 
Figure 3:5 Smoking And Exercise ........................................................................... 127 
Figure 3:6 Involvement in Care ............................................................................... 128 
Figure 3:7 Hill Satisfaction Questionnaire ............................................................... 129 
Figure 4:1 Fatigue Scores in Initial Study ............................................................... 145 
Figure 4:2 Changes with Treatment in SF-36 in Early RA. ..................................... 152 
Figure 4:3 Fatigue Scores and HAQ Categories ...................................................... 156 
Figure 5:1 ROC of “Tender Minus Swollen Joint Counts” ..................................... 180 
Figure 5:2 Fibromyalgic RA and Assessments of Active Disease .......................... 184 
Figure 5:3 “Tender Minus Swollen Joint Counts”, DAS28 and HAQ Scores ......... 187 
Figure 5:4 “Tender Minus Swollen Joint Counts” DAS28 and HAQ Levels .......... 188 
Figure 5:5 Distribution of Pain Thresholds in RA ................................................... 189 
Figure 5:6 Pain Thresholds, Tender Points and Disease Duration .......................... 192 
Figure 6:1 Fibromyalgic RA Over Time .................................................................. 204 
Figure 6:2 Changes in DAS28 Scores over Time .................................................... 205 
Figure 6:3 DAS28 Remission and High Disease Activity over Time ..................... 205 
Figure 6:4 Fibromyalgic RA and DAS28 Over Time .............................................. 206 
Figure 6:5 Changes in Tender Joint Counts over Time ........................................... 207 
Figure 6:6 Changes in Swollen Joint Counts over Time ......................................... 207 
Figure 6:7 Changes in Patient Global Assessment over Time ................................. 208 
Figure 6:8 Changes in ESR Over Time.................................................................... 208 
Figure 6:9 NSAID And DMARD Use Over Time .................................................. 209 
Figure 6:10 Other RA Treatments Over Time ......................................................... 209 
Figure 6:11 Treatment Changes and DAS28 Category............................................ 211 
Figure 6:12 Treatment Changes In Patients with High Disease Activity ................ 212 
Figure 6:13 Fibromyalgic RA and Treatment Changes ........................................... 213 
Figure 6:14 Treatment Changes, DAS28 Categories and Age ................................ 216 
Figure 6:15 Treatment Changes, Current Age and Age at RA Onset ...................... 216 
Figure 6:16 DMARD Use, Current Age and Age at RA Onset ............................... 217 
Figure 6:17 Steroid Use, Current Age and Age at RA Onset .................................. 218 
Figure 6:18 Biologic Use, Current Age and Age at RA Onset ................................ 218 
Figure 7:1 Synopsis of Current Specialist Management .......................................... 244 




LIST OF ABBREVIATIONS 
Activities of living (ADL) 
American college of rheumatology (ACR) 
Amyloid a (AA) 
Anti−citrullinated protein antibody (ACPA) 
Anti-cyclic citrullinated peptide (anti-CCP) 
Antigen presenting cells (APCs) 
Arthritis and musculoskeletal alliance (ARMA)  
Arthritis impact measurement score (AIMS)  
British society of rheumatology (BSR) 
Clinical disease activity index (CDAI) 
Cognitive behavioural therapy (CBT) 
C-reactive protein (CRP) 
Cyclo-oxygenase (COX) 
Disease activity score (DAS) 
Disease activity score for twenty-eight joints (DAS28) 
Disease modifying anti-rheumatic drug (DMARD) 
Distal interphalangeal (DIP) 
Early morning stiffness (EMS) 
Early rheumatoid arthritis network (ERAN 
Erythrocyte sedimentation rate (ESR) 
European league against rheumatism (EULAR) 
Euroqol (EQ-5d) 
Functional assessment of chronic illness therapy –fatigue scale (FACIT-F) 
GP with a specialist interest (GPSI) 
Health assessment questionnaire (HAQ) 
Hospital anxiety and depression scale (HADS) 
Human -fetoprotein (AFP) 
Human leukocyte antigen (HLA) 
Hypothalamic-pituitary-adrenal (HPA) 
Interferon gamma (IFNγ) 
Interleukin (IL) 
International classification of disease (ICD) 
12 
 
Interstitial lung disease (ILD) 
Magnetic resonance imaging (MRI) 
Medication adherence rating scale (MARS) 
Metacarpophalangeal (MCP) 
Metatarsophalangeal (MTP) 
Modified HAQ (mHAQ)   
Multidimensional assessment of fatigue (MAF) 
Multidimensional fatigue symptom inventory (MFSI) 
Multidimensional HAQ (mdHAQ) 
National audit office (NAO) 
National institute for health and clinical excellence (NICE) 
National rheumatoid arthritis society (NRAS) 
Non steroidal anti-inflammatory drugs (NSAIDs) 
Nottingham health profile (NHP) 
Occupational therapists (OTs) 
Oral contraceptive pill (OCP) 
Outcome measures in rheumatoid arthritis clinical trials (OMERACT) 
Overall status in RA (OSRA)  
Patient global assessment (PGA) 
Physician global assessment (PhysGA) 
Primary care trust (PCT) 
Proximal interphalangeal (PIP) 
Quality and outcomes framework (QOF)  
Quality of well being scale (QWB scale) 
Rheumatoid arthritis impact of disease (RAID) 
Randomised controlled trial (RCT) 
Receiver operator characteristic (ROC) 
Receptor activator of nuclear factor kappa b (RANK) 
Rheumatoid arthritis (RA) 
Rheumatoid arthritis pain scale (RAPS)  
Ritchie articular index (RAI) 
Short form 36 (SF-36) 
Simple disease activity index (SDAI) 
13 
 
Standard gamble (SG) 
Standardised mortality rate (SMR) 
Statistical package for the social sciences (SPSS) 
Swollen joint count (SJC) 
Systemic lupus erythematosus (SLE) 
Tender joint count (TJC) 
Time trade off (TTO)  
Total quality management (TQM) 
Tuberculosis (TB) 
Tumour necrosis factor (TNF) 
Ultrasound (US) 
Verbal rating scale (VRS) 




Many colleagues have given me invaluable help and assistance in making this thesis 
possible. I am eternally grateful in particular to my supervisor Professor David Scott 
for his unending help, advice and patience and without him this thesis would not 
have been possible. I would also like to thank my other supervisors, initially Dr 
Ernest Choy and latterly Dr Gabrielle Kingsley for their invaluable advice and 
comments. Several members of staff within the Academic Department of 
Rheumatology have provided help and support including Dr Heidi Lempp whose 
experience and assistance with the qualitative research was greatly appreciated and 
Janice Jimenez for all her help with all things administrative.  
 
I am forever in the debt of the late Cathy Morrison and the nursing staff in the 
rheumatology department at King’s College Hospital for facilitating the recruitment 
of patients. My appreciation also goes to all the medical and clinical staff within the 
rheumatology department at King’s College Hospital for their help. My greatest 
thanks go to all those patients who agreed to give their time and participate in my 
research as without them this thesis would not have been completed.  
 
I would especially like to thank Dr Fowzia Ibrahim for all her advice, support and 
guidance with the statistical analyses. Also I need to thank Dr Nora Donaldson 
whose statistical assistance was invaluable in the early stages of my thesis.  
 
The support and encouragement I have received from family and friends has been a 
major contributor to my finally completing my thesis despite significant set-backs 
along the way. You have my gratitude for putting up with me over the last few years 
and I am truly thankful. 
 
Finally I would like to express my appreciation to the Guy’s and St Thomas’ Charity 






ABSTRACTS PRESENTED AT MEETINGS 
Pollard LC, Choy EH, Scott DL, Gonzalez JG. Fatigue in rheumatoid arthritis (RA): 
Its causes and consequences Source: Rheumatology 2005; 44 (Suppl 1): I101. 
 
Pollard LC, Scott DL. Evidence in favour of fibromyalgic rheumatoid arthritis: High 
trigger point counts and fatigue scores indicate a different clinical phenotype. 
Rheumatology 2007; 46 (Suppl 1): I99. 
 
Pollard LC, Morrison C, Scott DL.ARMA standards of care audit for patients with 
inflammatory arthritis: Opportunities for better care. Rheumatology 2008; 47 (Suppl 
2): II117. 
 
Pollard L, Scott IC, Kiely P, Williams R, Walsh D, Scott DL, Young A. Assessing 
health status in early rheumatoid arthritis (RA) using SF-36 to identify unexplored 
treatment needs. Rheumatology 2008; 47 (Suppl 2): II33 
 
Pollard L, Khoshaba B, Kingsley GH, Choy EH, Scott DL. Nottingham health 
profile (NHP) and responses to disease modifying drugs (DMARDs), steroids and 
TNF inhibitors in active rheumatoid arthritis. Rheumatology 2008; 47 (Suppl 2): 
II44. 
 
Pollard LC, Scott DL, Choy EH. Evidence for chronic pain in rheumatoid arthritis 
(RA) resulting in central sensitisation. Rheumatology 2008; 47 (Suppl 2): II8. 
 
Pollard LC, Scott DL, Donaldson N, Choy EH. Fatigue is an independent driver of 
disability in rheumatoid arthritis. Arthritis Rheum 2008; 58 (Suppl): S278-S279 
 
Graves H, Pollard LC, Lempp H, Kingsley GH, Scott DL. Perceived Barriers To 
Integrated Care In Rheumatoid Arthritis (RA): Views Of Providers And Recipients 




Pollard LC, Scott DL, Donaldson N, Choy E. Fatigue is an independent driver of 
disability in rheumatoid arthritis. Rheumatology 2009; 48 (Suppl 1): I131-I132 
 
Ma MH, Pollard LC, Kingsley GH, Scott DL. Rheumatoid arthritis (RA): the 
assessment of disease activity in clinical practice. Does it influence treatment 
decisions? Rheumatology 2009; 48 (Suppl 1): I134-I134. 
 
Pollard LC, Scott DL, Donaldson N, Choy EH. Fatigue in rheumatoid arthritis, what 
are we measuring? A factor analysis of fatigue instruments. Rheumatology 2009; 48 
(Suppl 1): I135 
 
Ma MH, Ibrahim F, Pollard L, Fekete Z, Kingsley GH, Scott DL. Treatment 
decisions in rheumatoid arthritis: do we undertreat the elderly population? 
Rheumatology 2010: 49 (Suppl 1); I23. 
 
FULL PAPERS 
Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of 
life measures in the individual patient. Clin Exp Rheumatol 2005; 23(5 Suppl 39): 
S43-52. 
 
Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid 
arthritis reflects pain, not disease activity. Rheumatology 2006; 45: 885-9. 
 
Pollard LC, Kingsley GH, Choy EH, Scott DL. Fibromyalgic rheumatoid arthritis 
and disease assessment. Rheumatology 2010; 9: 24-8. 
 
Pollard LC, Graves H, Scott DL, Kingsley GH, Lempp H. Perceived barriers to 
integrated care in rheumatoid arthritis: views of recipients and providers of care in an 
inner-city setting. BMC Musculoskelet Disord 2011; 12: 19. 
 
Pollard LC, Ibrahim F, Choy EH, Scott DL. Pain thresholds in rheumatoid arthritis: 
the effect of tender point counts and disease duration. J Rheumatol 2012; 39: 28-31. 
17 
 
CHAPTER 1.   INTRODUCTION 
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1.1. AN OVERVIEW OF RHEUMATOID ARTHRITIS 
1.1.1. History 
Rheumatoid arthritis (RA) is one of the most common types of chronic polyarthritis 
affecting approximately 1% of the world population [Gibofsky A. 2012] and it leads 
to significant disability through a combination of synovitis, pain and fatigue. RA can 
affect both sexes but is more common in females and has a peak onset during the 
fifth decade of life. Although research has given us a clearer understanding of the 
inflammatory pathways which are involved in the pathogenesis of RA [Choy et 
al,.2001], there is still no cure and therefore treatment is aimed at reducing 
inflammation, improving symptoms and ultimately reducing disability and improving 
quality of life for these patients. 
 
The first recognised description of rheumatoid arthritis was in 1800 by the French 
physician Landré-Beauvais (1772-1840). This was part of his doctoral thesis, 
although at the time he recognised it as distinct from previously described gout, he 
termed the ‘new’ disease asthenic gout. Landre-Beauvais studied nine patients at 
Salpêtrière hospital in Paris and described permanent swelling of the joints and 
deformities and after several years some patients became severely disabled. Post 
mortem examinations showed abnormally thickened tissue in the joints as well as the 
surface of joints showing swelling, ulcers and ‘invasion by flesh’. [Landré-Beauvais 
2001] 
 
Although RA may be thought of as a modern disease, the earliest appearance of RA 
was noted in remains of Indian skeletons dating from 4500 BC found in what is now 
known as Tennessee [Uhlig 2011]. It has also been suggested the in RA may have 
evolved from ankylosing spondylitis based on remains found in Sicily dating back to 
the Hellenistic period (330-210 B.C.) [Kelpinger 1978] 
The term rheumatoid arthritis was first coined by Sir Alfred Garrod in 1859 and he 
was the first person to distinguish it from gout [Storey 2001]. RA as a term was 
adopted officially in 1922 by the Empire Rheumatism Council and in 1941 by the 





1.1.2. Diagnostic Criteria 
There is no single laboratory test or sign which will diagnose RA. The diagnosis 
relies on a thorough history and examination in combination with laboratory and 
radiological findings. Until recently the most widely used criteria used to 
differentiate RA from other inflammatory arthritides were the 1987 American 
College of Rheumatology (ACR) diagnostic criteria. [Arnett et al. 1988] (Table 1.1) 
These have recently been updated to allow earlier diagnosis of disease and include 
the anti-cyclic citrullinated peptide (anti-CCP) antibody [Aletaha et al. 2010]. (Table 
1.2) 
 
Table 1:1 1987 ACR Criteria for the Classification of Rheumatoid Arthritis 
 
Criterion Definition 
1. Morning Stiffness Morning stiffness in and around the joints, lasting at 
least 1 hour before maximal improvement 
2. Arthritis of 3 or more joint 
areas 
At least 3 joint areas simultaneously have had soft 
tissue swelling or fluid (not bony overgrowth alone) 
observed by a physician. The 14 possible areas are 
right or left PIP, MCP, wrist, elbow, knee, ankle, and 
MTP joints 
3. Arthritis of hand joints At least 1 area swollen (as defined above) in a wrist, 
MCP, or PIP joint 
4. Symmetric arthritis Simultaneous involvement of the same joint areas (as 
defined in 2) on both sides of the body (bilateral 
involvement of PIPs, MCPs, or MTPs is acceptable 
without absolute symmetry) 
5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or 
extensor surfaces, or in juxta-articular regions, 
observed by a physician 
6. Serum rheumatoid factor Demonstration of abnormal amounts of serum 
rheumatoid factor by any method for which the result 
has been positive in <5% of normal control subjects 
7. Radiographic changes Radiographic changes typical of rheumatoid arthritis 
on posteroanterior hand and wrist radiographs, which 
must include erosions or unequivocal bony 
decalcification localized in or most marked adjacent 
to the involved joints (osteoarthritis changes alone do 
not qualify) 
 
For classification purposes, a patient shall be said to have rheumatoid arthritis if 
he/she has satisfied at least 4 of these 7 criteria. Criteria 1 through 4 must have been 
present for at least 6 weeks. 
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Table 1:2 2010 ACR/EULAR Classification Criteria For Rheumatoid Arthritis 
 
Target population (Who should be tested?): Patients who: 
 
1) have at least 1 joint with definite clinical synovitis (swelling)  
2) with the synovitis not better explained by another disease 
Classification criteria for RA (score-based algorithm: add score of categories A–D; a 
score of ≥6/10 is needed for classification of a patient as having definite RA) 
 
A. Joint involvement  
1 large joint 0 
2−10 large joints 1 
1−3 small joints (with or without involvement of large joints)  2 
4−10 small joints (with or without involvement of large joints) 3 
>10 joints (at least 1 small joint)  
 
5 
B. Serology (at least 1 test result is needed for classification)   
Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high-positive ACPA 
 
3 
C. Acute-phase reactants (at least 1 test result is needed for classification)  
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
 
D. Duration of symptoms 
 
<6 weeks 0 
≥6 weeks 1 
 
ACPA = anti−citrullinated protein antibody. 
 
Joint involvement refers to any swollen or tender joint on examination, which may 
be confirmed by imaging evidence of synovitis. Distal interphalangeal joints, first 
carpometacarpal joints, and first metatarsophalangeal joints are excluded from 
assessment. Categories of joint distribution are classified according to the location 
and number of involved joints, with placement into the highest category possible 
based on the pattern of joint involvement. 
 
“Large joints” refers to shoulders, elbows, hips, knees, and ankles. 
 
“Small joints” refers to the metacarpophalangeal joints, proximal interphalangeal 
joints, second through fifth metatarsophalangeal joints, thumb interphalangeal joints, 
and wrists. 
 
Duration of symptoms refers to patient self-report of the duration of signs or 
symptoms of synovitis (e.g., pain, swelling, tenderness) of joints that are clinically 





RA is estimated to affect approximately 1% of the UK population [Symmonds et al. 
2002]. Its annual incidence is 1-5 per 10,000 per population. The incidence and 
prevalence of RA may have decreased in recent years; several factors have been 
implicated. A study published in 2002 by Symmonds et al, looking at the prevalence 
of RA in the UK based on the 1987 ACR criteria; showed a fall in incidence since 
the 1960s. This fall may have been related to the protective effect of the oral 
contraceptive pill (OCP) or other factors related to OCP use. They found no fall in 
women aged 75 and over, who would not have had the OCP available to them; there 
was little evidence of a fall in prevalence in men.  
 
In 2009 the national audit office estimated that in England some 580,000 adults have 
RA, with around 26,000 new diagnoses each year. They also estimated that RA costs 
the NHS around £560 million a year in healthcare costs, with the majority of this in 
the acute sector, and that the additional cost to the economy of sick leave and work-
related disability is £1.8 billion a year. [National Audit Office 2009] The economic 
burden of RA is high in other Western societies as well, including Canada and the 
United States of America (USA). [Zhang et al. 2011] Whilst RA is fairly common in 
northern Europe and North America, in other parts of the developing world such as 
rural West Africa it appears rare. [Ouédraogo 2011] These variations may be 
indicative of different genetic risks and environmental exposures 
 
Alamanos et al [2006] systematically reviewed incidence and prevalence studies of 
RA based on the 1987 revised ACR criteria. They identified 28 relevant studies. Nine 
were incidence studies, 17 were prevalence studies and 2 estimated both prevalence 
and incidence rates. They found a significant difference of prevalence estimates 
between northern European and American countries and developing countries. South 
European countries had lower incidence rates than North American and north 
European countries. They concluded that the occurrence of RA varies among 
countries and areas of the world. Although a decreasing trend was observed in 
countries with high rates of RA incidence and prevalence, the relatively small 
number of studies for most areas of the world and the lack of incidence studies for 
the developing countries limits the understanding of worldwide RA. The difference 
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between the incidence and prevalence rates are summarised in Tables 1.3 and 1.4. 
[Alamanos et al. 2006] 
 
Table 1:3 Incidence Studies of Rheumatoid Arthritis 
 






    Total Male Female  
Doran 2002 USA Retrospective 0.5 0.3 0.6 ≥18 
Savolainen 2003 Finland Prospective 0.4 0.3 0.5 ≥16 
Chan 1993 USA Retrospective 0.3 0.2 0.5 ≥18 
Kaipiainen-
Seppanen 
2000 Finland Retrospective 0.3 0.2 0.4 ≥16 
Riise 2000 Norway Retrospective 0.3 0.2 0.4 ≥20 
Uhlig 1998 Norway Retrospective 0.3 0.1 0.4 20–79 
Kaipiainen-
Seppanen 
2001 Finland Retrospective 0.3 0.2 0.4 ≥16 
Drosos 1997 Greece Retrospective 0.2 0.1 0.4 ≥16 
Symmons 1994 England Prospective 0.2 0.1 0.3 ≥16 
Soderlin 2002 Sweden Prospective 0.2 0.2 0.3 ≥16 





Table 1:4 Prevalence Studies Of Rheumatoid Arthritis 
 




Population Age (y) 
    Total Male Female  
Gabriel 1999 USA Retrospective 10.7 7.4 13.7 ≥35 
Symmons 2002 England Cross-sectional 8.5 4.4 11.2 ≥16 
Hakala  1993 Finland Retrospective 8.0 6.1 10.0 ≥16 
Andrianako  2003 Greece Cross-sectional 7  19  
Simmonson 1999 Sweden Cross-sectional 5.1  20–74  
Saraux 1999 France Cross-sectional 5.0 2.4 7.6 ≥18 
Carmona 2002 Spain Cross-sectional 5 2 8 ≥20 
Power 1999 Ireland Cross-sectional 5    
Akar 2004 Turkey Cross-sectional 3.6 1.5 7.7 ≥20 
Kvien 1997 Norway Cross-sectional 4.4 1.9 6.7 20–79 
Riise 2000 Norway Retrospective 4.3 2.7 5.8 ≥20 
Pountain 1991 Oman Cross-sectional 3.6 16   
Drosos 1997 Greece Retrospective 3.5 1.9 4.5 ≥16 
Lau 1993 China Cross-sectional 3.5   ≥16 
Cimmino 1998 Italy Cross-sectional 3.3 1.3 5.1 ≥16 
Guillemin 2005 France Cross-sectional 3.1 0.9 5.1 ≥18 
Dai 2003 China Cross-sectional 2.8 1.4 4.1 ≥16 
Spindler 2002 Argentina Retrospective 2.0 0.6 3.2 ≥16 




The prime target for inflammation in RA is the synovium, which when inflamed is 
termed synovitis. The synovium in a normal joint serves as an important source of 
nutrients for cartilage as cartilage itself has no blood supply. Another important 
function of the synovium is the production of hyaluronic acid, which acts as 
lubrication for the joint. Hyaluronic acid is present in small volumes in the normal 
joint and helps normal movement and function. The synovial cells also produce 
collagens and fibronectins which make up the structural framework of the synovial 
interstitium. In RA, the inflamed synovium produces larger quantities of synovial 
fluid, which clinically is seen as joint swelling or effusion and is one of the hallmarks 
of RA. The fluid is also less viscous than normal synovial fluid and contains high 
levels of inflammatory cells and other mediators of the inflammatory process.  
 
The lining of normal synovium is only a few cells thick (1-3), with few if any 
inflammatory cells, but in RA the lining becomes markedly hypertrophied, up to 8-
10 cells thick. Cells seen in the layer in RA are predominantly macrophages and 
fibroblasts. The layer below this, the subintimal layer, contains the blood vessels 
which supply the synovium and normally contains very few cells. However, in RA, 
this layer is heavily infiltrated with inflammatory cells, including T cells, B cells and 
macrophages. Accompanying this heavy infiltration is new blood vessel formation, 
called angiogenesis. The greatly hypertrophied synovium is also called pannus and it 
has almost tumour like qualities as it invades and erodes adjacent cartilage and bone, 
which leads to the erosions seen on x-ray. 
 
It is felt that T cells play a central role in the pathogenesis of RA, but other cells such 
as B cells, macrophages, fibroblasts and osteoclasts also play vital roles in the 
inflammatory process. [Choy et al. 2001] The first step in the inflammatory process 
in RA is the uptake of antigen by antigen presenting cells (APCs), which is then 
degraded into peptides which are inserted into the groove of HLA-DR molecules on 
the surface of the APCs and presented to CD4+ T cells. The antigens which trigger 
this process are unknown; they may be autoantigens, microbial antigens or other 
external antigens. The T cell receptor recognises the HLA-DR, antigenic peptide 
complex and through a series of molecular events and gene transcription the T cell 
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becomes activated. [Goronzy et al. 1993] In order for the T cell to become fully 
activated several co-stimulation signals are also required. Without this second signal 
the T cell fails to activate and become anergic. This co-stimulation pathway has 
become the target of new therapy for RA. [Fiocco et al. 2008] 
 
After activation of the T cell, there is release of a number of proinflammatory 
cytokines. Interleukin-2 (IL-2) is released, which is a growth factor for T cells and 
leads to their clonal expansion. T cells also release a number of other mediators, 
some of the most important being interferon gamma (IFNγ) and IL-17. IL-17 
activates osteoclasts which in turn erode bone and IFNγ activates macrophages 
which release chemokines and inflammatory cytokines including IL-1 and tumour 
necrosis factor alpha (TNFα), which have also become targets for therapy in RA. The 
inflammatory cytokines also work on synovial fibroblasts and or synoviocytes to 
activate them and the chemokines are responsible for the migration of monocytes, 
neutrophils, T and B cells into the synovium. [Choy 2012] 
 
In addition to releasing proinflammatory cytokines the T cell can also interact 
directly with macrophages, synovial fibroblasts and osteoclasts. T cells can directly 
activate osteoclasts via cell to cell interaction. Activated T cells within the RA 
synovium possess a ligand called receptor activator of nuclear factor κB (RANK) 
ligand. Non activated T cells do not express RANK ligand. Osteoclast precursors 
express a receptor for RANK ligand on their surface. When RANK ligand on an 
activated T cell interacts with the RANK receptor on the osteoclast precursors, a 
series of molecular events leads to the differentiation of the precursors into 
osteoclasts, as well as their activation and survival and thus bone resorption. 
[Shiozawa et al. 2011] 
 
The role of B cells in the pathogenesis of RA has come to the fore with the 
successful treatment of RA patients with anti B cell therapy [Edwards et al. 2001]. 
The B cell has several possible roles in the inflammatory pathway in RA. B cells can 
act as antigen presenting cells to T cells and also as a co-stimulatory signal for T cell 
expansion. B cells themselves are also capable of secreting proinflammatory 
cytokines such as TNFα. B cells also produce rheumatoid factor and other 
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autoantibodies, which can produce immune complexes and fix complement leading 
to inflammation.  
 
1.1.5. Outcome Predictors 
1.1.5.1. Genetics 
RA is a complex disease and is often heterogeneous in its clinical presentation. This 
heterogeneity can continue throughout the course of disease with variable disease 
progression, severity and response to treatment. This variability between individuals 
is likely secondary to genetic factors. 
 
The role of HLA DRB1 genes has been known for many years. The first clue that T 
cells may be an important driver of inflammation in RA came with the discovery of 
the link between RA and HLA-DR4/DR1 [Winchester 1981]. The only known 
function of DR molecules is to present antigen to T cells. 
 
Several different HLA DRB1 alleles have been shown to be associated with RA and 
some alleles have much stronger associations than others; HLA DRB1*0404 is a 
much stronger susceptibility factor than HLA DRB1*0401. [Weyand et al. 1992] In 
contrast some HLA DRB1 alleles may actually be protective. Recent thinking 
suggests that the association between HLA DRB1 and RA is related to severity of 
disease rather than risk of development of disease. [Toda et al. 1994] Twin studies 
have shown that RA has a heritability of approximately 60%. [MacGregor et al. 
2000] 
 
1.1.5.2. Sex and Hormonal Factors 
RA affects almost three times as many females as males. Therefore a lot of research 
has focused on examining the role of hormonal and reproductive factors in the 
development and risk of RA. Interestingly testosterone levels are lower in men who 
have RA. [Spector et al. 1988] However, there are no differences in levels of sex 
hormones in females with RA compared to unaffected females. [Heikkila et al. 1998] 
There is some evidence that exogenous hormones exert some effect. It was initially 
felt that the oral contraceptive pill reduced the risk of developing RA, but a 
subsequent study found that the protective effect was lost over time, thus, although 
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the oral contraceptive pill does not reduce the overall risk, it does appear to delay the 
onset of RA. [Hannaford et al. 1990] 
 
Studies looking at the influence of pregnancy have produced conflicting results. With 
some studies suggesting that women who have had no children are at greater risk of 
developing RA, with other studies showing there to be no increased risk in single 
women. [Spector et al. 1989] Although it is well accepted that RA tends to remit 
during pregnancy, the mechanisms have not been established. [Ostensen et al. 2002] 
Symptomatic relief becomes more pronounced as the pregnancy progresses, with 
more patients achieving remission by the third trimester. [Da Silva et al. 1992] This 
remission coincides with the increase in maternal and fetal levels of human -
fetoprotein (AFP), which has immunomodulatory properties; [Irony-Tur-Sinai et al. 
2006; Hooper et al. 1989] hence; it may be a significant contributory factor. AFP is 
produced at low levels throughout life; however, the fetus produces much higher 
levels of AFP. During pregnancy, AFP reaches maximal concentrations during the 
third trimester. After delivery, levels of AFP fall to normal levels. [Pollard et al. 
2007] 
 
The postpartum period appears to be a high risk time for development of disease, 
particularly after a first pregnancy. Some of this risk is now felt to be due to 
breastfeeding and those females who breastfeed after their first pregnancy have the 
highest risk of developing RA. It has been postulated that this may be due to 
exposure to prolactin which has proinflammatory properties. [Silman et al. 1994]  
 
1.1.5.3. Infection 
For many years there has been a widely felt belief that RA is triggered by an 
infection. Although a substantial number of people develop RA within a few weeks 
of an infection, numerous studies have failed to identify a specific causal antigen. 
 
1.1.6. Clinical Features 
Most cases of RA develop insidiously over a few weeks to months. Patients often 
initially notice stiffness in the joints with associated pain on movement and 
tenderness to palpation of the affected joints. Although a few joints may be affected 
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at onset, the disease is usually polyarticular and there is usually a sequential addition 
of involved joints. The small joints of the hands (metacarpophalangeal, proximal 
interphalangeal and wrist joints) and feet (metatarsophalangeal joints) are invariably 
involved, usually at an early stage. However, a smaller number of patients may 
present with a large joint onset of disease, in those that have a monoarticular onset, 
the knee is the most commonly affected joint. Occasionally patients have an acute or 
‘explosive’ onset of symptoms over 24 to 48 hours. [Hart 1997] 
 
The stiffness associated with RA is characteristically worse in the mornings and lasts 
usually more than an hour but can last for several hours and its duration can be a 
useful gauge of disease activity. [Sierakowski et al. 2011] Although the stiffness in 
RA is most common in the morning, stiffness also commonly develops in the 
evenings and after long periods of inactivity, often referred to as ‘gelling’. This is in 
contrast to patients with degenerative arthritis who also have stiffness with inactivity 
but this usually only lasts for a few minutes. 
 
1.1.6.1. Clinical Presentation and Subtypes 
RA has heterogeneous clinical features and although it usually presents with 
polyarticular or monoarticular arthritis, there are a number of other clinical subtypes 
that are well recognised. [Scott et al. 2007] These include palindromic and 
polymyalgic onset RA. Palindromic RA is characterised by transient synovitis that 
can affect different joints. The transient synovitis can last anywhere between a few 
hours to a few days and then completely resolve. Between episodes the joints often 
feel normal. The time between episodes is very variable. A significant number of 
people with palindromic RA will develop into classical RA. In polymyalgic onset 
RA, patients often develop symptoms very similar to polymyalgia rheumatica with 
muscle pain and prolonged stiffness in predominantly the shoulder girdle but also the 
pelvic girdle. 
 
Another evolving clinical subtype is fibromyalgic rheumatoid. This has been 
partially defined by Wolfe and colleagues in RA on the basis of high levels of pain, 
fatigue and disability without significant synovial inflammation. [Wolfe et al. 2004] 
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It is worthwhile identifying this subtype, which resembles fibromyalgia seen in the 
general population, because it may respond to different therapeutic approaches. 
 
1.1.6.2. Disease Course 
Disease expression is variable but the majority of patients have a gradually 
progressive course of disease with joint damage and deformity leading to disability. 
A proportion of patients will have a fairly mild course of disease with little 
impairment. The extent of disability is often determined within the first few years of 
disease, with gradual worsening of the level of functioning thereafter. [Masi 1983; 
Morel et al. 2005] This confirms the need to treat disease early and aggressively in 
order to prevent disability. 
 
1.1.6.3. Joint Involvement 
Chronic synovitis leads to progressive joint damage. Pannus formation erodes into 
adjacent cartilage and bone. Joint involvement in RA is characteristically 
symmetrical and commonly affects the MCPs, PIPs, wrists, elbows, shoulders, knees 
and MTPs. Early in the disease process swelling in these joints may be apparent and 
chronic inflammation leads to joint destruction and the typical joint deformity which 
is characteristic of RA.  
 
The typical deformities include ulnar deviation at the MCPs and swan neck 
deformities of the digits, which is defined as hyperextension at the PIP joints and 
flexion at the distal interphalangeal (DIP) joints. These deformities are a 
consequence of joint swelling and also associated tenosynovitis. In early disease 
these deformities may be correctable; however, later in disease other deformities of 
the hands such as boutonnière’s may develop which impact on the functioning of the 
hand. Boutonnière deformities are defined as hyperextension at the MCP joints, 
flexion at the PIP joints and hyperextension at the DIP joints. The thumb deformity 
associated with RA is the so called Z deformity, which is flexion at the MCP and 




1.1.6.4. Systemic Involvement 
RA is a chronic inflammatory arthritis and most commonly affects the joints, 
however, RA can be a systemic disease and severe arthritis shortens life expectancy 
by 6-10 years, equivalent to the impact of diabetes, Hodgkin’s disease, and triple 
vessel coronary artery disease. [Rasker et al. 1981] 
 
Systemic or extra-articular manifestations of RA are present in approximately 8-12% 
of patients and there is evidence that those patients with systemic manifestations 
have increased morbidity and mortality compared to those with no extra articular 
features. [Turesson et al. 1999] The extra-articular manifestations are often 
associated with high levels of disease activity, high inflammatory markers and high 
levels of rheumatoid factor. These patients are known to have a poor prognosis and 
therefore early aggressive therapy should be instituted to lower the risk of systemic 
manifestations and reduce morbidity and mortality. [Turesson et al. 2002] 
 
Constitutional features include fatigue, fever, anorexia and weight loss. Many of the 
systemic features are driven by IL-6; it activates the hypothalamic-pituitary-adrenal 
(HPA) axis to produce fever, stimulates haematopoiesis, including stimulating 
megakaryocyte progenitors which cause an increase in platelets, activating 
hepatocytes to produce the acute phase reactants CRP and amyloid A, as well as 
stimulating the activation of osteoclasts which have as major role in osteoporosis. 
[Hashizume et al. 2011] Extra-articular manifestations in RA can affect almost any 
system in the body, although the most commonly affected are the skin (rheumatoid 
nodules, eyes and mouth (secondary Sjögren’s) and lungs (pulmonary fibrosis). 
[Turesson et al. 2003]  
 
 
1.1.7. Impact of Rheumatoid Arthritis on Society and the Individual 
The impact of RA on the individual can be obvious in those with observable 
disability and deformities from longstanding inflammation. However, other forms of 
disability are less obvious such as the impact of chronic disease on mental health and 
the often accompanying chronic pain. RA itself is a significant cause of morbidity 
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and mortality and is said to reduce life expectancy by up to five years. [Wolfe et al. 
1994] 
 
The cost of RA to the individual and society can be thought of in terms of ‘direct’ 
and ‘indirect’ costs. The ‘direct’ costs are fairly easily measurable in terms of costs 
of hospital appointments with specialists and allied health care professionals, drug 
treatments, drug monitoring, investigations and hospital admissions. The ‘indirect’ 
costs are less easily measurable and include less tangible costs such as loss of 
productivity, loss of work time, incapacity and disability benefits as well as the 
impact on family with many relatives often acting as unpaid carers.  
 
Patients with RA often leave full time employment early in disease and a proportion 
will never return to full time work. Those who do work often need considerable time 
off for repeated hospital appointments, monitoring of the possible side effects 
associated with treatment and sessions with allied health care professionals such as 
physiotherapists and occupational therapists. Numerous tools have been designed to 
measure outcomes in RA patients with regards to disease activity, overall health and 
disability; however, tools which attach a monetary value have been attempted but 
have been less successful. 
 
1.1.7.1. Disability 
Historically, the impact of chronic diseases including RA on patients’ lives has been 
defined in terms of three different levels defined by the World Health Organization: 
impairment, disability and handicap. In essence impairment is a loss of anatomical or 
psychological function, disability is an inability to perform normal activities due to 
impairment and handicap is the disadvantage for an individual resulting from an 
impairment or disability that limits the fulfilment of a normal role in life. This 
overarching concept is now being superseded by the International Classification of 
Functioning, Disability and Health (the ICF framework). This latter approach 
classifies patients’ problems into four different components, which can be used to 
generate an individual code that is akin to that generated by the international 
classification of disease (ICD-10). These four components comprise body functions 
and structures (similar to the previous concept of impairment), activities and 
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participation (similar to the previous concepts of disability and handicap), 
environmental factors, and personal factors. The first two components define 
functioning and disability, whilst the second two are regarded as contextual factors.  
 
1.1.7.2. Work Disability 
Approximately half of RA patients in the UK are of working age at the onset of 
symptoms. [Symmons et al. 1994] A study from the US suggests that the greatest 
risk of work disability seems to occur within the first three years following the onset 
of symptoms. [Sokka 2003] One longitudinal study of patients with early RA in the 
UK has shown that just over a fifth of patients who were in employment at the onset 
of symptoms of RA stopped working after 5 years of disease onset because of their 
RA. [Young et al. 2002] A study from Canada showed that about a third of RA 
patients from their cohort of 239 patients left employment early, although this was 
influenced by socioeconomic factors. [Backman et al. 2004] 
 
Work related disability is particularly common for RA, with around 9.4 million 
working days lost in the UK due to RA in 1999-2000, equivalent to £833 million in 
lost production. [ARMA standards of care for people with inflammatory arthritis 
2004] This is clearly a significant sum of money, especially considering the current 
economic situation. In recent years there has been more focus on the cost of RA 
work disability, predominantly spearheaded by the drug companies responsible for 
the development of biologic therapies who are understandably eager to show that 
their treatments are cost beneficial given their relatively higher costs compared to 
traditional DMARDs. The ASPIRE study which compared methotrexate 
monotherapy with methotrexate, infliximab combination therapy showed a 
significant reduction in unemployment at 1 year in those on combination therapy 
compared to monotherapy (14% unemployed vs. 8% unemployed). The study also 
showed that those patients receiving combination therapy had a significantly higher 
likelihood of employability (Odds ration 2.4).  Significantly fewer employed patients 
receiving combination therapy reported lost working days than those on 
monotherapy and 79% vs. 67% of patient on monotherapy reported no lost working 




1.1.7.1  Mortality 
Several studies have shown that there is an increase in premature mortality 
associated with RA. [Arnett et al. 1988; Fries et al. 1980; Symmons et al. 1994; 
Wolfe et al. 1994] The standardised mortality rate (SMR) associated with RA is 
approximately 50% higher than the general population, with similar SMRs of about 
1.2-1.3 in inception cohorts and 1.6-1.7 in non-inception cohorts seen over 60 years.  
[Sokka et al. 2008] 
 
The attributable causes of death in RA patients does not seem to have changed 
greatly over the last few years and is in some ways similar to the general population 
with cardiovascular disease as the leading cause of death in RA patients, albeit at an 
earlier age compared to the general population. This has led to a renewed interest in 
the association of increased cardiovascular risk in RA patients over the last few years 
with a rise in the number of studies looking at the possible causes for this apparent 
association. [Cavgna et al. 2012; Kerola et al. 2012; Arts et al. 2012] Infections, 
respiratory and renal disease as attributable causes of death are more common in RA 
than the general population. In the UK 760 deaths were recorded as related to RA 
(Office of National Statistics 2005), this may be an underestimation of mortality rates 
as RA may not appear on the death certificate. 
 
Patients with severe active RA are most likely to die early and those with clinical 
measures indicating more severe disease are prognostic for premature mortality. The 
most significant predictors of premature death appear to be worse functional and 
global assessments as well as co morbidities. [Sokka et al. 2008] 
 
1.1.8. Treatment  
The aims of treatment in RA should be to reduce pain, reduce disability and improve 
function, improve quality of life, retard disease progression and joint damage by 
disease modification and finally to improve prognosis. The management of RA 
should be provided by a multidisciplinary team and includes patient education, 
physical therapies such as occupational therapy, physiotherapy and podiatry, in 
conjunction with medication, surgery, psychological and social support. NICE 
guidance on the management of RA was published in 2009 [NICE clinical guideline 
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79] which emphasises a patient centred approach, regular specialist reviews, early 
combination treatment with DMARDs, access to surgery when needed and access to 
a multidisciplinary team. 
  
1.1.9. Non-Pharmacological Interventions 
1.1.9.1. Occupational Therapy 
Occupational therapists (OTs) provide help for RA patients in a variety of ways. 
They predominantly help with common activities of daily living through the 
provision of aids but more specialist areas of occupational therapy such as hand 
therapy can improve hand function in RA patients. [Mathieux et al. 2009] 
 
OTs who specialise in hand therapy have a particularly important role in the 
management of RA patients. They can assess patients in the early stages of RA and 
give advice about exercises and joint protection. They can also make and supply 
specialist splints to help support and rest the hand and wrist joints. Even later in 
disease hand therapists have a role in improving function of the hands and reducing 
pain through exercises, wax baths and splints. Tripoint rings can improve function in 
patients with swan neck deformities; they are splints which look like jewellery and 
keep the PIP joint lined up, protect the joint from hyperextending, and still allow the 
PIP joint to bend.  
 
1.1.9.2. Physiotherapy 
Before the days of effective DMARDs many RA patients were prescribed bed rest as 
treatment for their inflamed joints. Although rest and joint immobilisation can help 
an inflamed joint, prolonged rest can lead to muscle weakness. The aims of 
physiotherapy are to prevent disability, to increase functional capacity, to provide 
pain relief, and to provide patient education. Physiotherapy aims to maintain, 
improve and restore function through exercise. Physiotherapists use a combination of 
techniques when treating RA patients. These include physiotherapy techniques; hot 
and cold applications, hydrotherapy and electrical stimulation (eg Transcutaneous 
electrical nerve stimulation (TENS) therapy) as well as rehabilitation techniques; rest 
and splinting, assistive devices such as walking sticks, massage therapy, therapeutic 




Podiatrists also have a role in early RA, as early podiatric intervention has been 
shown to improve foot pain and function. [Woodburn et al. 2002] The podiatrist has 
a number of roles in RA patient care at all stages of RA. In the early stages they can 
give advice about foot hygiene and footwear as well as providing customised 
orthoses and insoles to improve foot and toe posture and function. They can also help 
with toe nail trimming as well as minor surgery. In later stages of disease they can 
also provide specialist footwear. 
 
1.1.9.4. Surgery 
Despite the improvement in available treatments for RA, surgery still plays a major 
role for many patients. A variety of procedures are used by surgeons and many 
specialise in specific regions, notably hand surgeons. One of the most common 
procedures is joint replacement or arthroplasty; the joints which can be replaced 
include hip, knee, elbow, shoulder and MCP. Some joints which are not amenable to 
replacement such as the wrist and ankle can be fused which stabilises the joint as 
well as providing pain relief, although does lead to a reduction in joint movement. 
Surgery is required to stabilise atlanto axial subluxation which is one of the more 
serious complications of RA.  
 
Surgical decompression can help entrapment neuropathies often associated with RA 
such as carpal tunnel syndrome. Specialist hand surgeons use a variety of techniques 
to improve severe deformities so as to improve hand function in RA patients, such as 
tendon tightening, loosening or repair as well as fusing hand or wrist joints or 
replacing MCPs.  
 
1.1.10. Pharmacological Interventions 
Several classes of drugs are used in the treatment of RA. These can be divided into 
the following groups: Analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), 





The old treatment pyramid approach for RA [Wilske et al. 1989] which consisted of 
initial ‘first line treatment’ with symptomatic drugs such as analgesics and NSAIDs, 
then only adding DMARDs later has now been completely turned on its head. This 
approach was based on the assumption that there was a gradual decline in quality of 
life and good health over time in RA; however, it has clearly been shown that there is 
a rapid decline in health and quality of life after the onset of RA. Therefore early and 
aggressive treatment with combination DMARDs is now recommended. [NICE 
clinical guideline 79] 
 
1.1.10.1. Analgesics 
Analgesics are painkillers that can be used to symptomatically help the pain 
associated with RA. They are can be used in combination with other drugs such as 
DMARDs. There are several types of analgesics available including paracetamol, 
codeine, tramadol and opiate analgesics. Paracetamol and codeine are often used in 




Steroids have a powerful anti-inflammatory effect and are one of the quickest acting 
drugs used in RA. They are often used early in disease in combination with 
DMARDs which have a slower onset of action and are commonly used to rapidly 
suppress inflammation if disease flares. The main problem which limits their use is 
the well documented side effects associated with prolonged use. These include 
cataracts, adrenal suppression, hypertension, fluid retention, musculoskeletal 
(osteoporosis, myopathy and avascular necrosis) and metabolic (diabetes, 
hyperlipidaemia and obesity) effects. 
  
1.1.10.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 
DMARDs are a group of unrelated drugs which are defined by their use in RA to 
slow disease progression. These drugs are distinct from anti-inflammatories which 
simply reduce inflammation without having an effect on the course of disease. 
Although these drugs were first used in RA there use has become much more 
widespread and they are used in other inflammatory conditions including other types 
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of inflammatory arthritis as well as connective disease diseases and inflammatory 
bowel disease. It is not clear how some of the drugs used in RA exert their effect and 
in fact only two DMARDs were developed specifically for RA; oral auranofin (no 
longer used) and leflunomide. A list of current DMARDs and their mechanisms of 




Table 1:5 DMARDS and Their Mechanisms of Action 
 
DMARD Proposed Mechanism 
Azathioprine Purine synthesis inhibitor 
Ciclosporin Inhibits calcineurin and reduces T lymphocytes 
D-Penicillamine Unclear but felt it inhibits proliferation of T lymphocytes 
Gold Salts Felt to be similar to D-penicillamine 
Hydroxychloroquine Interference with antigen processing 
Leflunomide Pyrimidine synthesis inhibitor (dihydroorotate 
dehydrogenase inhibitor) 
Methotrexate Inhibits metabolism of folic acid (dihydrofolate reductase 
inhibitor) 
Sulfasalazine Possible Inhibitor of NF-kappaB 
 
All DMARDs have side effects some of which are fairly minor such as nausea and 
diarrhoea but many can have potentially serious side effects requiring regular 
monitoring of patients receiving such drugs. These side effects include bone marrow 
suppression, hepatitis and rarely fulminant liver failure, hypertension, pneumonitis 
and an increased risk of infection.  
 
Methotrexate is now probably the most widely used DMARD in RA. It can be used 
as monotherapy as well as in various combinations. When new studies are designed 
for new drug treatments in RA, methotrexate is used as standard therapy and in the 
trials of new biologic therapies, methotrexate is usually trialled in combination with 
any new drug. 
 
DMARDs are now used early in disease and there is good evidence that 
combinations of DMARDs are better from the outset than monotherapy DMARDs. 
[Verhoeven et al. 1998] Common combinations include so called ‘triple therapy’; 
methotrexate, sulfasalazine and hydroxychloroquine [O’Dell et al. 1996] as well as 
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ciclosporin and methotrexate. [Choy et al. 2008] Those patients who fail to respond 
to good doses of combination therapies should be considered for biologic therapies. 
 
1.1.10.4. Biologic Therapies 
The introduction of biologic therapies has revolutionised the treatment of RA over 
the last two decades. These new therapies stemmed from a better understanding of 
the pathogenesis of RA and the important inflammatory pathways involved in the 
establishment and maintenance of disease. These therapies have been shown to 
improve signs and symptoms of RA as well as reduce progression of joint damage. 
The first biologic therapies to become available were anti-tumour necrosis factor 
alpha (TNF-α) drugs. These drugs are still widely used today and are usually 
considered the first line biologic therapy. Shortly after anti-TNF therapy became 
available, the drug Anakinra came onto the market, which targets interleukin-1 (IL-
1). Although it was felt that both TNF-α and IL-1 were the most important cytokines 
in the inflammatory pathway in RA, Anakinra has not proven as efficacious as anti-
TNF therapy.  
 
Despite the undoubted success of anti-TNF therapy, it has failed to become the ‘cure’ 
that it was once heralded. There are also problems with anti-TNF therapy, the most 
common of which is the increased risk of infection and the particular problem of 
reactivation of tuberculosis (TB). Anti-TNF therapy can also worsen heart failure 
and a significant proportion of patients do not respond to therapy. Therefore, there 
has been ongoing research to identify other potential targets in the inflammatory 
pathway. A number of newer biologic therapies have come onto the market in the 
last few years. These include anti-B cell therapy, T cell co-stimulation blockade and 
anti-IL-6 therapy.  
 
Conventional drugs inhibit small molecules; however, as cytokines are large 
peptides, large molecules are required to inhibit them. Therefore, biologics are large 
proteins based on immunoglobulins and are delivered by infusion or injection. The 
bioengineering required to produce these drugs is expensive and contributes to their 
significantly higher costs as compared to traditional DMARDs. Ideally these 
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biologics would be replaced with small molecules which can inhibit the intracellular 
targets of cytokines. However, this ideal is still some way into the future. 
 
1.1.10.5. Tumour Necrosis Factor-Alpha (TNF-α) 
Indications: TNF-α inhibitors should be considered when patients continue to have 
active disease despite an adequate trial of DMARDs. In the UK, the 
recommendations for the use of biologics by the national Institute for Health and 
Clinical Excellence (NICE), state that TNF-α inhibitors should be used when a 
patient has active disease as defined by a DAS28 score of 5.1 or above on at least 
two occasions one month apart; despite a trial of at least two DMARDs, one of 
which must be methotrexate. A ‘trial’ is considered to be six months unless the drug 
was stopped due to intolerance. [NICE guidance TA130] TNF-α inhibitors can be 
added to existing DMARD therapy, particularly methotrexate. In some cases TNF-α 
inhibitors can replace DMARDs, particularly if intolerance to DMARDs is a 
problem. At present in the UK, TNF-α inhibitors are not recommended as first line 
agents in the treatment of RA, however, there are many clinical trials ongoing which 
are looking at their use in early RA, which in part are looking at the possibility of 
turning off inflammation early in the disease process.  
 
Infliximab: Infliximab is a chimeric IgG1 anti–TNF-α monoclonal antibody in 
which the antigen-binding region is derived from a mouse antibody and the constant 
region from a human antibody. It binds with high affinity to both soluble and 
membrane bound TNF-α. Infliximab exerts its effect in two different ways; firstly it 
interferes with binding of TNF-α to its receptor, secondly it can kill cells that express 
TNF-α via antibody dependent, complement driven pathways. Infliximab is given by 
intravenous infusion and the standard dose in RA is 3mg/kg every eight weeks after 
initial front loading. Although trough levels of infliximab are usually seen at eight 
weeks, the pharmacokinetics of infliximab can vary hugely between patients. 
Therefore, in patients whose symptoms return prior to their next infusion, reducing 
the time between doses may be effective at increasing trough levels and therefore 
improving efficacy. Certainly studies have shown a benefit in reducing the interval 
time in patients who lose efficacy with infliximab and some success has also been 




Etanercept: Etanercept differs from infliximab in that it is a TNF-receptor fusion 
protein rather than a monoclonal antibody. It comprises two dimers; each dimer has 
an extracellular, ligand-binding portion of the higher-affinity type 2 TNF receptor 
(p75) which is linked to the Fc portion of human IgG1. Initially a monodimeric drug 
was engineered but this did not have sufficient biologic activity. Etanercept exerts its 
effects by binding to both TNF-α and TNF-β, preventing them from interacting with 
their receptors. Etanercept was initially given at a dose of 25mg twice a week 
subcutaneously, but over the last couple of years a once weekly dosing of 50mg has 
been introduced. 
 
Adalimumab: Like infliximab, adalimumab is an IgG1 anti-TNF-α monoclonal 
antibody; however, it differs from infliximab in that it is fully humanised. Like 
infliximab it exerts its effects in two different ways; it binds with high affinity to 
TNF-α and consequently inhibits its binding to its receptors, it can also lyse cells 
which express TNF-α on their surface. Unlike infliximab, adalimumab is given 
subcutaneously once every two weeks. Peak absorption is reached by 120 hours, 
although this can vary widely between patients.  
 
Other Anti-TNF Therapies: Since the introduction of anti-TNF therapies several 
new drugs have come to the market as possible treatment for RA. Specifically 
Certolizumab [Choy et al. 2002] and Golimumab [Keystone et al. 2009], both are 
anti-TNF-α monoclonal antibodies and they have recently been approved by NICE 
[NICE guidance 2010 and 2011]. 
  
Therapeutic Effects: TNF-α inhibitors can produce major improvements in 
symptoms and signs of RA. Improvements are typically seen within 12 weeks of 
commencement of treatment. There is no evidence that one TNF-α inhibitor is more 
effective than any other and other than patient choice with regards to administration, 
no particular reason for any specific agent to be used first.  
 
In the UK, the NICE guidelines suggest TNF-α inhibitors should be continued 
provided the patient continues to show a treatment response which is defined as a 
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reduction in DAS28 of 1.2 or more from baseline. [NICE guidance TA 130] There 
are two types of non-responders; primary non-responders are those patients who fail 
to respond to a TNF-α inhibitor and secondary non-responders are those patients who 
initially show a response to treatment but then lose this effect. In patients who are 
primary non-responders, the drug should be stopped. It has been common practice to 
switch these patients who are primary non-responders to another TNF-α inhibitor. 
Evidence from biologic patient registers, such as the one in Sweden [STURE: van 
Vollenhoven et al. 2005] have shown that a substantial number of patients who 
switch from one TNF-α inhibitor to another for whatever reason will have a response 
to the second TNF-α inhibitor. In patients who are secondary non-responders, several 
different tactics have been employed, including increasing the dose of the TNF-α 
inhibitor, reducing the dosing interval or switching TNF-α inhibitor. Again, there is 
some evidence that increasing the dose or reducing the dosing interval is beneficial in 
these patients. However, guidance from NICE suggests that non-responders to a first 
TNF-α inhibitor should not be switched to another TNF-α but should be changed to 
anti-B cell therapy which is another type of biologic therapy and is discussed below. 
[NICE guidance TA 195] 
 
There is growing evidence that TNF-α inhibitors slow radiographic progression of 
RA to a much greater degree than DMARDs alone. In some patients they seem to 
completely halt progression and the evidence for this is greater in patients with early 
RA and also in those patients who are also on concomitant methotrexate. The 
relationship between clinical and radiological response is not necessarily similar and 
as the effect of reducing radiological damage but not reducing clinical signs and 
symptoms is not clear in the long term, decisions should not be made solely on the 
benefits of radiological response.  
 
Adverse effects: Some of the most common side effects seen with TNF-α inhibitors 
are local injection site reactions with etanercept and adalimumab. These usually 
present with redness and itchiness at the site of injection. Headaches and nauseas are 
common with infliximab and are generally minor. Less commonly seen adverse 
effects are hypersensitivity like responses with infliximab such as urticaria, 
thankfully serious anaphylactic reactions are far more rare but well documented and 
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antihistamines, steroids and epinephrine should be available when infliximab is 
given. 
An increase in infections are commonly seen in patients on TNF-α inhibitors, 
although there is debate on whether there is an increase risk of serious or 
opportunistic infections compared to those patients with severe RA treated with 
DMARDs or steroids. In those patients who develop a serious infection the TNF-α 
inhibitor should be stopped and a new TNF-α inhibitor should not be started if the 
patient has an infection. Some of the more common infections seen in patients taking 
TNF-α inhibitors are respiratory tract infections, skin infections including cellulitis 
and abscesses and septic arthritis, including infected prosthetic joints and 
osteomyelitis. These have been recorded and reported in the UK by the British 
society for rheumatology rheumatoid arthritis register. [Galloway et al. 2011; 
Galloway et al. 2013; Galloway et al 2011] 
 
1.1.10.6. Other Biological Therapies 
Other biological therapies now approved for use in RA after failure of anti-TNF 
therapy include Rituximab which is a monoclonal antibody directed against CD20 
positive B cells [Leandro et al. 2002], Abatacept which is a co-stimulation blocker 
[Pollard 2007], preventing activation of T-cells and Tocilizumab [Maini et al. 2006] 
which is a monoclonal antibody directed against IL-6. All have shown efficacy in 
treating RA and are recommended by NICE. Rituximab is recommended as the next 
drug to be used if a patient has failed anti-TNF therapy and abatacept and 
tocilizumab are recommended for patients who have failed Rituximab [NICE 
Guidance 2010]. 
 
1.2. DISEASE ASSESSMENTS IN RHEUMATOID ARTHRITIS 
1.2.1. Joint Swelling and Tenderness 
Swollen joints in RA are a result of inflammation and therefore reflect disease 
activity. Swelling in RA joints is due to a combination of synovial 
thickening/inflammation (synovitis) and joint effusion. Swelling in RA joints is often 
described as fluctuant and should not be mistaken for hard bony swellings such as 
those seen in nodal osteoarthritis or the apparent swelling of joints due to 
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subluxation, such as that seen in the metacarpophalangeal joints of RA patients with 
subsequent uncovering of the head of the metacarpal giving the appearance of 
swelling.  Several studies have shown there is often inter-observer error when 
measuring swollen joint counts, so in trials ideally the same person should assess 
swollen joint counts on each visit.  
 
A tender joint in RA is defined as a joint where pain is felt either at rest when 
pressure is applied by an assessor, or by movement of a joint or by questioning about 
joint pain. The amount of pressure applied by the assessors thumb and index finger to 
the joint should be sufficient to turn the assessor’s nail bed ‘white’. There is less 
inter-observer error in assessing tender joints in RA patients. Classically an active 
inflamed joint in RA is both swollen and tender, however, in routine practice some 
patients will have some swollen joints which are not tender and conversely and 
perhaps more commonly some patients will have significantly more tender joints 
than apparent swollen joints. The cause of the discrepancy between swollen and 
tender joints is not clear; some have suggested that in those patients with large 
number of tender joints this may be due to the coexistence of fibromyalgia, so called 
‘fibromyalgic RA’ [Wolfe et al. 2004]. 
 
Several indices measure swollen and tender joint counts. These differ in the joints 
assessed and some also grade the amount of tenderness in a joint. The most 
commonly used are the American College of Rheumatology (ACR) extended 66/68 
counts for swollen/tender joints, the Ritchie Articular index [Ritchie et al. 1968] and 
the reduced 28 joint count [Fuchs et al. 1989]. As there seems to be no advantage in 
measuring large numbers of joints the reduced 28 joint count is becoming the most 
widely used method of joint count (Figure 1.1). 
 
ACR 66/68 Joint Count 
Upper Limb: 
Temporomandibular (n=2), sternoclavicular (n=2), acromioclavicular (n=2), shoulder 
(n=2), elbow (n=2), wrist (n=2), metacarpophalangeal (n=10), interphalangeal of the 





Hip (n=2), knee (n=2), ankle mortise (n=2), ankle tarsus (n=2), metatarsophalangeal 
(n=10), interphalangeal of great toe (n=2), proximal/distal interphalangeal joints 
(n=8). 
Joint tenderness is assessed as being present or not. The 66 joints to be examined for 
swelling are the same as those examined for tenderness, except the hips joints are 
excluded.  
 
The Ritchie Articular Index (RAI) 
Upper Limb 
Temporomandibular (treated as a single unit), cervical spine, sternoclavicular 
(treated as a single unit), acromioclavicular (treated as a single unit), shoulder (n=2), 
elbow (n=2), wrist (n=2) metacarpophalangeal (each side treated as a single unit) and 
proximal interphalangeal joints (each side treated as a single unit). 
 
Lower Limb: 
Hip (n=2), knee (n=2), talocalcaneal (n=2), midtarsal (n=2), metatarsophalangeal 
joints (each side treated as a single unit). 
 
Tenderness is graded 0-3 (0 - no tenderness, 1 - patient complained of pain, 2 - 
patient complained of pain and winced, 3 – patient complained of pain, winced and 
withdrew) 
 
The 28 Joint Count 
Upper Limb: 
Shoulder (n=2), elbow (n=2), wrist (n=2), metacarpophalangeal (n=10), 
interphalangeal joints of thumb (n=2) and proximal interphalangeal joints (n=8) 
 
Lower limb: 
Knee (n=2), Tenderness is assessed as being present or not. The same 28 joints are 








The simplicity of the 28 joint count with its lack of grading makes it an appealing 
measure to use in routine clinical practice. Indeed Prevoo et al in 1993 compared a 
number of different joint counts and indices and found little difference in their 
validity and reliability, though indices which included weighting did not perform as 
well. In 1995 Smolen et al compared the 28 joint count with the extended ACR 66/68 
joint count in a prospective study of 735 RA patients. They concluded that the joints 
chosen in the 28 joint count were those most commonly involved in RA and the two 
indices were highly correlated. These studies show that the 28 joint count is the 
preferred method as it is not only as valid and reliable as the 66/68 joint count but is 
also easier and quicker to perform. A potential problem however, with the 28 joint 
count is that the feet are not included and for some patients the feet may be their 





1.2.2. Patient and Physician Global Assessment 
Global assessments, usually in the form of double anchored visual analogue scales 
(Figure 1.2) are widely used in routine clinical practice and clinical trials. There has 
recently been a call to standardise the question asked when assessing patient global 
assessment to ensure a more accurate score. The advantage of a patient global 
assessment is that it is quick and simple to use and score, the disadvantages are that 
scores are often highly correlated with pain visual analogue scores and may not be a 
true reflection of disease activity as the score may also be influenced by RA factors; 
this may be improved by careful explanation to the patient. The physician global 
assessment of disease activity is often not used formally in routine clinical practice, 
but clearly this is automatically taken into account by the physician when making 
treatment decisions as the physician is able to consider the impact of other co 
morbidities. 
 
Figure 1:2 Visual Analogue Assessments 
 
 
1.2.3. Laboratory Measures 
Blood tests are frequently used in the management of RA. Patients often undergo 
regular blood tests as part of DMARD monitoring but they can also be used to 
monitor disease activity as well as help with diagnosis and prognosis. Erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) are commonly used to 
monitor disease activity as valid indicators of inflammation. Their main drawback is 
that they are not specific for RA inflammation and therefore can be influenced by 
concomitant infection or inflammation from a different source. Currently there is no 
specific test to monitor disease activity in RA. Other blood tests that reflect disease 
activity in RA include a rise in other acute phase proteins such as alkaline 






mistake a rise in alkaline phosphatase as a side effect of drug treatment), ferritin, 
platelets and immunoglobulins. Conversely active disease in RA can be associated 
with a reduction in haemoglobin and albumin. 
 
A persistently raised acute phase protein in RA is an important observation to make 
as there is good evidence that these patients have a worse prognosis. There is good 
correlation between raised ESR and CRP with clinical measures, although this is 
predominantly with swollen joint counts rather than tender joint counts [Thompson et 
al. 1987; van Leeuwen et al. 1994]. Continued elevation of ESR and CRP are also 
associated with more rapid radiological progression compared to those RA patients 
with a normal ESR and CRP. This increased radiological progression has been 
shown in both early disease [van Leeuwen et al. 1994] as well as more longstanding 
disease [Hassell et al. 1993].  
 
Although in general acute phase proteins provide a good marker of disease activity in 
RA, some patients may only have small joint involvement which may not mount a 
large enough inflammatory response to be detected and in a small number of patients 
despite evidence of widespread synovitis clinically, there is no significant rise in 
acute phase proteins.  
 
Blood tests useful in the diagnosis and prognosis of RA include rheumatoid factor 
and the more recently described anti-cyclic citrullinated peptide (anti-CCP) 
antibodies. Rheumatoid factor is an immunoglobulin directed against the Fc portion 
of IgG. It is reported as being positive in about 70-80% of RA patients although 
negative results do not rule out disease. [Wolfe et al. 1991] Rheumatoid factor may 
be seen in other rheumatological diseases particularly Sjogren’s syndrome but also 
SLE and non rheumatological conditions such as hepatitis C. Low titres of 
rheumatoid factor can also be seen in the normal population with increasing 
incidence with age in the absence of any pathology. 
 
The need to identify RA patients early led to the development of anti-CCP antibody 
test. Blood tests and x-rays may be normal in up to 60-70% of patients with early RA 
[Emery 1994] and rheumatoid factor has only low sensitivity and moderate 
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specificity in diagnosing RA [van Zeben et al. 1992]. In the last 10 years it has been 
discovered that RA patients develop antibodies to modified
 
(citrullinated) arginine 
residues, and this has resulted in
 
the development of the anti-CCP
 
antibody test, 
which has a sensitivity of 68% and a specificity
 
>97% [Schellekens et al. 2000]. 
Further improvement in the testing method has improved the sensitivity to about 
80% and the specificity >98% [van Venrooij et al. 2002]. It has also been shown that 
35-40% of rheumatoid factor negative patients are anti-CCP antibody positive. Anti-
CCP antibodies also have prognostic implications as studies have shown that they 
along with rheumatoid factor, ESR and female gender are independent predictors of 
radiographic progression. Patients with high levels of anti-CCP antibodies seem 
particularly prone to radiographic progression [Syversen et al. 2008]. 
 
1.2.4. Using Multiple Measures to Assess Disease Activity 
1.2.4.1. Core Data Set 
In RA no single measure is universally appropriate. As there remains no cure for RA, 
treatment aims to reduce symptoms and slow disease progression. Previously clinical 
trials in RA would include different outcome measures to assess response to 
treatment. This made comparing trials and results impossible, therefore there was a 
drive to have a consensus view on a ‘core data set’ of outcome measures which 
should be included in every clinical trial in RA. Both the OMERACT (Outcome 
Measures in Rheumatoid Arthritis Clinical Trials) initiative [Tugwell et al. 1993] and 
EULAR (European league against rheumatism) [Smolen 1992] set up working 
groups to decide on the preferred outcome measures that should included in  the core 
data set.  The outcome measures included in the core data set include measures of 
disease activity (swollen and tender joint counts, patient and physician global 
assessment, pain assessment and acute phase markers), functional assessment (HAQ) 
and radiological assessment of disease progression. (Table 1.6) At the last 
OMERACT meeting there was a call to include more patient centred outcomes in the 
core data set, following this meeting it was agreed that fatigue should be added to the 






Table 1:6 OMERACT and EULAR Core Data Set for RA 
 
Number of swollen joints 
Number of tender joints 
Pain assessed by the patient 
Patient's global assessment of disease activity 
Assessor's global assessment of disease activity 
Laboratory evaluation (ESR, CRP, or equivalent) 
Self administered functional assessment (eg HAQ) 
X-ray assessment for joint damage 
 
1.2.4.2. Composite Measures of Disease Activity 
Composite indices incorporate several outcome variables into one simple 
measurement which has major advantages in both clinical trials and routine practice. 
Several composite measures have been designed over the years dating back to 1958 
(Table 1.7). Two composite measures have been widely incorporated into clinical 
trials (Table 1.8). One is the ACR response criteria which were developed by Felson 
et al to simplify the assessment of response in clinical trials. [Felson et al. 1995] 
They use components of the core data set and involve improvements in both swollen 
and tender joint counts and three out of: patient global assessment, physician global 
assessment, pain, ESR and a functional measure such as HAQ. Improvements can be 
at 20%, 50% or 70% levels (termed ACR-20, ACR-50 and ACR-70 responses). The 
main drawback with the ACR response is that it is categorical and not a continuous 
measure and its primary use is in clinical trials of drug treatments in RA.  
 
The other is the Disease Activity Score (DAS)
 
[van de Heijde et al. 1993]. The initial 
DAS score included a 44 swollen and tender joint count but this has now been 
modified for use with 28-joint counts for tenderness and swelling [Prevoo et al. 
1995], making it simpler to use and it is equally as valid as more comprehensive 
articular indices, which can be time consuming in routine practice.  
 
The DAS28 formula is: 
0.56×√ (TJC28) +0.28×√ (SJC28) +0.70×ln (ESR) +0.014× (PGA).  
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Table 1:7 Composite Disease Activity Scores 
 
Year Authors Main features 
1958 Lansbury EMS, fatigue, aspirin consumption, grip strength, ESR, 
Haemoglobin 
1956 Lansbury and Haut As above plus area weighted articular index 
1981 Mallya and Mace An index of disease activity 
1990 Davis Stoke index 
1990 Van der Heijde DAS 
1990 Stewart The index of disease activity 
1993 Jones  Modified Stoke index 
1995 Symmons Overall status in RA (OSRA) - activity and damage score 
1995 Prevoo Modified DAS  (for 28-joint counts) 
 
The DAS28 gives a continuous measure with lower numbers indicating less disease 
activity. The DAS28 can also be categorised into mild (score ≤3.2), moderate (score 
>3.2 and ≤5.1) and severe disease (score >5.1). Response to treatment can also be 
categorised into no response (improvement≤0.6 and DAS>3.7), moderate response 
(improvement≤1.2 and >0.6, and DAS>2.4 and ≤3.7) and good response 
(improvement>1.2 and DAS≤2.4). The DAS28 has become the most important 
composite measure in the UK as eligibility for biologic therapies depends on severe 
active disease as defined by a DAS28 of >5.1 on two occasions, therefore the DAS28 
is now often measured routinely in clinical practice. Although there have been 
criticisms of the DAS28, particularly for its calculation which puts greater emphasis 
on tender joint counts rather than swollen joint counts, it remains the most widely 
used composite measure in routine clinical practice and currently there appears to be 




Table 1:8 ACR Response Criteria and the DAS28 
 
ACR Response Criteria 
≥20%/50%/70% 
Improvement in: 
Swollen Joint Count 
Tender Joint Count 
Improvement in at least 3 of the following 
 Patient global assessment 
 Physician global assessment 
 Patient pain scale 
 Health assessment questionnaire 
 ESR or CRP 
DAS28 Swollen joint count (28 joints) 
 Tender joint count (28 joints) 
 ESR or CRP 
 Patient global assessment 
Calculated using formula:  
0.56×√(TJC28)+0.28×√(SJC28)+0.70×ln(ESR)+0.014×(patient global assessment) 
 
 
1.2.4.3. Radiological Assessments 
X-rays are used in routine clinical practice to help with diagnosis but also to assess 
disease progression. Several scoring methods to assess the amount of joint damage in 
RA have been employed over the years. Despite simplifying the number of joints 
used to focus on joints most commonly affected in RA the scoring methods remain 
time intensive and are not suitable for routine use [Kaye 1991] but are commonly 
used in clinical trials to determine the reduction in disease progression over time. 
The two x-ray scoring methods widely used are the Sharp scoring method [Sharp et 
al. 1971] and the Larsen scoring method. [Larsen et al. 1979] 
 
The Sharp Score  
In 1971 Sharp [Sharp et al. 1971] first described a scoring method which included 
the hands and wrists. In total 29 areas were assessed for erosions and twenty seven 
areas for joint space narrowing. Erosions were graded 0-5 and joint space narrowing 
graded 0-4. This original scoring method has since been modified several times and 
the original scoring method is no longer used. The modification proposed by Sharp et 
al in 1985 is currently considered the standard for the Sharp method. The modified 
version has been simplified and includes 17 areas for assessment of erosions and 18 
areas for assessment of joint space narrowing again the hands and wrists. Each 
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erosion scores one point up to a maximum of 5 for each area. Joint space narrowing 
is still graded 0-4 with ankylosis of a joint scoring 4 points. Subluxation is not 
scored. In 1986 Fries et al, suggested a further modification, which gives more 
weight to erosions compared to joint space narrowing. Erosions scores are combined 
with the worst joint space narrowing scores from 6 areas. In 1987 Kaye et al, 
proposed a further modification to the Sharp score which included scores for 
dislocation or marked subluxation. Van der Heijde further modified the Sharp score 
in 1999 [van der Heidje 1999] by including feet in the assessment although hands 
had greater weighting because more joints are scored and subluxation was again 
included. 
 
The Larsen Score 
In 1974 Larsen [Larsen 1974; Larsen 1975] first developed a method of scoring 
based on comparison of patients x-rays with a standardised set of reference films. 
The method gives an overall measure of joint damage as the joints are categorised 
into six stages from 0 (normal) to 5, which reflect the gradual progression of joint 
damage. The original method has undergone several modifications between 1977 and 
1995. The six different stages described in the 1977 version [Larsen et al. 1977] are 
as follows: Grade 0 = normal; grade 1 = slight abnormalities (periarticular soft tissue 
swelling and periarticular osteoporosis and slight joint space narrowing); grade 2 = 
definite early abnormalities; grade 3 = medium destructive abnormalities; grade 4= 
severe definite abnormalities; and grade 5 = mutilating abnormalities. Larsen further 
modified the scoring system so as to useful in evaluating x-rays in long term studies. 
The main differences suggested in the 1995 modification were to delete the scores 
for the thumbs and great toes, divide the wrists into four quadrants and a grading 
system for the size of erosions. The grading scale ranges from 0-5 with an overall 




Table 1:9 Larsen Grading System for Erosions 
 
Grade Assessment 
0 Intact bony outlines and normal joint space 
1 Erosion less than 1mm in diameter or joint space narrowing 
2 One or several small erosions (diameter more than 1mm) 
3 Marked erosions 
4 Severe erosions (usually no joint space left and the original bony 
outlines are only partly preserved) 
5 Mutilating changes (the original bony outlines have been destroyed) 
 
 
Scott et al proposed a modification to the grading system of the Larsen score in 1995. 
The changes were to the grades 1-4 with grade 0 and 5 left unchanged; this was felt 
to allow a higher correlation of grade 1 between raters.  
 
Although plain radiographs are still the most common method by which RA 
progression is monitored there are disadvantages including variability of 
radiographic techniques, the difficulty in scoring radiographs despite the systems 
described above and the relative insensitivity of plain radiographs to detect changes 
in early RA. More recently ultrasound (US) and magnetic resonance imaging (MRI) 
have been shown to detect joint damage in RA earlier than plain radiographs and also 
give information regarding synovial thickening and active synovitis. The cost of MRI 
makes regular serial scans an unviable option in many cases; ultrasound (US) 
however is much cheaper and has been shown to correlate well with MRI in RA. The 
disadvantage of US is that it is operator dependent. 
 
 
1.3. QUALITY OF LIFE IN RHEUMATOID ARTHRITIS 
It is important to consider quality of life in RA as it is a chronic disease with no cure. 
RA can impact on many different aspects of life. It has physical impacts such as pain, 
fatigue and ultimately disability but it can also have an impact psychologically 






1.3.1.  Pain 
Pain remains the major concern for most patients with RA. Its persistence is an 
important negative consequence of disease. Although controlling pain is one 
indication of successful treatment, the majority of RA patients have significant 
amounts of pain despite therapy. Patients consistently rate pain as their most 
important symptom. [Heiberg et al. 2002] Other than drug studies looking at the 
effect of reducing inflammation, there are few studies which have specifically looked 
at pain pathways and the cause of chronic pain in RA patients. [Lee 2013] 
 
Despite pain being a dominant symptom in RA it is not routinely measured and is not 
part of commonly used composite measures that assess RA such as the DAS28. The 
most common way of measuring pain is the double anchored 100mm visual analogue 
scale (VAS), labelled ’No pain at all’ at one end, and ’Pain as bad as it could be’ at 
the other end. The VAS was first developed in rheumatology in 1974 by Huskisson 
et al and takes only a few seconds to complete. The pain VAS is part of the 
American College Rheumatology (ACR) and EULAR/OMERACT core data set 
[Felson et al. 1993; van Gestel et al. 1996]. 
 
The verbal rating scale (VRS) is another simple measure which has been shown to 
correlate strongly with the VAS [Tugwell et al. 1992] The VRS consists of words 
which describe the severity of pain – such as ‘none’, ‘mild’, ‘moderate’, ‘severe’ and 
‘extreme’.  This is not as widely used as the VAS although one study has shown that 
certain patients may prefer this to the VAS [Clark et al. 2003]. 
 
There are other more detailed pain questionnaires available which have been used in 
clinical studies and add much to the understanding of pain in RA. Their place in 
routine clinical practice is limited by the amount of time needed to complete the 
questionnaires. The McGill pain questionnaire [Melzack 1983] has 102 words in 20 
categories and patients are asked to circle words that describe their current pain. The 
complete McGill pain questionnaire also has a diagram so that patients can indicate 
the location of their pain. There are also questions relating to the intensity of pain 
and how it changes with time. Although this questionnaire provides detailed 
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knowledge and insight into the pain experienced in RA it takes at least 15-20 minutes 
to complete. Even the short version of the questionnaire [Melzack 1987] is too long 
to use in routine clinical practice but is useful in the research setting. The rheumatoid 
arthritis pain scale (RAPS) was designed specifically to measure pain in RA 
[Anderson et al. 2001]. This 24 item questionnaire has 4 domains and is measured 
using a seven-point Likert scale. Like the McGill questionnaire, RAPs provides more 
information than the VAS but its use is limited to specialised clinical studies.   
 
1.3.2.  Fatigue 
Fatigue is common in rheumatoid arthritis (RA) and its absence characterises disease 
remission [Pinals et al. 1981]. Qualitative studies have highlighted the importance 
people with RA attribute to fatigue and RA patients believe reducing fatigue should 
be a key treatment aim [Carr et al. 2003; Ahlman et al. 2005] and patients regard 
fatigue as a major determinant of their quality of life [Rupp et al. 2004] and disability 
[Scott et al. 2005].  Between 40-80% of RA patients attending specialist clinics have 
clinically relevant fatigue, which is a feature of active disease. [Belza 1995; Belza et 
al. 1993; Pinals et al. 1981; Wolfe et al. 1996] By contrast few cases (under 5%) are 
in remission [Balsa et al. 2004], in which there is no fatigue. These observations 
suggest disease activity is one underlying factor, in the pathogenesis of fatigue in 
RA. Surprisingly the ways in which disease activity influence RA fatigue has not 
been investigated to any extent. However, interest in this issue has been stimulated 
by a large randomised controlled trial (RCT) of adalimumab, an anti-TNF agent, 
which significantly reduced fatigue in RA [Weinblatt et al. 2003]. The improvement 
in fatigue was associated with falls in disease activity, providing the best evidence 
yet that inflammatory synovitis is a potentially important causal factor for RA 
fatigue. There is relatively little data on whether conventional disease modifying 
anti-rheumatic drugs (DMARDs) reduce fatigue. Only one RCT has looked at this to 
any extent. It compared leflunomide with methotrexate and showed both DMARDs 
improved SF-36 energy and vitality scores, which are equivalent to fatigue measured 
with specific instruments [Strand et al. 2005]. 
 
Several other factors influence RA fatigue, including psychosocial factors, health 
beliefs, illness perceptions and poor social support [Huyser et al. 1998; Riemsma et 
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al. 1998]. Fatigue also has strong relationships to pain and depression [Belza 1995; 
Belza et al. 1993; Wolfe et al. 1996; Huyser et al. 1998; Riemsma et al. 1998; Rupp 
et al. 2004; Tack 1990; Fifield et al. 1998; Wolfe et al. 2004; Suurmeijer et al. 2001; 
Fifield et al. 2001; Crosby 1991; Jump et al. 2004]. These inter-relationships led 
Wolfe to coin the term "fibromyalgic RA" to describe the sub-set of patients with 
high levels of fatigue, pain and depression [Wolfe et al. 2004]. Previous studies have 
also shown that high fatigue scores are associated with greater levels of disability 
[van Hoogmoed et al. 2010]. This finding might be explained by fatigue being a 
marker of disease activity. Alternative explanations for the relationship of fatigue to 
disability include the interaction of fatigue with psychological symptoms or perhaps 
a more direct link to disability.   
 
Despite these findings fatigue is not routinely measured in clinical practice or in 
studies. Also, there is no agreement on the most appropriate measure of fatigue in 
RA, but the most commonly used instrument is the VAS. Like the pain VAS it 
usually takes the form of a double anchored 100mm scale, labelled with ‘No 
tiredness’ at one end and ‘Absolutely no energy at all’ at the other end. This is a 
simple and easily reproducible method of measuring fatigue but does not capture the 
multidimensionality of fatigue in RA.  
 
1.3.2.1. Measuring Fatigue in Rheumatoid Arthritis 
There are a number of multidimensional instruments available that measure fatigue 
but no consensus on the most appropriate instrument to use in RA. Most 
multidimensional instruments were designed for use in other chronic illnesses but 
have been applied to RA. Two of these measures have been validated in RA. The 
first of which is the multidimensional assessment of fatigue (MAF) [Belza et al. 
1993]. This is a 16 item scale with 4 domains; severity, distress, degree of 
interference of daily living and timing. 
 
The other validated instrument is the functional assessment of chronic illness therapy 
–fatigue scale (FACIT-F) [Cella et al. 2005], which has 13 questions with 4 domains; 
general, physical, mental fatigue and vigour. Other multidimensional instruments 
that have been used include an instrument developed for cancer (the MFSI) [Stein et 
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al. 1998], the Chalder fatigue scale [Chalder et al. 1993], and the fatigue symptom 
inventory [Hann et al. 1998]. Generic health measures such as the SF-36 which can 
be used in any disease also have subscales (energy and vitality) that measure fatigue, 
though these are less specific. There are no reported head to head comparisons of all 
these instruments.  However, Wolfe [2004] has shown that in RA the VAS performs 
well in comparison to the MAF, energy and vitality scale of the SF-36 and brief 
fatigue inventory, in terms of sensitivity to change and correlation with clinical 
variables. 
 
These patients had substantially worse quality of life. Clearly further work focusing 
specifically on fatigue in RA is needed, specifically, to determine the most 
appropriate instrument. 
 
1.3.3. Fibromyalgic Rheumatoid Arthritis 
Rheumatoid arthritis (RA) spans several distinct clinical phenotypes. One of these 
includes coexisting fibromyalgic features; this phenotype has been termed 
“fibromyalgic RA” [Scott et al. 2007]. Very little research has been done in this area 
but Wolfe and colleagues [Wolfe et al. 1984; Wolfe et al. 2004] have highlighted its 
importance and concluded that in their cohort of 11,866 RA patients approximately 
17% had fibromyalgic features. Fibromyalgia was detected using a regional pain 
scale and a fatigue VAS. These patients had more comorbidities, greater 
sociodemographic disadvantage, more severe symptoms, higher HAQ levels and 
worse quality of life than RA patients without fibromyalgic features. Clearly further 
work needs to be to determine whether this RA subtype does indeed exist; using 
objective measures such as tender points rather than just subjective scores. 
 
The high pain and disability scores that are seen in fibromyalgic RA suggest that 
these patients will also have high scores using summative assessments such as the 
Disease Activity Score for twenty-eight joints (DAS28) which includes assessments 
of tender joint counts, swollen joint counts, ESR and patient’s global assessments. 
This perception is supported by previous research that shows DAS scores are often 
high in patients with fibromyalgia without RA [Leeb et al. 2004]. In this context 
DAS28 scores of 5.1 or more are considered indicative of active disease. DAS scores 
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are particularly important in treatment decisions about disease modifying anti-
rheumatic drugs (DMARDs) and biologics [Meyer et al. 2007; Fautrel et al. 2008]. If 
DAS scores are disproportionately high in relation to the level of inflammatory 
synovitis in fibromyalgic RA, the value of DAS assessments in these patients is open 
to question. This is a particularly cogent issue as a recent study of fibromyalgic RA 
by Coury et al suggested DAS28 over-estimated disease activity in these patients 
[Coury et al. 2009]. 
 
1.3.4.  Psychological Impacts 
Depression, which is often associated with high levels of fatigue, has been identified 
as a problem for a large proportion of patients with RA [Zautra et al. 1994] and some 
studies have suggested that depressive symptoms are present in 25% or more of 
patients [Frank et al. 1988]. Many patients also have high levels of anxiety 
[VanDyke et al. 2004]. Depression has been shown to be associated with reduced 
health status, as well as higher pain and fatigue levels and reduced quality of life 
[Katz et al. 1993]. RA often causes chronic pain and the effects of chronic pain on 
patients' physical, psychological and social functioning are widely recognised 
[Anderson et al. 1985]. Factors other than pain have also been found to be important 
in psychological adjustment in patients with RA. Specifically social support is 
particularly significant in adjustment to RA given the limitations that physical 
disability may create. Social support has been found to minimise the effects of 
physical limitations resulting from RA [Doeglas et al. 1994; Goodenow et al. 1990]. 
The situation is further complicated by RA patients with a pre-existing history of an 
affective disorder such as depression; who have higher levels of fatigue and ill 
health, with self-efficacy playing an important mediating role in this relationship 
[Jump et al. 2004]. In early RA, if there are baseline symptoms of depression or 
anxiety, fewer patients achieve clinical remission compared with patients without 
these conditions. However, in early RA, patients who achieve DAS28 clinical 
remission experience an improvement in depression and anxiety symptoms [Kekow 
et al. 2011].  
 
There are many different instruments that have been designed to assess depressive 
symptoms, such as the Hospital Anxiety and Depression score [Zigmond et al. 1983] 
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and the Beck Depression Inventory [Beck et al. 1961]. Despite the fact that these 
symptoms are common in patients with RA, they are very rarely documented or 
assessed in clinical practice and are only assessed in specialised studies. 
 
Pain and disability inevitably affect patients’ psychological status and general feeling 
of well-being. Although there is no evidence that patients have primary 
psychological disturbances, chronic illness may cause substantial long-term 
psychological effects. In a large study by Polsky et al in 2005 they examined the risk 
of developing significant depressive symptoms following a new diagnosis of a 
chronic illness over a six year period. In all illnesses there was a high risk of 
depressive symptoms developing in the first two years after diagnosis, although the 
risk decreased after this period. However, in patients with arthritis there was a 
significantly higher risk of developing depressive symptoms 2-4 years after 
diagnosis. 
 
Comparative studies of different chronic diseases show that psychological 
functioning contributed to overall quality of life for all disorders, whereas physical 
and social functioning contributed in only some diseases [Arnold et al. 2004]. The 
relationship between disability and psychological morbidity is thus relatively specific 
for RA. Interestingly illness perceptions, which are an individualistic view of 
disease, may be key factors in determining the impact of RA [Groarke et al. 2004], 
according to the results of a small study of 75 women with RA. Depression was 
found to be associated with high use of coping by denial and with less frequent use 
of active coping, planning and seeking instrumental social support. It appears that 
illness perceptions have significant implications for adaptation to illness and 
outweigh the impact of medical disease status on depression, physical function and 
pain.  
 
A recent EULAR initiated study has finalised and validated a patient derived 
composite measure of impact of RA [Gossec et al. 2011]. The rheumatoid arthritis 
impact of disease (RAID) score, takes into account pain, functional capacity, fatigue, 
physical and emotional wellbeing, quality of sleep and coping. Further studies are 




1.3.5.  Disability 
The increasing focus on patients’ perspectives of their health [Heiberg et al. 2005; 
Kirwan et al. 2003] has resulted in an increasing interest in using health status 
measures to capture patients’ views on their disease [Scott et al. 2000]. Disability in 
RA is usually measured with self-assessment questionnaires. Most clinicians use 
disease-specific measures, such as the Health Assessment Questionnaire (HAQ) 
[Wolfe 2000] or the Arthritis Impact Measurement Score (AIMS) [Meenan et al. 
1980]. Alternatively, there are generic measures such as the SF-36 [West et al. 2005], 
the Nottingham Health Profile (NHP) [Uutela et al. 2003] and the EQ-5D [Picavet et 
al. 2004]. Although disease-specific measures are often preferred, generic measures 
can be used to compare across different diseases [Stavem et al. 2000], and have been 
shown to detect changes in early disease [Soderlin et al. 2004]. There is still no 
consensus on the best overall measure of quality of life in RA and new measures 
continue to be devised [Currey et al. 2003]. However, it would seem sensible to use a 
disease specific-measure in RA as generic measures can be insensitive with 
significant floor and ceiling effects. Although the AIMS questionnaire is disease 
specific it is somewhat complex to use and therefore has not been widely adopted. 
The HAQ has become the most widely used instrument and is relatively easy to use 
taking only a few minutes to complete and to score.  
 
1.3.5.1. Health Assessment Questionnaire 
The HAQ assesses disability in eight domains; dressing, arising, eating, walking, 
hygiene, reach, grip and common activities. There are twenty questions over the 
eight domains with four possible answers; without any difficulty, with some 
difficulty, with much difficulty, unable to do. Each of the disability items has a 
companion aids or devices variable, which is used to document whether the patient 
requires the assistance of a device and or the assistance of another person to perform 
each task. The HAQ can be seen in the appendix. 
 
There are a number of variations to the original HAQ score, including the shortened 
modified HAQ [Pincus et al. 1983] and the shortened RA-HAQ, a study by Wolfe 
[Wolfe et al. 2001] of 2,491 clinic patients with RA with active disease showed the 
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conventional HAQ is better at detecting treatment change, and identifies the extent of 
functional disability better than the shortened questionnaires. The benefits of the 
MHAQ and RA-HAQ are that they are short and easier to score but this comes at a 
price, which is loss of sensitivity and loss of sensitivity to change.  
 
An alternative termed the HAQ-II, which involves 10 items, has also been 
developed. This has been studied in 14,038 RA patients with rheumatic disease over 
a 2-year period [Wolfe et al. 2004]. It is reliable, has a longer scale than the 
conventional HAQ, and may therefore be better equipped to avoid floor and ceiling 
effects. Conversion from HAQ to HAQ-II and from HAQ-II to HAQ for research 
purposes is simple and reliable. [Anderson et al. 2010] The HAQ-II can be used in all 
places where the HAQ is now used, and it may prove to be easier to use in the clinic. 
Another modification of the HAQ is the multidimensional HAQ (MDHAQ), 
developed and validated on 688 patients by Pincus et al in 1999. One of the problems 
of the MHAQ and HAQ as mentioned above is the floor effect. The MDHAQ by 
adding 6 advanced questions on activities of living (ADL) to the 8 ADL included on 
the MHAQ aimed to overcome this floor effect. Whereas patients may report no 
problems performing simple tasks, they may experience difficulty performing 
advanced tasks. Also psychological items which assess depression, anxiety and poor 
sleep which are included may be used to screen for these common problems. The 
MDHAQ has been subsequently revised [Sokka et al. 2005] and the number of ADL 
items reduced to 10 items. This was found to provide similar information to the 14 
item MDHAQ but to be more easily completed. The MDHAQ is a simple 2-page 
questionnaire that could be completed at every clinic visit and takes only seconds to 
score. It may be that the HAQ-II and MDHAQ will become more widely used over 
the next few years. 
 
Another simplification in HAQ scores that has been suggested is using visual 
analogue scales to assess function. Wolfe and Michaud [Wolfe et al. 2005] studied 
394 RA patients comparing HAQ, the HAQ-II, and a visual analogue functional 
scale. They found that the distribution differences between HAQ and HAQ-II and the 
VAS-F suggest that patients do not see minor limitations as problematic, but rate 
major limitations as being particularly limiting and worthy of high ratings. They 
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concluded that a visual analogue functional scale, which represents a patient-
weighted functional assessment in which additional interpretation is given to the 
meaning of the limitations by the patient, may be suitable for use in the clinic and in 
research.  
1.3.5.2. Arthritis Impact Measurement Scales 
The Arthritis Impact Measurement Scales (AIMS) were developed by Meenan et al 
in 1980; they are a combination of pre-existing instruments such as the Rand Health 
Insurance Study Scales and the Quality of Well Being (QWB) scale and newly 
created health status scales which assess physical, emotional, and social well-being 
in nine dimensions: mobility, physical activity, activities of daily living, dexterity, 
household activities, pain, social activity, depression and anxiety. [Meenan et al. 
1980] These nine dimensions can be combined to form three major health status 
components: physical function, psychological status and pain. A further 21 questions 
define general health, the patients' health perceptions, overall impact of arthritis, 
medication intake, co-morbidity and demographic data. The questionnaire takes 
approximately 15-20 minutes to complete and shorter versions exist and the original 
questionnaire has been ‘anglicised’ for use in the UK and has been extensively 
validated and translated into several different languages. 
 
1.3.6. Generic Measures of Quality of Life 
There are a number of different generic measures which have been designed to 
measure quality of life. The questionnaires capture different aspects of quality of life 
and as they are generic can be used in different diseases. 
 
1.3.6.1. SF-36  
The SF-36 [Ware et al. 1992; McHorney et al. 1993] is the most widely used generic 
measure of health status. [Garratt et al. 2002] The SF-36 can be self-administered or 
with the use of an interviewer. It can be completed in 5-10 minutes and has been 
applied to large populations in a number of countries and to patients with a variety of 
illnesses of all age groups. There are 36 questions in the SF-36, these items are 
grouped into 8 scales; physical functioning (PF), role-physical (RP), bodily pain 
(BP), general health (GH), vitality (VT), social functioning (SF), role-emotional 
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(RE) and mental health (MH). There are 2 summary measures which aggregate the 8 
scales; Physical Health (PF, RP, BP, GH) and Mental Health (VT, SF, RE, MH). All 
but one of the 36 items are used to score the 8 SF-36 scales. Each item is used in 
scoring only one scale. These 8 scales were selected from the 40 used in the Medical 
Outcomes Study, those chosen were felt to represent the most frequently measured 
concepts in widely-used health surveys and those most affected by disease and 
treatment. A shortened version of 12 items (SF-12) [Hurst et al, 1998] has been 
developed but due to less precise scores can only really be used in large studies and 
also provides less information on health status and outcomes than the SF-36.  
 
There have been many previous studies of SF-36 profiles in RA. Ruta and colleagues 
[Ruta et al. 1998] reported that in 233 patients with RA the SF-36 scales were 
reliable, correlated with core disease activity measures and were responsive to 
improvements in health. Birrell and colleagues [Birrell et al. 2000] studied 86 RA 
patients attending specialist clinics and found that impairment of health status was 
moderate to marked by the SF-36, with significant differences from population 
norms and chronic disease states such as low back pain. They concluded that it is a 
practical tool for use in patients with RA.  
 
1.3.6.2. Nottingham Health Profile 
Although the NHP was initially designed as a 2-part questionnaire, only the first part 
is widely used as part 2 is not applicable to all responders. Part 1 which is commonly 
used consists of 38 statements which are grouped into 6 subscales; physical mobility, 
pain, sleep, emotional reaction, social isolation and energy. These statements were 
generated from large surveys of the general population. Each question has a yes or no 
answer, each being weighted according to perceived severity. There are a number of 
problems when using the NHP. Each statement has a simple yes or no question, 
limiting the subjects’ response; the method of weighting the severity of items can 
give confusing results. There are also problems with floor and ceiling effects, 
improvements in those with minor ailments who started with a zero score may not be 
detected, those subjects who score maximally on an item will continue to have the 




There have also been a number of previous studies of the NHP. Houssien and 
colleagues [Houssien et al. 1997] reported high scores for pain, physical mobility and 
energy level sections, and also considerable distress levels for sleep and emotional 
reactions. There were moderate associations between NHP scores and disease 
activity measures, including the number of tender and swollen joint. Not all studies 
found an impact on sleep and emotional reaction. For example, Uutela and 
colleagues [Uutela et al. 2003] evaluated 99 RA patients and found that NHP scores 
for mobility, pain and energy were very different from control values but sleep, 
emotional reaction and social isolation were similar between RA patients and 
controls. The association between abnormal NHP scores and disease activity is 
shown in all studies and was most recently confirmed by Sivas and colleagues [Sivas 
et al. 2004], who reported that in 100 RA patients all subgroups of the NHP 
significantly correlated to pain and the articular index, but not with C-reactive 
protein levels. 
 
1.3.6.3. EuroQol and Others 
In view of new and increasingly expensive treatments for RA, clinical studies often 
include economic evaluation in the form of cost-utility analysis. In this method a 
utility is used
 
as a global, health related quality of life measure. A utility being the 
preference of patients for given states of health. It is expressed as a value between
 
0 
(equal to death) and 1 (equal to full health). Thus, living
 
1 yr with a utility of 0.5 is 
equal to living half a year in
 
full health. The three most widely used methods of 
utility measurement are the standard gamble (SG), the time trade off (TTO), and the
 
VAS. [Sakthong 2008] With the SG,
 
the respondent is asked to make a choice 
between two options.
 
The first option is the certainty of living with a certain illness 
for the rest of one’s life. The other option is a gamble with two possible outcomes, 
living for the rest of one's life
 
in perfect health or immediate death. The chances in 
the gamble
 
are varied to determine the point at which a subject is indifferent
 
about 
the choice between the certain option and the gamble. The TTO asks the subject to 
value health states in terms of
 
duration of life in a state of perfect health that would 
be equivalent
 
to some period with a particular illness such as their own. In large 
populations,
 
descriptive instruments such as the EuroQol (EQ-5D) are used. 




The EuroQol is available in English and many other European languages. It is a 
validated quality of life questionnaire which has five questions based on mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression, with
 
three levels 
of answers (no/some/severe problems). From these five questions, descriptive health 
states were derived and assessed using TTO/SG to create a social tariff.  
 
1.4. QUALITY OF CARE IN RHEUMATOID ARTHRITIS 
The focus of patient care, particularly in those people with chronic illness has 
recently shifted from recording simple outcomes to focusing specifically on the 
quality of care provided within the National Health Service (NHS) in the UK.  
 
A number of UK national bodies and groups have reported on the components of 
quality care for people with rheumatoid arthritis (RA). Key recent reports have been 
published by the NICE [NICE clinical guideline 2009], the National Audit Office 
[National Audit Office, 2009] and the King’s Fund [Stewart et al. 2009]. These built 
on earlier reports from ARMA [ARMA Standards of Care 2004] and BSR guidelines 
[Kennedy et al. 2005]. These reports overlap with the new focus on quality care 
throughout the National Health Service (NHS) [Department of Health 2006] [Darzi 
2008].  
 
NICE guidance from 2009 [NICE clinical guidance 79] clearly state that patient 
centred care should be at the heart of RA management. NICE reviewed many 
observational and qualitative studies [Bath et al. 1999; Carr et al. 2003; Iaquinta et al. 
2004; Jacobi et al. 2004; Kjeken et al. 2006; Neame et al. 2005; Ward et al. 2007; 
Williams et al. 2007; Wolfe et al. 2007; Barlow et al. 1999; Lempp et al. 2006] and 
determined that the areas of care most important to patients were knowledge of RA, 
information about medications, good communication and access to practitioners 
between appointments. The areas of care that RA patients deemed inadequate were 
the lack of a multidisciplinary team approach with different team members not 
having access to their files, lack of care coordination between team members; limited 
contact with providers of care; lack of continuity of care; lack of social support and 
to be more involved in treatment decisions. 
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If true patient centred care is to be established it will be important to identify any 
barriers that may exist in the current system that prevent this. Deficiencies can be 
identified using existing standards of care such as ARMA standards of care [ARMA 
2004]; these deficiencies may be relevant on a national level but equally may be 
specific to certain areas. This is best done by engaging with RA patients as well as 
providers of care using both qualitative and quantitative measures.  
 
1.4.1. Standards of Care  
The Arthritis and Musculoskeletal Alliance (ARMA) is a UK umbrella association 
that brings together a number of organisations that range from patient support groups 
to national professional bodies and major research organisations in the field of 
arthritis and other musculoskeletal conditions. At present ARMA has twenty-eight 
member organisations but is always looking to expand.  
 
The mains aims of ARMA are to raise the awareness of arthritis and other 
musculoskeletal conditions and highlight the need for high quality services in these 
areas. ARMA also promotes the development of treatment, prevention and 
rehabilitation. ARMA promotes co-operation, understanding and mutual support 
between all individuals and organisations concerned with these conditions. In view 
of its diverse membership it also provides an ideal forum for the exchange of ideas 
and information.  
 
Although the Department of Health has produced a musculoskeletal framework it is a 
generic tool for all musculoskeletal conditions and not specific for RA. [Department 
of Health Musculoskeletal Services Framework 2006]. ARMA, however, has devised 
and published UK standards of care for a number of conditions. ARMA initially 
published guidance on inflammatory arthritis, osteoarthritis and back pain. [ARMA 
standards of acre 2004] Since then they have published standards of care for people 
with connective tissue diseases, metabolic bone disease and regional musculoskeletal 
pain. [ARMA standards of care 2007] 
 
The standards of care emphasise the key mechanisms, which ensure people with 
musculoskeletal conditions get the best healthcare possible. They also however, 
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touch upon some of the other factors that affect people with musculoskeletal 
conditions such as social support and the effect on their families. 
 
The core aims of the standards of care are to: 
 Improve the quality of life for people with musculoskeletal conditions 
 Identify the care people with musculoskeletal conditions can expect 
 Enable the NHS to improve resource management by preventing avoidable 
disability, so reducing return GP and hospital appointments 
 Promote consistent, evidence-based approaches to advice, prevention and 
treatment 
 Improve productivity and reduce the benefits bill, where appropriate, by 
supporting people to remain economically active.  
 
The standards of care for people with inflammatory arthritis were devised after 
consultation with a range of stakeholders, and were welcomed by the Secretary of 
State. The standards define the services needed across three broad themes.  
 Access to information, support, and knowledge. The key components are the 
general promotion of musculoskeletal health, providing guidance on self-
management and when to seek advice, and offering information on services, 
treatments and providers. 
 Access to the right services that enable early diagnosis and treatment. The key 
components are early access for diagnosis, the assessment of needs, the use of 
evidence-based care, preparing individualised care plans, supporting patients to 
remain in or return to work, and involvement of people with inflammatory 
arthritis in the development of services for their care. 
 Access to ongoing and responsive treatment and support. The key components 
are the presence of multi-disciplinary teams, ensuring patients are involved in 
self-management, delivering annual specialist reviews, giving continued access 
to medical care, surgical care and rehabilitation and support. 
 
1.4.2. Measuring Patient Satisfaction 
Patient satisfaction has become an important part of the National Health Service 
(NHS) in the UK. This has been highlighted with the publication the ‘Darzi report – 
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High Quality for All 2008’ which puts quality of care for patients at the heart of new 
policy for the NHS. Measuring patient satisfaction has been written into GP 
contracts. Patient satisfaction is affected by every part of the patient pathway, 
including waiting times, environment and the consultation itself and its outcome. 
Patient satisfaction can be measured anecdotally or systematically by questionnaires. 
In order to improve satisfaction, patients’ views over a number of specific issues 
need to be obtained, which is most easily done with multi-item questionnaires. The 
results of such questionnaires can then be used to develop and improve services, for 
the benefit of service users.   
 
Many different patient satisfaction questionnaires exist which can be specific, such 
as measuring satisfaction with a particular treatment or intervention or more general 
such as the practice accreditation and improvement survey (PAIS) [Greco et al. 
2001], which gives an overall view of a practice and its healthcare professionals and 
is commonly used in general practice. In 1992 Hill et al designed the Leeds 
Satisfaction Questionnaire which was specifically designed to measure RA patients’ 
satisfaction with outpatient rheumatology services. Tijhuis et al in 2003 designed a 
patient satisfaction questionnaire for patients with RA receiving outpatient clinical 
nurse specialist care, inpatient care, or day patient team care. 
 
Leeds Satisfaction Questionnaire  
The Leeds Satisfaction Questionnaire was developed to measure satisfaction amongst 
patients attending a rheumatology outpatient clinic. It is self-administered 
questionnaire with 45 statements; possible responses are on a 1 to 5 scale ranging 
from “strongly agree” to “strongly disagree”.  The domains included in the 
questionnaire are listed below. Satisfaction with each individual domain can be 
calculated and also the results can be combined to give an overall measure of 
satisfaction. 
 
 General satisfaction 
 Giving of information 
 Empathy with the patient 
 Technical quality and competence 
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 Attitude towards the patient 
 Access and continuity 
 
Tijhuis Satisfaction Questionnaire 
The Tijhuis satisfaction questionnaire was designed to capture satisfaction with more 
complex multidisciplinary care that is often provided for RA patients. The 
questionnaire has 28 items with 8 domains, which were felt to be the most important 
according to RA patients’ perception of quality of care and are listed below. 
 
 









1.4.3. The Use of Qualitative Research 
Unlike quantitative research which relies on statistics and numbers, qualitative 
research analyses unstructured information; which can be anything from transcripts 
of individual interviews to emails and videos. Qualitative research is used to 
understand people’s beliefs, attitudes, behaviours and the reasons behind them. 
Because of the in depth information that is needed in qualitative research, smaller 
samples in general are needed compared to quantitative research. 
 
Until the 1970’s the term ‘qualitative research’ was a term used in the study of 
anthropology or sociology; however, qualitative research is now used in many areas 
of research including medical and non-medical sciences as well as in the consumer 




Focus groups and individual interviews are some of the more distinctive and 
common methods used in collecting data in qualitative research.  The focus group 
technique involves a moderator facilitating a small group discussion between 
selected individuals on a particular topic. Both individual interviews and focus 





1.5. RATIONALE FOR RESEARCH  
Medical intervention, particularly early intervention, improves the long-term outlook 
in arthritis [Scottish Intercollegiate Guidelines Network, 2000]. Unfortunately the 
provision of specialist services and access to modern treatments is uneven with many 
parts of the UK having limited specialist services; there is also insufficient training 
for health professionals about the care and support of people with inflammatory 
arthritis [Scott et al. 1998]. This has consequences for individual patients and for 
society more widely. Given the costs of inflammatory arthritis to the NHS and to 
national productivity, it is unfortunate there is no National Service Framework for 
inflammatory arthritis and other musculoskeletal conditions. This lack of priority 
status is also reflected in the fact that these conditions are omitted from the Quality 
and Outcome Frameworks of the General Practitioners’ (GPs) General Medical 
Services (GMS) contracts. 
 
Despite the established and successful “medical model” of care in specialist clinics, 
many ARMA Standards are not met in Lambeth and Southwark. Partly this is 
because the Standards highlight aspects of care overlooked in conventional clinical 
management; for example patients’ need for help with work. In addition, they 
emphasise aspects of health falling outside the traditional scope of specialist clinics. 
Recent qualitative research by KCL Rheumatology highlighted these issues, 
including patients’ concerns about mobility, fatigue, sleep disturbance and 
psychosocial difficulties, lack of social support and work related problems. In 
addition pain remains a problem for many RA patients and has been shown to be 
linked with general well being, fatigue and disability, despite treatment with 
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DMARDs [Lee et al. 2011]. Many current clinic attendees use alternative therapies 
and additional non-prescribed medication as their pain is insufficiently treated.  
 
The principal limitations of the current services seem to comprise: (a) insufficient 
information for people about inflammatory arthritis and the limited integration of 
care across the primary-secondary care interface; (b) the lack of focus on outcomes 
that are important to patients including fatigue and pain (c) the need for 
individualised care plans that incorporate recommendations over and above the 
treatment of synovitis. 
 
1.6. AIMS AND OBJECTIVES 
The research in this thesis is based on the underlying concept that the clinical 
outcomes of RA will be improved by adopting a more patient-centred model of care 
in place of the current medical model, which mainly focuses on minimising the 
extent and severity of joint inflammation using disease modifying anti-rheumatic 
drugs (DMARDs). This concept provides a theoretical framework on which the 
research has been based; it is not a single hypothesis, because it is impractical to 
devise one or more studies which could test the null hypothesis in a manner suitable 
for it to be rejected.  
 
Delivering such patient-centred care depends on three critical pieces of knowledge. 
Firstly, it is important to understand the limitations of current care, and in particular 
to identify what is not covered in the current approach focusing on controlling joint 
inflammation. Secondly, it is crucial to explore the key additional assessments, 
which could be used to extend the current model of care. Finally, it is essential to 
understand the impact of current care, both in terms of how it has improved 
outcomes over time and also the way in which clinical decisions about treatment 
changes to minimise joint inflammation are currently made. 
 
The research therefore principally addresses identifying those strategies which are 
needed to improve patient centred outcomes in RA. This involves concentrating on 
the following three inter-related aspects of clinical care: 
a. Firstly, identifying the main current challenges for providing patient-centred care. 
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b. Secondly, focusing on patient important outcomes; fatigue and pain. Studies in 
this area are further subdivided as follows: 
 Investigating the assessment of fatigue, a dominant patient-related 
problem and its associated features in treated RA. 
 Investigating the assessment of pain and the effect of concomitant 
fibromyalgia in treated RA,  
 Recognising the close interactions between fatigue, pain and fibromyalgic 
features. 
c. Finally, examining temporal changes in the conventional outcomes of treatment 
in RA and evaluating the way in which current clinical decisions are made about 
the treatment of established RA. 
 
The research focuses on the delivery of specialist care within rheumatology units. It 
does not specifically address alternative models of care, nor does it consider in detail 
the involvement of general practitioners or other specialist services in the treatment 
of patients with RA. These associated but important issues lie outside the topics 
evaluated in this thesis. 
 
1.6.1. Plan of Investigation 
The research assesses current clinical care provided in specialist units using 
quantitative and qualitative methods, investigates patient centred outcomes, 
particularly fatigue and pain and their effects in RA, and examines the ways in which 
clinicians make crucial treatment decisions when managing RA. 
 
1.6.1.1. Assessing Current Performance 
An initial survey of 100 patients will benchmark adherence to ARMA Standards 
evaluating the following: promotion of musculoskeletal health, guidance on self-
management information on services, early access for diagnosis, full assessment of 
needs, evidence-based care, individualised care plans, support at work/disability 
support, involvement of people with arthritis in service development, functioning 
multi-disciplinary teams, self-management, annual specialist reviews, continuing 




Focus groups of patients and healthcare professionals will provide information on 
what patients want and expect from outpatient services and what limitations and 
barriers exist that prevent seamless integrated care. 
 
1.6.1.2. Measuring Satisfaction.  
Satisfaction will be measured using instruments already designed to measure 
satisfaction in RA populations such as those developed by Hill [Hill et al. 1992] and 
by Tijhuis [Tijhuis et al. 2003]. 
 
1.6.1.3. Establishing a Local ARMA Framework 
PCTs, GPs, allied health professionals (physiotherapists, occupational therapists and 
podiatrist), psychologists, orthopaedic surgeons and rheumatologists all need to be 
involved together with patients and their carers. Setting up a local Arthritis and 
Musculoskeletal Alliance (ARMA) network will enable closer working relationships 
between all stakeholders involved in RA care and ensure effective local translation of 
any findings. 
 
1.6.1.4. Focusing On Fatigue and Pain 
Current clinical outcome measures, which reflect the requirements of randomised 
clinical trials for standardised data collection, are too medically focused. From 
previous studies it is clear that pain, fatigue and disability are important outcome 
measures for patients [Lempp et al. 2006]. There has been little work looking at the 
contributors to fatigue in RA and the ways in which disease activity influences RA 
fatigue has not been investigated to any extent. If fatigue is to be used as an RA 
outcome measure, it is essential to investigate further its association with other RA 
outcome measures and it will also be crucial to identify the best assessment 
instrument; VAS fatigue scores are simple and reproducible; however, 
multidimensional assessments may provide a more complete picture and improve the 
understanding of the clinical relationships of fatigue.  
 
Despite substantial improvements in the development of treatments for RA, pain 
remains a major issue for many RA patients. There has been very little research 
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looking at chronic pain in RA and its possible contributors including the existence of 
concomitant fibromyalgia; so-called fibromyalgic RA. 
 
Treatment decisions are now commonly driven by composite disease activity 
measures, specifically the DAS28 in Europe. However, the DAS28 may be driven by 
other subjective patient centred outcomes such as pain. Therefore, further work is 
needed to establish if patient centred outcomes such as pain and fatigue effect disease 









The studies all evaluated patients with RA who met the 1987 American College of 
rheumatology Criteria [Arnett FC et al. 1988] and who were attending specialist 
rheumatology outpatient clinics in South East London, with the exception of the 
ERAN (Early Rheumatoid Arthritis Network) patients who are from a network of 19 
centres across the UK. Due to the ethnic mix within the South East London area a 
higher proportion of patients with afro-Caribbean and Asian descent were seen 
compared to other parts of the UK. For example in the studies in South East London 
the percentage of Caucasian patient ranged between 80-88%, whereas within the 
ERAN patients the percentage was 96%. In South East London Afro-Caribbean, 
patients made up 10-15% of patients while 3-7% were Asian; in the ERAN network 
only 4% were non-Caucasian. The patients included in the study are summarised in 
Figure 2.1. 
 
2.1.2. Obtaining Patients Views 
2.1.2.1. Patient Focus Groups 
Both male and female patients were enrolled with early and late disease of differing 
ages and in different ethnic groups. The appropriate representative number of these 
patients was estimated from the demographics collected from patients in previous 
research studies using this population.  
 
Patients were recruited from the rheumatology outpatient clinic at King’s College 
Hospital. Patients were approached via the rheumatology specialist nurses and 
physicians. The study aimed for six to eight patients in each focus group and six 
patients agreed to take part in each; there was one drop out in the second focus 
group. 
 
2.1.2.2. Health Care Professionals Focus Group 
Health care professionals who are part of the multidisciplinary team which care for 
patients with RA were invited to take part. This included a consultant 
rheumatologist, consultant orthopaedic surgeon (specialist hand surgeon), 
rheumatology nurse specialist, occupational therapist, physiotherapist and podiatrist. 
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All health care professionals were involved in the care of patients at King’s College 
Hospital. 
 
2.1.3. Standards of Care and Satisfaction Survey 
Prospective data were collected from 100 consecutive patients with RA from 
specialist rheumatology outpatient clinics at King’s College Hospital. Eligible 
patients were identified from clinic letters of patients attending rheumatology 
outpatient clinics and blood monitoring appointments. 
 
2.1.4. Fatigue in RA: Patients in Clinical Association Studies 
The study looked at two patient groups. The initial clinical association study assessed 
fatigue using a visual analogue scale (VAS). These patients were attending 
rheumatology outpatient clinics in one of two hospitals; a large university teaching 
hospital and a large district general hospital, both located in metropolitan south east 
London. 
 
All visits entered onto the ‘rheumatoid arthritis database’ at both hospitals between 
January 2003 and July 2004 were included. This consisted of 639 clinic visits from a 
total of 260 patients. For those with multiple clinic visits during this period, only the 
most recent clinic visit data was used. Of the 260 patients, 22 patients had some data 
missing from their visit. These visits were therefore not included in the analysis. The 
data from the remaining 238 patients’ visits were analysed. 
The second clinical association study (alternative measure study) also used the 
vitality scale of the SF-36 as an alternative measure of fatigue.  
 
2.1.5. Fatigue in RA: Patients in Treatment Effects Studies 
2.1.5.1. Early RA 
Data collected from patients enrolled in the early rheumatoid arthritis network 
(ERAN) were used for the early rheumatoid arthritis study. ERAN is a national 
network of rheumatologists following outcomes in patients with RA for less than two 
years at enrolment. There are 19 centres across the UK and Ireland and standardised 
information is collected on case report forms at first presentation to secondary care, 
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then again at 3 to 6 months, at 1 year and annually thereafter. The choice and 
intensity
 




2.1.5.2. Established RA 
Data were collected from 54 patients receiving DMARDS and 30 patients receiving 
anti-TNF therapy in one rheumatology outpatient department in south east London. 
These patients met the 1987 criteria for RA. Data were collected prior to treatment 
and after 6 months of DMARD therapy and after 3 months of anti-TNF therapy. 
Patients who stopped treatment for any reason were excluded.  
 
2.1.6. Fatigue Measurements Study 
For the fatigue measurements study, data were collected from 105 patients with RA 
as defined by the 1987 ACR criteria, who were consecutive attendees in a routine 
outpatient clinic at King’s College Hospital. The sample comprised 80 females and 
25 males. Their mean age was 60 years (range 24-88); mean disease duration 13 
years (range 0.1-54) and 70% were rheumatoid factor positive. 20 patients were 
receiving biologics and 78 patients receiving single or combination disease 
modifying drugs. Their mean DAS28 was 4.53 (SD 1.44) and HAQ 1.49 (SD 0.8).  
 
2.1.7. Initial Fibromyalgic RA and Pain Threshold Study 
For the first part of the study to confirm there is evidence of fibromyalgic RA, 
prospective data were collected from 105 patients with RA as defined by the ACR 
criteria who were consecutive attendees in a routine outpatient clinic at King’s 
College Hospital.  
 
The sample comprised 80 females and 25 males. Mean age was 60 years and mean 
disease duration 13 years. The ethnic grouping of patients recruited into the study 
represented Caucasian, 80%, Afro-Caribbean, 15%, Asian, 3% and Oriental, 2%. At 
the time of assessment, the majority of patients (93 of 105, 89%) were on second line 
therapy. Within this group of 93 patients, twenty patients were on biologic therapy, 
namely adalimumab, etanercept and infliximab. There were 78 patients on single, 
combination and triple DMARD therapy, which comprised 49 on methotrexate, 21 
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on sulfasalazine, 7 on hydroxychloroquine, 17 on leflunomide, 1 on IM-gold and 16 
on prednisolone. In total 85 patients were either on NSAIDs or analgesics or both. 
 
2.1.8. Replicate Fibromyalgic RA Study (Established RA) 
Data collected from patients for a previous study were used in the replicate study. 
These patients were part of a study to design a patient derived disease activity score. 
The patients were attending outpatient clinics at four hospitals in South London. The 
sample comprised 245 females and 76 males.  Mean age was 60 years and mean 
disease duration 9 years. The ethnic grouping of patients recruited into the study 
represented Caucasian, 88%, Afro-Caribbean, 10%, Asian, 7% and Oriental, 0.6%. 
At the time of assessment, the majority of patients (244 of 321, 76%) were on second 
line therapy. Within this group of 244 patients, thirteen patients were on biologic 
therapy, namely adalimumab, etanercept and infliximab. There were 231 patients on 
single, combination or triple DMARD therapy, which comprised 151 on 
methotrexate, 44 on sulphasalazine, 17 on hydroxychloroquine, 12 on leflunomide, 
15 on IM-gold, 10 on azathioprine, 9 on ciclosporin, 12 on D-penicillamine and 42 
on oral corticosteroids. Thirty patients had been given either intra articular or 
intramuscular depomedrone. In total 245 patients were either on NSAIDs or 
analgesics or both.  
 
2.1.9. Fibromyalgic Early RA Study 
Data collected from patients enrolled in the early rheumatoid arthritis network 
(ERAN) were used for the early rheumatoid arthritis study. The sample comprised 
265 females and 130 males. Mean age was 55 years (range 18-88). The ethnic 
grouping of patients recruited into the study represented Caucasian, 96%, others 4%. 
At initiation into ERAN, 378 patients were on single or combination DMARD 
therapy, which comprised 17 patients on hydroxychloroquine, 148 on sulfasalazine, 
173 on methotrexate, 11 on other monotherapy and 29 on combination DMARDs.  
 
2.1.10. Temporal Changes Study 
All patients met the 1987 ACR criteria for RA. They comprised in total 987 patients. 
Data were collected from five different time points; 1997, 2003, 2006, 2008 and 
2010. There were five separate cohorts of patients. All patients were attending 
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rheumatology outpatient departments from two hospitals within South East London, 
either a large teaching hospital or a district general hospital. These patients were 
receiving routine clinical care. 
 
2.1.11. Treatment Changes Study 
The patients in the treatment changes study all met the 1987 ACR criteria for RA and 
were attending outpatient departments in South East London in either a large 
teaching hospital or a district general hospital. Patients were consecutive attendees at 
the rheumatology departments in each hospital. This was a cross-sectional study with 
data collected over a two year span. Patients were receiving routine clinical care. 
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Figure 2:1 Summary Of Participants’ Included In The Study 
 
IDENTIFYING LIMITATIONS OF CURRENT CARE  
RA Patient Focus Group 1 
N=6 
KCH 
 RA Patient Focus Group 2 
N=5 
KCH 
 Healthcare Professionals Focus Group 
N=6 
KCH and Southwark PCT 
 
GP Individual Interviews 
N=13 
Lambeth PCT, Southwark PCT, 
Lewisham PCT 
 Secondary Care Healthcare 
Professional Individual Interviews 
N=15 
KCH, UHL, GSTT 









Standards of Care Survey and Initial Satisfaction survey (Tijhuis) 
N=100 
KCH 
 Second Satisfaction Survey (Hill) 
N=100 
KCH 






FATIGUE IN RA 
Clinical Association Studies 
Initial Fatigue Association Study 
N=238 
KCH 



















FIBROMYALGIC RA AND PAIN THRESHOLDS IN RA 




 Replicate Fibromyalgic RA Study in 
Established RA 
N=321 
KCH, UHL, GSTT, Woolwich 






UNDERSTANDING TREATMENT DECISIONS 
Temporal Changes Study 
N=987 
(1997 – 202; 2003 – 300; 2006 – 105; 2008 – 
71; 2010 – 309) 
KCH, UHL 






* This represents the same group of patients 
§ This represents the same group of patients 
KCH – King’s College Hospital; UHL – University Hospital Lewisham; GSTT – Guy’s and St Thomas’s Trust; Woolwich – Woolwich Hospital 
ERAN Network – A network of British rheumatology departments who collect & monitor clinical details on all early RA patients in a standard way in order to assess outcome in the 
long term on a national basis.  
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2.2. ETHICAL CONSIDERATIONS AND CONSENT 
Ethics Research Committee and Research and Development approvals were obtained 
before the studies began. In accordance with the guidelines of the Ethics Research 
Committee, all participants received patient information sheets (Appendix) before 
deciding whether or not to participate in the studies. All patients signed written 
informed consent forms (Appendix). Patients GPs were also informed of their 
participation in the research. Although four patients who underwent individual 
interviews declined to have their GP informed as they felt their GP to have a lack of 
involvement or interest in their RA care. 
 
Patients were approached within the rheumatology departments of the participating 
hospitals by a member of the clinical team or the researcher. 
 
2.2.1. Ethics Committee Approval 
Ethics Committee Approvals were obtained for each part of the study via the local 
research ethics committee and were registered with the relevant NHS Research and 
Development Committees. 
 
2.2.2. Informed Consent 
Informed consent was taken from patients participating in each part of the different 
studies. The forms can be seen in the appendix. 
 
2.3. ASSESSMENTS AND ANALYSES 
2.3.1. Qualitative Research in Focus Groups 
Qualitative research is used to gain insight into many aspects of people’s lives, 
including their beliefs, concerns and values. Qualitative research has been used in the 
business world and politically to inform decisions and policy. In medical research 
qualitative research is often used to gain insight into health beliefs and as well as 
explore patient experiences. Formal approaches include individual interviews, focus 
groups, but can also include unstructured materials such as feedback forms. Unlike 
quantitative research it doesn’t rely on statistics or numbers but involves content and 




The audio taped focus groups and 1:1 interviews were carried out in private rooms 
using a semi structured interview guide [Britten 1995]. The interview schedules were 
based on related literature [Lempp et al. 2006; Kelly et al. 1996] and the researchers’ 
experiential knowledge. Focus groups and interviews took between one to two hours. 
Interview and focus group information was transcribed verbatim. Each transcribed 
text (interview or focus group) was initially loaded into the NVivo Revision 
computer software [Richards et al. 1999] to manage and organise the volume and 
complexity of the interviews. This qualitative computer software was used to analyse 
and handle the data. The data was examined using content analysis [Hsieh et al. 
2005] where close attention was paid to what the interviewees reported. Secondly 
discourse analysis [Hodges et al. 2008] was applied where the language that patients 
used to describe their experiences was scrutinised e.g. patients trying to please 
medical and nursing staff, descriptions of self-determination or the impact of RA on 
their mental health.  
 
The results are presented with verbatim quotations as well as a summary table to 
highlight the key themes and to help clarify the importance of themes, frequency 
counts have been added where appropriate. Throughout the data analysis simple 
counts are made of key themes or issues, this combination of qualitative and 
quantitative analysis helps assist in the generalisability of the findings. [Seale 1999]. 
For validation of the data, external qualitative co-researchers, not involved in the 
data gathering and analysis, cross-checked initial codes and reached agreement with 
the researchers about the codes for further data analysis. In addition the data were 
also presented to two experienced clinicians to assess resonance and plausibility with 
their clinical experiences. To determine the significance for routine clinical practice 
in an inner city setting, data from all six qualitative studies was studied for relevance 
in response to the recent publications.  
 
2.3.2. Standards of Care  
In contrast to qualitative research, quantitative research is about asking questions in a 
structured fashion. To get reliable statistical results fairly large numbers of people 
need to be sampled as opposed to qualitative research where often much smaller 
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numbers are required. ARMA (the Arthritis and Musculoskeletal Alliance) is the 
umbrella body for the arthritis community in the UK. It is unique in bringing together 
over 30 organisations from across the patient, research and professional fields to 
work to improve the lives of people with arthritis and musculoskeletal conditions in 
the UK.  
 
The national Standards of Care published by ARMA were developed by patients and 
health professionals to provide guidelines as to what care patients with inflammatory 
arthritis should receive. These standards bring together the evidence and best practice 
and set out a framework for services. The standards and the audit tool were 
developed by a working group that included representatives from professional bodies 
such as the British Society for Rheumatology, Royal College of Nursing 
Rheumatology forum as well as representatives from patient groups such as the 
National Rheumatoid Arthritis Society. The standards are based on 3 main themes: 
 Access to information, support and knowledge that optimise musculoskeletal 
health and enable self-management. 
 Access to the services that enable early assessment and management. 
 Access to ongoing and responsive treatment and support. 
 
Patients completed ARMA standards of care audit tool. The full questionnaire can be 
found in the Appendix. The questionnaire is formed of six main sections and the 




Table 2:1 Main Themes of ARMA Standards of Care Audit 
 
Section Data Items Requested 
Section A 
Your Diagnosis 
 Type of arthritis 





 Smoking status 
 Smoking cessation advice (if current smoker) 




 Suspicion of arthritis-related condition prior to first visit 
to GP 




 Health care professionals seen within first 6 months of 
diagnosis 
 Medications offered at first diagnosis 
 Information offered during first 6 months of diagnosis 
(written information, information about support 
organisations, employment and benefits information, 
teaching and education sessions, details of NHS expert 
patient programme, helpline number, information about 
continuing leisure activities) 
 Opportunities to discuss ongoing concerns 
Section E 
Your Treatment 
 Involvement in treatment decisions 
 Written care plans 





 Advice when disease flares 
 GP assessments between outpatient visits (Heart disease, 
general health) 
 Regularity of assessments of arthritis by health care 
professionals 
 Assessments of interests and emotional needs 
 Assessment of pain 





 Any further comments about multidisciplinary team. 
 
 
2.3.3. Satisfaction Questionnaires 
Initially a satisfaction questionnaire by Tijhuis [Tijhuis et al. 2003] was used. This 
questionnaire was designed to measure satisfaction with multidisciplinary care. It 
was designed with the help of patients with RA. It is shown in Appendix. However, 
patients who completed the questionnaire often found it confusing and difficult to 
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answer. Therefore a second satisfaction questionnaire by Hill and colleagues was 
used [Hill J et al. 1992]. This was designed to measure satisfaction of the outpatient 
care received by patients with RA. It is shown in Appendix. The Hill patient 
satisfaction questionnaire is self-administered, with patients ticking boxes to indicate 
their level of agreement with a series of 45 statements. Possible responses are on a 1 
to 5 scale ranging from “strongly agree” to “strongly disagree”. This provides a score 
out of 5 for each aspect of care. Scores above 3 indicate satisfaction and below 3 
dissatisfaction. Statements are included on the following aspects of care. 
 General satisfaction 
 Giving of information 
 Empathy with the patient 
 Technical quality and competence 
 Attitude towards the patient 
 Access and continuity 
In addition to indicating levels of satisfaction with the above, the results can be 
combined to provide a measure of overall satisfaction.  
 
2.3.4. Defining the Associations of Fatigue 
2.3.4.1. Fatigue Measurements Study 
Fatigue was assessed using four specific measures: A double anchored 100mm visual 
analogue scale (VAS) and three fatigue questionnaires; the FACIT-F [Cella et al. 
2003], the MAF [Belza 1995] and the multidimensional fatigue symptom inventory 
(MFSI) [Stein et al. 1998]. The vitality subscale of the SF-36 questionnaire was also 
used. All questionnaires were self administered.  
 
The fatigue VAS was labelled at one end ‘no tiredness’, and at the other end 
‘absolutely no energy at all’. The question read ‘How tired are you today? ’. The 
range of the scale was 0 (no tiredness) to 100 (absolutely no energy at all). 
 
2.3.4.2. FACIT-F 
The FACIT-F is a 13 item questionnaire and scores range from 0-52, it is an inverse 
scale, the higher the score the less the fatigue. The FACIT-F has four subscales; 




2.3.4.3. Other Fatigue Scores 
The MAF contains 16 items and scores range from 0 (no fatigue) to 50 (severe 
fatigue). The MAF has four subscales; Severity, distress, degree of interference of 
daily living and timing. The MFSI includes 30 items and scores range from -24 to 96. 
The MFSI has five subscales; General fatigue, emotional fatigue, mental fatigue, 
vigour and physical fatigue.  
 
Anxiety and depression were assessed using the Hospital anxiety and depression 
scale (HADS). This is a self completed questionnaire which has 14 items; seven 
items measure anxiety and 7 items measure depression. [Zigmond et al. 1983] 
Anxiety and depression are measured separately with a range of scores between 0 
and 21 for each subscale. Scores of 0-7 in respective subscales are considered 
normal, with 8-10 borderline and 11 or over indicating clinical 'caseness'. 
 
2.3.4.4. Clinical Association Studies 
Data analysis was done by the Statistical Package for the Social Sciences (SPSS for 
Windows 11). Fatigue was analysed in two ways. On the first approach, taking 
fatigue as a continuous variable, simple linear regression was used to study the 
individual effects of continuous variables like age, pain, patient global assessment 
and DAS28. The effects of binary variables were assessed with two sample t-tests.  
 
To determine the key factors that contribute to fatigue in rheumatoid arthritis, simple 
linear regression was followed by a multiple linear regression model fitted to all the 
variables in a stepwise manner, paying special attention to multi-collinearities, 
interactions and potential mediating relationships. 
 
2.3.4.5. Treatment Effects Studies 
To assess changes in the SF-36, simple descriptive analyses of baseline data were 
calculated. Means for all 8 domains of the SF-36 were assessed. To investigate 
changes over time paired results at baseline and at 12 months were calculated and 
bivariate correlations and linear regression analyses were undertaken between 
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different domains. Missing data was imputed using the standard method 
recommended for SF-36. 
 
To assess the effects of treatment on fatigue two sample independent t-tests and 
bivariate Spearman’s correlations were used. 
 
2.3.4.6.  Fatigue Measurement Study 
To determine the associations between disability and fatigue simple descriptive 
analyses (including means and standard deviations) were applied to all the data. 
Bivariate Spearman’s correlations were carried out for each variable against HAQ 
and each measure of fatigue. Simple linear regression was undertaken; any variable 
which did not reach significance at this level was not included in any further 
analysis. Simple regression was followed by stepwise backward multiple regression 
using HAQ as the dependent variable. In the multiple regression models the DAS28 
was used as the measure of disease activity, therefore, tender joint count, swollen 
joint count, ESR and patient global assessment were not used as the DAS28 is a 
composite measure of these variables. A multiple regression model for each measure 
of fatigue was undertaken. Collinearity analysis was carried out for each final model. 
 
2.3.4.7. Factor Analysis 
To explore the different dimensions captured in each fatigue questionnaire and also 
assess their relationship with anxiety and depression, simple descriptive analyses 
were applied to the data, as well as Spearman’s correlations. In this study, 
correlations of r≥0.6 are reported as strong correlations, r≥4 and <6 as moderate 
correlations and r<4 as weak correlations. Cronbach’s alpha was used to test the 
internal validity of the items in the fatigue questionnaires. Cronbach’s alpha is a 
coefficient of internal consistency which is commonly used as an estimate of the 
reliability of a psychometric test. Where validity is concerned with the extent to 
which an instrument measures what it is intended to measure. [Following this an 
exploratory factor analysis of the fatigue questionnaires was undertaken. A rotated 
factor matrix was performed with all the questions from each questionnaire as well as 




In order to identify the most appropriate questions and reduce down the number of 
items, all items which were not highly correlated were excluded (loading <0.6). To 
further reduce this both clinical interpretation and statistics were employed to 
exclude any very similar questions. The questions were the examined by the 
investigator and a second rheumatologist and using clinical judgement and after 
agreement between the two clinicians if two questions had almost identical wording 
or it was felt they were asking the same question then the question with the lowest 
loading was rejected and the question with the highest loading was retained. For 
example: I feel nervous and I feel tense were felt to be asking the same question. The 
loading into the factor analysis rotated factor analysis was 0.889 for I feel nervous 
and 0.672 for I feel tense; therefore, I feel tense was excluded from the final model. 
Consideration was also made to ensure that each dimension was represented. 
 
2.3.5.  Fibromyalgic Rheumatoid Arthritis 
2.3.5.1. Initial Study 
All analyses used the Statistical Package for the Social Sciences (SPSS® 14 for 
Windows). Group data was reported using means (standard deviations) and ranges.  
The inter relationships between tender points and measures of disease activity were 
assessed using bivariate Spearman’s correlations. To determine the factors 
influencing tender points, simple regression was followed by backwards stepwise 
multiple regression using tender points as the dependent variable. 
 
To determine the impact of tender points on patient outcomes, the patients were 
divided into two groups according to the number of positive tender points used in the 
diagnosis of fibromyalgia; those with 11 or more positive tender points and those 
with 10 or less positive tender points.  
 
To determine if tender minus swollen joint counts could identify fibromyalgic RA as 
accurately as tender points, Receiver Operator Characteristic (ROC) analysis was 
employed. ROC curve analyses are used in medicine to determine a cut-off value for 
a clinical test. This is a statistical approach to try and distinguish “normal” from 
“abnormal”. [Altman et al. 1994] The ROC curve is a graph of sensitivity vs. 
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specificity. Sub-groups were compared using Students t-test and frequencies using 
the odds ratio. 
 
To assess the factors associated with pain threshold univariate and multivariate 
Ordinal logistic regression models were performed using STATA version 10 
(StataCorp, Texas, 2007). As the distribution of pain thresholds was not linear, they 
were divided into tertiles for analysis. All continuous measures were entered into the 
models as continuous variables.  For these analyses the crude and adjusted odds 
ratios with 95% confidence interval are presented, p-values are two-tailed 
throughout. Any variables that had a p value ≤0.05 in the univariate analysis were 
carried forward into multivariate analysis. Factors showing significant collinearity 
were excluded from the final model. 
  
2.3.5.2. Replicate Study (Established RA) 
To determine if the tender minus swollen joint count formula could identify 
fibromyalgic RA patients, the formula was applied to data from a group of patients 
with established disease and they were divided into two groups. The impact of 
‘tender minus swollen joints’ was assessed by calculating means with 95% 
confidence intervals for the outcome measures assessed. To determine the effect of 
fibromyalgic RA on response to treatment, mean DAS28 scores after 6 months of 
treatment were compared in the two groups using independent T-test. 
 
2.3.5.3. Early RA Study 
To determine if the tender minus swollen joint count formula could identify 
fibromyalgic RA patients, the formula was applied to data from a group of patients 
with early disease and they were divided into two groups. The impact of ‘tender 
minus swollen joints’ was assessed by calculating means with 95% confidence 
intervals for the outcome measures assessed. To determine the effect of fibromyalgic 
RA on response to treatment, mean DAS28 scores after 24 months of treatment were 
compared in the two groups using independent T-test. 
 
2.3.6. Understanding Treatment Decisions in RA 
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2.3.6.1. Temporal Changes Study 
Data analysis was done by the Statistical Package for the Social Sciences (SPSS for 
Windows 16). Simple descriptive analyses were applied to all data. Mean DAS28 
scores with standard deviations and standard errors were calculated for each time 
period. This was repeated for all the DAS28 constituents (tender joint count, swollen 
joint count, patient global assessment and ESR). Patients were divided by DAS28 
categories into four groups: Remission (DAS28<2.6), low disease activity (DAS28 
2.6 to <3.2), moderate disease activity (DAS28 3.2 to <5.1) and high disease activity 
(DAS28 ≥5.1). The percentage of patients in each DAS28 category was calculated 
for each time point. The patients were also grouped into fibromyalgic and non-
fibromyalgic RA. Mean DAS28 scores for fibromyalgic and non-fibromyalgic 
patients were calculated including standard deviation and standard errors. 
 
2.3.6.2. Treatment Changes Study 
Data analysis was done by the Statistical Package for the Social Sciences (SPSS for 
Windows 16). Simple descriptive analyses were applied to all data. Patients were 
divided by DAS28 categories into four groups: Remission (DAS28<2.6), low disease 
activity (DAS28 2.6 to <3.2), moderate disease activity (DAS28 3.2 to <5.1) and 
high disease activity (DAS28 ≥5.1). For each category the percentage of patients 
who had a treatment change was calculated. In those with high disease activity 
(DAS28≥5.1) the rate of treatment change was examined further and patients were 
divided further into five groups according to DAS28. These groups comprised 
DAS28 of 5.1-5.5, DAS28 of 5.5 to 6.0, DAS28 of 6.0-6.5, DAS28 of 6.5-7.0 and 
those with a DAS28 of over 7.0. Again percentages of patients who had a treatment 
change were calculated for each group. The percentage for each type of treatment 
change was also calculated for each DAS28 category. 
 
To determine what influenced treatment changes binary regression was performed 
for each variable (univariate analysis) and reported as odds ratios (as there were 
categorical and continuous variables). Any variable which showed significance 
(p≤0.05) at this level was carried forward into the multivariate analysis and the odds 
ratios are reported. Two models were analysed, firstly DAS28 was used as a measure 
of disease activity and its constituents were excluded. In the second model the four 
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constituents of the DAS28 (tender joint count, swollen joint count, ESR and patient 
global assessment) were included and the DAS28 composite measure was excluded. 
 
Patients were categorised as fibromyalgic and non-fibromyalgic RA (Tender minus 
swollen joint counts) to explore the effect of fibromyalgic RA on treatment 
decisions, patients were grouped into fibromyalgic and non-fibromyalgic RA. Chi-
squared testing was then used to determine any if there were differences between 
groups in treatment changes and also the kind of treatment change that was initiated. 
 
To explore the effect of age on treatment decisions, patients were placed into three 
categories; under 45 years, 45-65 years and over 65 years. The effect of age of onset 
on treatments decisions was also explored: patients were again placed into three 
categories depending on age at onset of disease; under 45 years, 45-65 years and over 
65 years at onset of disease. Chi-squared testing was then used to determine any if 
there were differences between groups in treatment changes and also the kind of 
treatment change that was initiated. 
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The focus of patient care, particularly in those people with chronic illness has 
recently shifted from recording simple outcomes to focusing specifically on the 
quality of care provided within the National Health Service (NHS) in the UK. To 
ensure that good quality of care is provided, rheumatologists need to engage with 
patients and ensure that they are meeting their expectations as well as ensuring that 
they meet standards set out by nationally recognised organisations such as the 
National Institute for Health and Clinical Excellence (NICE) as well as more disease 
specific organisations such as the British Society of Rheumatology (BSR) and the 
Arthritis and Musculoskeletal Alliance (ARMA).  
 
A number of UK national bodies and groups have reported on the components of 
quality care for people with rheumatoid arthritis (RA). Key recent reports have been 
published by the NICE [NICE clinical guideline 2009], the National Audit Office 
[National Audit Office, 2009] and the King’s Fund [Stewart et al. 2009]. These built 
on earlier reports from ARMA [ARMA Standards of Care 2004] and BSR guidelines 
[Kennedy et al. 2005]. These reports overlap with the new focus on quality care 
throughout the National Health Service (NHS) [Department of Health 2006] [Darzi 
2008]. It would seem commonsense that long-term disorders like RA require similar 
seamless integrated care across the primary/secondary interface such as those 
networks already established for diabetes [Overland et al. 2001].  
 
This study set out to look at what is currently being provided to RA patients in 
secondary and also primary care. It used both quantitative and qualitative methods. It 
audited care in an inner city teaching hospital environment against published 
standards of care devised by ARMA. It also aimed to capture how satisfied patients 
are with current services by surveying an unselected group of RA patients attending 
clinics in a London teaching hospital.  
 
Qualitative methods were used to review the services for RA provided in an inner 
city environment serving an ethnically diverse and relatively deprived population. In 
a focus group setting patients were interviewed about their experiences in 
rheumatology outpatients and asked what they feel should be provided. Using 
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individual interviews as well as focus groups the perceived barriers were assessed 
that prevent the provision of seamless integrated care across the primary and 
secondary healthcare sectors. The varying perspectives of patients, carers, specialists 
and general practitioners (GPs) were examined. Studying such a representative and 
diverse group of patients, carers and clinicians avoids limitations from concentrating 
on selected patients and clinical staff linked to national groups.  
 
3.2. OUTLINE OF PATIENTS AND METHODS 
3.2.1. Focus Groups 
3.2.1.1. Patient Focus Groups 
For the focus groups, in order to have diversity and a breadth of views, purposive and 
quota sampling of patients with RA as defined by the 1987 American college of 
Rheumatology criteria [Arnett et al. 1988] were undertaken. The aim was to include 
patients with early disease, late disease, both male and female patients, differing ages 
and patients in different ethnic groups. Quota sampling using demographic data from 
a previous study of RA patients in the same population allowed for estimation of the 
correct number of male patients and ethnic mix in the focus groups. 
 
All patients were recruited from the rheumatology outpatient clinic at King’s College 
Hospital, aiming for six to eight patients in each focus group. Patients were 
approached either directly by Dr Pollard or by one of the rheumatology nurse 
specialists. Six patients agreed to take part in each focus group. All patients signed 
an informed consent (Appendix 1).There was only one dropout in the second focus 
group, which therefore consisted of five patients. The patient who dropped out was 
female of Asian background. The demographics for the patients who participated in 
the focus groups are summarised in Table 3.1. 
 
3.2.1.2. Patient Focus Group Process 
The focus group was conducted in a private room at the Weston Education Centre 
which is contained within the King’s College Hospital site. The focus group was 
recorded using audio equipment. Dr Lempp conducted the focus group as Dr Pollard 
was the clinician in charge of the care of some of the participants and it was felt that 
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this may inhibit some discussions. As most participants had not had their comments 
recorded previously the interviewer tried to establish a relaxed atmosphere and 
refreshments were provided. The group were informed that they could request that 
the recording was stopped at anytime and that all comments would remain 
anonymous. For the focus groups a semi-structured interview schedule was used 
[Britten 1995]. The content of interview schedule covered three broad topics; 
Information needs, access to care and outpatient assessment (Appendix 2). 
 
Table 3:1 Patients in Focus Groups 
 
Variable 
Focus Group 1 
(n=6) 
Focus Group 2 
(n=5) 
Female 5 3 
Male 1 2 
Age, mean years (range) 58 (45-70) 57 (33-70) 
Disease duration, mean years (range) 15 (0.5-32) 9 (1-20) 
Ethnicity Caucasian 4 4 
 Afro-Caribbean 2 1 
 Asian 0 0 
 
3.2.1.3. Health Care Professionals Focus Group 
Health care professionals who are part of the multidisciplinary team which care for 
patients with RA were invited to take part. This included a consultant 
rheumatologist, consultant orthopaedic surgeon (specialist hand surgeon), 
rheumatology nurse specialist, occupational therapist, physiotherapist and podiatrist. 
All health care professionals were involved in the care of patients at King’s College 
Hospital and signed an informed consent form (Appendix 3) 
 
3.2.1.4. Health Care Professional Focus Group Process 
The focus group was conducted in a private room at the Weston Education Centre 
which is contained within the King’s College Hospital site. The focus group was 
recorded using audio equipment. Dr Pollard conducted the focus group with the help 
of Dr Lempp. The group were informed that they could request that the recording 
was stopped at anytime and that all comments would remain anonymous. For the 
focus groups a semi-structured interview schedule was used [Britten 1995]. The 
content of the interview schedule covered three broad topics; interaction between 
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primary and secondary care, interaction of the multidisciplinary team and outpatient 
assessment (Appendix 4). 
 
3.2.1.5. Focus Groups Data Analysis 
Data were drawn from each focus group. Each focus group was transcribed verbatim 
and loaded into NVivo 8 computer software to manage and organise the transcripts. 
A three stage structured approach as described by Fisher [Fisher, 1999] was 
followed: (1) managing the data, (2) reading the data and (3) building categories or 
themes.  
 
Data were examined through content analysis by paying close attention to what the 
interviewees in each focus group reported. Discourse analysis [Tonkiss 1998; Potter 
1997] was also applied. This meant that language was not only considered as a 
means of communicating information or stories, but also as a medium from which 
knowledge can be built. Applying both categories in the data analysis is an approach 
endorsed by Silverman [Silverman 1993] and Seale [Seale 1998]. 
 
To increase the clarity of the results, they are presented in the form of verbatim 
quotations, as well as by summary of key themes along with frequency counts where 
appropriate. Throughout the data analysis the occurrence of key events is noted by 
using simple counts. This approach assists in the generalisability of the findings 
[Seale 1999]. Such methods can aid validation and credibility of qualitative work 
[Seale 1999; Silverman 1993; Bryman 1988]. 
 
3.2.2. Perceived Barriers to Integrated Care in RA 
Focus groups and face to face interviews held between 2005-8 involved 79 
participants working in or attending three hospitals and three primary care trusts 
(PCTs). These groups comprised:  
 
a. Two patient focus groups: As described above a purposive sample of 11 RA 
patients was obtained from one hospital outpatient department; their selection was 
stratified by disease duration, gender, ethnicity and age.  They comprised 8 females 
and 3 males with a mean age of 58 years and mean disease duration of 12 years; 
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eight were Caucasian and three from black and ethnic groups. One patient refused to 
take part. 
 
b. Patient interviews: Data from a previous qualitative study of individual interviews 
with 26 RA patients from two outpatient clinics was re-analysed to determine what 
patients want and expect from primary and secondary care. This study was part of a 
Total Quality Management (TQM) Project. The aim of the study was to explore 
patient’s experience of living with RA and their views about primary and secondary 
care [Lempp et al. 2006]. 
 
A quota sample of 26 patients was obtained from the same hospital as the focus 
group participants and one other hospital outpatient department to reflect socio-
demographic characteristics and duration of illness of the two RA clinics’ 
population. They comprised 22 females and 4 males of mean age 56 years and mean 
disease duration ten years; 18 were Caucasian and eight from ethnically diverse 
groups. There was no overlap in the patients between the individual interviews and 
focus groups. Nine patients refused to take part. 
 
c. Carers interviews: the carers consisted of a convenience sample of 11 carers from 
two hospital outpatient departments. They were approached by staff and the 
researcher through the RA patients they were caring for. They included five females 
and six males of mean age 61 years; seven were Caucasian and four from other 
ethnic groups. 
 
d. Specialist Health Care Professionals focus group: As described above, six 
representative members of one multidisciplinary team participated, consisting of 
consultant rheumatologist, consultant orthopaedic surgeon, rheumatology nurse 
specialist and allied health professionals (occupational therapist, physiotherapist and 
podiatrist).  
 
e. Specialist Health Care Professionals interviews: 15 secondary care specialist staff 
(6 consultants, 4 specialist registrars and 5 rheumatology nurse specialists) from 




f. Generalist Health Care professional interviews: Data from a previous qualitative 
study of individual interviews with 13 GPs from three Primary Care Trusts (PCTs) 
were re-analysed to determine the role GPs feel they have in the management of RA. 
The two aims of the interview study were to obtain the views and perceptions of 
local general practitioners about the quality of care they provide for RA, the quality 
of the interface between primary and secondary care for RA and also how they see 
their role in delivering care to patients with long term chronic illness. 
 
The decision to use previous data from individual GP interviews was twofold. 
Firstly, GPs work as individual practitioners so to get a better feel for the GPs 
perceived role in RA management views from multiple GPs is preferable rather than 
having one GP in the focus group. Secondly, recruitment for the GP individual 
interview study had proven very difficult and only 12 out of 99 GP surgeries 
approached agreed to take part and recruitment had taken 9 months. The strengths of 
using this approach is that we have included GP data in our study and this enables us 
to have looked at all stakeholders involved in RA care without having to have spent 9 
months trying to complete just this part of the study. The individual interviews were 
also in depth and allowed for exploration of different practices. The weakness of 
using this approach is that it did not allow us to ask the specific questions that were 
relevant to this study and it is possible that there were other themes that were not 
captured in the available data. 
 
All patients met the American College of Rheumatology 1987 criteria for RA. Socio-
demographic details of patients who were interviewed individually and carers are 
summarised in Table 3.2. Written consent was obtained from each participant and 
each study was fully approved by the relevant local Research Ethics and Research 











Female 22 5 
Male 4 6 
Age, mean years (range) 56 (25-85) 61 (36-74) 
Disease duration, mean years (range) 10 (1-29) N/A 
Ethnicity Caucasian 18 7 
 Afro-Caribbean 7 3 
 Asian 1 1 
 
3.2.2.1. Perceived Barriers to Integrated Care in RA: Data Analysis 
The audio taped focus groups and 1:1 interviews were carried out in private rooms 
using a semi structured interview guide [Britten 1995]. The interview schedules were 
based on related literature [Lempp et al. 2006; Kelly et al. 1996] and the researchers’ 
experiential knowledge. Focus groups and interviews took between one to two hours.  
  
Interview and focus group information was transcribed verbatim. Qualitative 
computer software NVivo 8 was used to analyse and handle the data. Content and 
discourse analysis were applied [Hsieh et al. 2005; Hodges et al. 2008], including 
single counting [Seale 1999] and deviant results [Seale 1999]. For validation of the 
data, external qualitative co-researchers, not involved in the data gathering and 
analysis, cross-checked initial codes and reached agreement with the researchers 
about the codes for further data analysis. In addition the data were also presented to 
two experienced clinicians to assess resonance and plausibility with their clinical 
experiences. To determine the significance for routine clinical practice in an inner 
city setting, data from all six qualitative studies was examined for relevance in 
response to recent publications.  
 
3.2.3. Standards of Care and Satisfaction Survey 
For the standards of care and satisfaction survey, prospective data was collected from 
100 patients with RA. All men and women with a diagnosis of RA according to the 
1987 ACR criteria attending outpatient clinics at King’s College Hospital were 
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eligible to take part. Eligible patients were identified from clinic letters of patients 
attending rheumatology outpatient clinics and blood monitoring appointments in the 
outpatient department at King’s College Hospital. 
 
These patients were then approached by Dr Pollard whilst in the rheumatology 
department at King’s College Hospital and invited to complete the ARMA standards 
of care audit tool and the Tijhuis satisfaction questionnaire [Tijhuis et al. 2003] with 
respect to the care they have received at King’s College Hospital. 
 
A second satisfaction survey was undertaken following the collection of the Tijhuis 
questionnaire as various comments were received from patients regarding problems 
with understanding the questionnaire which was used. The second satisfaction survey 
[Hill 1992] was completed again by 100 patients with RA as defined by the ACR 
criteria who were consecutive attendees in a routine outpatient clinic at King’s 
College Hospital. The questionnaires were completed anonymously in order to gain 
candid views of the outpatient services provided. Therefore no demographic data is 
available for the patients who completed the standards of care or satisfaction 
questionnaires. 
 
3.2.3.1. Standards of Care Questionnaire 
The ARMA standards of care for inflammatory arthritis audit tool is an anonymous, 
confidential, multi-part, self completed questionnaire. The audit tool was designed by 
ARMA. The full questionnaire can be found in the Appendix. (Appendix 5)  
3.2.3.1.1. Data Analysis 
Simple descriptive analyses were applied to the main data in all groups. As the 
treatment of RA has changed over the last few years with greater emphasis on 
multidisciplinary care and improved therapies, patients with early disease (as defined 
by disease duration of less than two years) were grouped together and the results for 






3.2.3.2. Satisfaction Questionnaires 
The Tijhuis satisfaction questionnaire [Tijhuis et al. 2003] was trialled initially; 
which was designed to measure satisfaction with multidisciplinary care. The 
questionnaire was designed with the help of patients with RA and in the study was 
used to compare satisfaction between inpatient and outpatient multidisciplinary care. 
(Appendix 6) However, after speaking to patients who completed the questionnaire, 
many found it confusing and difficult to answer. Therefore a second satisfaction 
questionnaire by Hill [Hill et al. 1992] was trialled. This was designed to measure 
satisfaction with the outpatient care received by patients with RA. The initial ten 
patients who completed this questionnaire found it easy, simple and quick to 
complete. (Appendix 7) The Hill patient satisfaction questionnaire is self-
administered, with patients ticking boxes to indicate their level of agreement with a 
series of 45 statements. Possible responses are on a 1 to 5 scale ranging from 
“strongly agree” to “strongly disagree”. This provides a score out of 5 for each aspect 
of care. Scores above 3 indicate satisfaction and below 3 dissatisfaction. Statements 
are included on the following aspects of care. 
 
 General satisfaction 
 Giving of information 
 Empathy with the patient 
 Technical quality and competence 
 Attitude towards the patient 
 Access and continuity 
 
In addition to indicating levels of satisfaction with the above, the results can be 
combined to provide a measure of overall satisfaction.  
 
3.3. RESULTS 
3.3.1. Clinical-User Group 
Louise Pollard was the convenor of the Lambeth and Southwark ARMA local 
network and members include a consultant rheumatologist and an orthopaedic 
consultant as well as specialist nurses from rheumatology at King’s College Hospital. 
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The allied health care professionals in musculoskeletal health are represented by 
podiatrists from Southwark and physiotherapists and occupational therapists from 
King’s College Hospital. Southwark Primary Care Trust (PCT) is represented and a 
number of patients sit on the steering committee. These include patients with 
inflammatory arthritis, who are cared for at King’s College Hospital, a representative 
from the National Rheumatoid Arthritis Society (NRAS) and the chair of the 
patients’ forum for primary care in Southwark.  
 
The network was used as a springboard to identify areas which could be improved 
within the local provision of services for people with musculoskeletal disorders. The 
audit against ARMA standards of care once completed was presented at a local 
network meeting. Several points were highlighted as areas on which the network can 
work. These include; improving access to information, particularly regarding benefits 
and patient groups, improving referrals to appropriate exercise programmes, ensuring 
timely assessments and review by allied health care professional (physiotherapists, 
occupational therapists and podiatrists) and also to ensure that patients are regularly 
assessed for other co-morbidities. 
 
In the first meeting the patient representatives highlighted the lack of a patient 
support group for patients attending King’s College Hospital, therefore a survey of 
patients with inflammatory arthritis attending King’s College Hospital rheumatology 
department was undertaken, to assess the need for a local patient support group. 
(Appendix 8)  
 
3.3.2.  Patient Support Group Survey 
A simple self-completed questionnaire was designed by Catherine Morrison 
(rheumatology specialist nurse and local network member) and Louise Pollard. 
Patients were asked if they thought setting up a support group was worthwhile and if 
so how often should the group meet and where. Patients were also asked whether 
they themselves would attend and if they would be involved in setting up and 





The total number of respondents was 60. The majority of patients felt setting up a 
patient support group was a good idea (85%) and 65% of patients stated that they 
would attend meetings, however, only 43.6% of patients would be willing to help set 
up and run the support group. With regards to the timings of such meetings, the 
majority (66.7%) were in favour of three-monthly meetings and just over half the 
patients felt they should take place in the mornings with 84.6% of patients feeling 
that the meetings should be held at King’s College Hospital (Table 3.4). 
 















































 2 Non-responders 
*
 King’s College Hospital 
‡ 
1 patient ticked both boxes. 
 
3.3.3. Focus Group Results 
3.3.3.1. Analytic framework 
An analytical framework emerged from the data from both focus group transcripts 
and three overarching themes became apparent. The three broad themes and their 
related sub-themes are described below. 
 
Theme 1: This theme refers to the personal impact of RA on the body and mind and 




Theme 2: This theme describes the information needs of RA patients, related to RA 
and its treatment and the services and benefits available as well as how to access the 
information.  
 
Theme 3: This theme documents specific issues related to health care delivery for 
RA patients.  
  
Theme 1: Personal Impact of RA 
Within this first theme, four specific subthemes were identified: 
 Coping Strategies  
 Signs, symptoms and diagnosis of RA 
 The impact of RA on the body and mind. 
 The impact of RA on everyday life and family. 
 
Theme 2: Information needs 
Within the second theme, three specific subthemes were identified: 
 Information about RA and its treatment 
 Information about social services and benefits available 
 Delivery of Information 
 
Theme 3: Health Service Delivery 
Within the final third theme, four specific subthemes were identified: 
 Access to care 
 Relationships with medical staff 
 Organisational issues 
 Expectations of care 
 
In the following presentation of the results, each participant’s direct account will be 
shown in quote brackets in italics and will be preceded by a study identification code 
(e.g. A2 = Second patient to speak in the first focus group, B5 = Fifth patient to 
speak in the second focus group). Any words that are underlined were emphasised by 
a participant to give them added importance during the focus group discussion. If any 
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quote needs clarification, an explanation will follow the quote in question within 
square brackets [ ] and are my own words rather than those of the participant. 
Patients’ actions such as laughter will also be placed within square brackets in the 
text. The strength of any particular topic will be indicated by how many participants 
made a similar point, for example, the majority of patients (7/11), means that 7 
participants made comments about a specific topic out of the total number of RA 
patients who took part in the focus groups. 
 
3.3.3.2. Theme 1: The Personal Impact of RA. 
Although the participants were not asked specifically to describe how they were 
diagnosed with RA or its impact upon them, most patients discussed (9/11) their 
symptoms, how they coped with their illness (7/11) and the impact RA has on their 
body and life in the private domain (7/11) as well as the impact on their body and life 
which is seen in the public domain (5/11). 
 
Coping Strategies  
Patients described using a variety of strategies to cope with the signs and symptoms 
of RA. These included, taking to their bed in times of flare (2/11), exercising/keeping 
active/distracting themselves (4/11), taking comfort in the fact that others are worse 
off (2/11), changing their diet (2/11). There was a common theme through many 
patients accounts of accepting that they had to get on with it and ‘grin and bear’ the 
pain and disability and not be beaten by rheumatoid arthritis. (6/11) 
 
A3: ‘I think if you, if you’re having a bad day and you’re feeling a bit down and you 
go out and you see someone who’s in a lot worse condition than you are, you look at 
these people and you say to yourself: “there for the grace of god go I, so buck 
yourself up and get on with it”. And that makes you feel a lot different…it lifts your 
own spirits and shakes you out of the doldrums because there are a lot of people that 
are a lot worse off than we are…’ 
 
A5: ‘everyone finds different ways to manage themselves. Everybody, there’s no 
separate set of fast rules. You have to know what works for you. And this is the 
method in which I work, never mind what anybody else doing, I will do what makes 
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me tick and if I find walking around the room, doing unnecessary dusting make me 
feel better, I will do that.’ 
 
B3: ‘I went into the homeopathic hospital for 2 weeks for them to analyse me...and I 
was put on a wheat free diet at one stage which I wasn’t allergic to but I didn’t need 
it in excess. I then was on a dairy diet, the same applied, I mean everything’s 
different but I don’t think now the diets [that] helped but they helped me with my 
pain, they didn’t get rid of the swellings or you know the rheumatoid factor but 
certainly they helped with the pain.’ 
 
B3: ‘You know I think it’s the personality of people with rheumatoid that we grin 
and bear it. We don’t ring up and say “help I’ve had the most terrible week or night 
or whatever it is, please I need to see somebody”. Generally, you don’t, you just get 
on with it don’t you?’ 
 
B5: ‘That’s what I do when I’m struggling to do something, they’re all like “let me 
help you” and I’m like “no”, you know let me give it my all and then if….and only if, 
will I let someone help me.’ 
 
Signs, Symptoms and Diagnosis of RA 
Almost all patients (10/11) discussed the signs, symptoms and diagnosis of RA. 
Several patients talked about the pain they endure from their RA (4/11) and the 
impact it has upon them, especially sleep (4/11) some describe the pain as sufficient 
to make them cry (3/11). Although not specifically asked many patients discussed 
their initial presentation, how they were diagnosed and their initial referral (7/11). 
Several patients reported being diagnosed quickly after their first consultation with 
their GP (3/11) but one patient described a lengthy delay in diagnosis and referral 
(1/11) 
 
A2: ‘that pain makes me cry, especially when I try to sleep and I can’t sleep because 
if I lie on this side I’m I pain, if I lie on that side, you don’t know where to go’ 
 
B1: ‘I’m getting pain in my hands for the last two years and it is absolutely 
indescribable pain and I have it all night long, I can’t sleep and actually I’m not 




B2: ‘My own doctor sent me directly here (rheumatology clinic)’ 
 
B5: ‘I used to tog to the gym so it took my GP nearly a year and a half to find out I 
had RA and it was only because I demanded an x-ray….the GP kept telling me it was 
poor ligaments and that I should stop going to the gym and rest.’  
 
The Impact of RA on the Body and Mind 
The majority of patients (6/11) described the effect RA has on their body and mind. 
Many patients (5/11) discussed how RA interferes with their ability to carry out what 
they would have previously considered to be normal daily activities. Two patients 
(2/11) specifically discussed the impact RA had on their ability to work. 
Several patients (4/11) described the emotional impact of RA and two patients (2/11) 
described how their inability to perform certain physical tasks in front of others 
added to their emotional load.  
 
A1: ‘but then at the end it got, you know, lifting you can’t do the job and you’ve got 
to say “I can’t do it [nursing task]”. I was very upset about it [not being able to 
carry out all the nursing duties].’ 
 
A2: ‘I could hardly open my hands at one time; I couldn’t pull anything down or 
tighten anything. Sometimes when I went shopping I had to put the bag over that 
side to carry it, my hands could hold nothing.’ 
 
A3: ‘Because you get a lot of emotional problems with it as well and a hell of a lot of 
emotional problems with RA.’ 
 
B4: ‘Or when you’re working, you can’t even hold your pen properly and you write 
scrawly, you know it’s very debilitating but also as well I mean that’s what the 
emotional aspect comes into it.’ 
 
The Impact of RA on Everyday Life and Family 
Patients (4/11) discussed the impact RA has on their everyday life and family. Three 
patients (3/11) talked about the negative impact RA had on their ability to work, with 
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two patients (2/11) specifically describing how they felt their diagnosis would 
impede their ability to gain employment.  
 
Several patients (3/11) described their embarrassment at work and in public 
situations because of the limitations caused by RA. Another theme discussed (4/11) 
was the apparent lack of understanding by not only work colleagues but also by 
members of family. Patients felt that people could not understand the limitations 
caused by RA. 
 
A3: ‘even family members don’t understand. When they sort of, oh well, especially 
when you first start off and you can’t do things like, even just opening a jar or 
something like that and you ask someone: “oh you can do that” you know. But you 
can’t do it and I mean my brother used to say to me: “oh do this, do that” and I’d 
say: “but I can’t do it”. “Of course you can do it”, you know, and they just don’t 
understand how you’re struggling. 
 
A5: ‘nobody understands, nobody knows what you’re talking about and they’re 
[colleagues] not willing to understand, not because probably they’re heartless but: 
“look I am a company boss and I want my job, my work done, so you just do it”. So 
it really is difficult when you’re at work, when you’re still at working age and have 
this, this illness [RA]. So you just have to say it [disclose the diagnosis] very 
carefully.’ 
 
B5: ‘That’s the scary thing with me being made redundant I’ve kind of had to lie to 
my new employer and say that my RA is under control and my RA isn’t. 
 
‘My boyfriend will take me out for a romantic meal and I’ll be sitting there while 
he’s cutting my dinner up for me in a restaurant, how embarrassing is that (laughs).’ 
 
3.3.3.3. Theme 2: Information Needs of RA Patients 
Information about RA was important to many patients (6/11) and they accessed this 
information in different ways. When discussing social services and benefits, the 
majority of patients told of their difficulty accessing any help (7/11). Patients talked 
about different delivery systems for information and from the data it is clear that no 




Information about RA and Its Treatment 
Most patients were as keen for as much information about RA as possible (6/11) and 
some mentioned that RA was not something they were aware of before being 
diagnosed (3/11). Almost half of patients (5/11) relied on medical staff for the 
majority of information, whereas some utilised other professionals such as 
pharmacists (3/11) for further information particularly about drugs. The leaflets 
available in clinic were found to be beneficial for some patients (5/11). A 
considerable number of patients gained useful information from fellow RA patients 
(5/11). 
 
A1: ‘Yeah you have to find out. I asked… I think word of mouth you find out a lot to 
be honest. You get, people saying “oh I get this” and you go “where, how did you 
get that?” And they tell [other people] you.’ 
 
B2: ‘So you do need to talk to you, know an expert who tells you what you might be 
getting or what you might not be getting or if you do get this. I mean that’s why the 
pamphlets are so good... ‘ 
 
B3: ‘The other person who’s helped me is my chemist because he’s got the list of all 
the drugs I’m on and he knows. So if I’ve got a cold or something I can go into him 
and say “can I take this with all that I’m on?”. I mean that’s helping on that side of 
it, he will say yes well that you can take not that.’ 
 
B4: ‘because I had not heard of rheumatoid arthritis when I was diagnosed’ 
 
Information about Social Services and Benefits Available 
On the whole patients talked negatively about their experiences with accessing social 
services and benefits, including how to contact them and many (7/11) discussed how 
difficult they were to access and how difficult the forms are to complete. A minority 
of patients had benefits in place already (3/11).  
 
A3: ‘I mean I think it’s still very hard to get registered as disabled unless you’ve got 
the physical attributes to see. But when you see people who’ve lost limbs and things 
and not being registered disabled, you think to yourself: “well what chance have I 
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got”. I mean when I’ve come to renew my disabled driving badge I very much doubt 
if I’ll get it [the badge] this time because I don’t look as bad as I did before.’ 
 
B1: ‘I think the information available is so limited. It ahm... leaves you in the dark 
you know, exactly where you are and what benefits you can get.’ 
 
B2: ‘I had experience of someone coming from social services coming and spending 
two hours in my home and they kept repeatedly telling me that I wasn’t entitled to 
benefits which would consist of going through all the motions, the paperwork, the 
history and everything else…’ 
 
 
Delivery of Information 
Patients had different ways of accessing information, some preferred using the 
internet (4/11); however two patients mentioned not having a computer and not being 
computer literate. Some patients still preferred information leaflets and felt they 
should be in plain, understandable English (3/11). One patient mentioned the expert 
patient programme but the other patients in that focus group were not aware of it. 
One patient talked very positively about a group they had attended at King’s college 
hospital where they had several sessions with input from physiotherapy, occupational 
therapy, rheumatology specialist nurses/doctors, fellow patients as well as someone 
from social services who explained what benefits were available and how to access 
them. The other patients in this focus group felt that they would have benefited from 
attending but had never heard of it/been offered to attend. However, one patient 
mentioned that they would prefer not to attend a group and preferred being given 
information one to one. 
 
B1: ‘Beef up you leaflets…’ 
 
B2: ‘In plain understandable English…’ 
 
B3: ‘The trouble with all these big groups, I’m not really a big group person, you 
know. Where if having somebody come to my house to talk me through something is 
one to one rather than being a whole group set up where you’re just a number and 
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.... it’s.... and it’s not really what you need, you only need that bit of information, 
rather than listen to a whole talk.’ 
 
B4: ‘I did go at that time to some self help groups that were arranged through 
occupational therapy [OH] here and found out more through that about what I 
could do to help myself, things like that and the rest of the information through the 
internet going on the internet and finding out information from there… Well when I 
was actually diagnosed in 2001 the hospital had some kind of group that we were 
coming to and the lady there she was really good, she said “you can apply for 
benefits” you know, “do this, get occupational Therapy to come in and assess you at 
home” and everything like that.’ 
 
3.3.3.4. Theme 3: Health Care Delivery for RA Patients 
Access to care 
Most patients (6/11) commented that it was important to have immediate access to 
care in times of need such as a flare of disease, although this could prove difficult. 
 Some patients used their relationships with specialist nurses to gain access to doctors 
(2/11), whereas others used a helpline number (2/11), although some patients were 
not aware of the helpline (4/11).  
 
A4: ‘And you’ve got their number (nurses), you can ring them.’ 
 
A3: ‘So you’ve got that fluidity there if you feel you need to see the doctor. You can 
always phone up the nurse and they’ll help you to get to see the doctor quicker than 
you would if you just try to change your appointment and fetch it [appointment] 
forward. If you say you’ve got a problem…’ 
 
B4: ‘I continuously phoned, continuously phoned … and I got through to Cathy to 
find out that they’re trying a new system but we weren’t told. No-one was told as you 
said. So you know, when I came up ahm... she said “oh well this person only works 
two afternoons part time”. That’s not helpful when you want help, you want to see 
someone, you know. Sometimes its a phone call because you can’t physically get 
there you know, in the end that’s what I had to do, physically come to clinic because 




Relationships with Medical Staff 
Patients talked very positively about their relationships with medical staff, 
particularly specialist nurses (9/11). They clearly described a different relationship 
with nurses compared to doctors (9/11) and felt more able to talk freely to nurses and 
patients felt the nurses understood them better. Some criticisms of rheumatologists 
were that some patients (5/11) felt their appointments were rushed, some (3/11) felt 
that the doctors were not interested in them. A few patients (3/11) mentioned that 
continuity of care was important as it allowed them to build up a relationship with 
their doctors. Some patients (3/11) criticised their GPs apparent lack of knowledge of 
RA, whereas some patients (2/11) had very little to do with their GPs and relied on 
the rheumatology department for the majority of their care. Two patients did describe 
a good relationship with their GPs. 
 
A1: ‘Mind you I find it quite easy to talk to the specialists. I’ve got to know the 
specialist quite well. I think I’ve seen him so many years, you do get to know them 
and they get to know you.’ 
 
B1: ‘The nurses are all hands on...it doesn’t bother me if I never have an 
appointment with the [rheumatologist] or any of them, it doesn’t bother me what so 
ever. It’s the nurses...if I see the nurses I’m quite happy and I see them every week 
because you can guarantee they’re there. You can guarantee they’re not going to 
phone you up or send you a letter we can’t be here this week or something like that 
you know. But I find that especially with the [rheumatologist]’ 
 
B3: ‘I do think you need a good nurse (agreement from rest of group). They’re your 
first port of call (agreement from rest of group) and if they understand you first and 
that you’re not exactly…. and they can see all your results and so they know you, 
what you’re talking about...’ 
 
B4: ‘You’re lucky if you get 10 minutes [with the rheumatologist]; I mean again if 
you’re working, you have to leave work early, you know to get here. Sometimes 
that’s another thing, when you see the waiting time is horrific and you go in and 
you’re talking to the rheumatologist, he’s not even looking at you, so you’re talking 





Several criticisms involving organisational issues were mentioned by patients; two 
patients complained about waiting times for blood monitoring in the hospital whereas 
more (3/11) were concerned that blood monitoring was going to be handed over to 
primary care. Other issues included long waiting times to be seen in rheumatology 
clinic (2/11) and repeated cancellations of appointments (2/11). Two patients also 
mentioned the problems with lack of interaction between primary and secondary 
care. 
 
B2: Your problem with the postponing of appointments, I had three postponed; three 
appointments and I told them I wasn’t happy. Three appointments and I said “This is 
the third one you know”... I was pushed to the side. 
 
B3: ‘Here is a nightmare; ….. you can be here an hour and a half and none of us 
have that much time…you have not got an hour and a half, to sit and wait to have 
your bloods taken…’ 
 
Expectations of Care 
Some patients clearly relied heavily on care provided by nurses but when seen by 
rheumatologists, patients (4/11) discussed the need to be examined thoroughly and 
for doctors to have a sympathetic approach. Patients also wanted to feel as if they are 
being listened to (2/11). 
 
A3: ‘It would be nice if they did automatic joint checks for you. I mean I know the 
nurses do at times when you’re having TNF but the doctors don’t tend to, not unless 
you’ve got a problem.’ 
 
B1: ‘Especially if it’s a period of time like 6 months [for an appointment with the 
rheumatologist], you know that’s a long time. If you’re up every week, I don’t think 
you’re going to drastically change, you know, but if it’s every 6 months, they should 
give you a thorough examination, send you for x-rays or god knows what, just to see 
how you’re coping.’ 
 





3.3.4. Perceived Barriers to Integrated Care in RA 
Through detailed examination of all the data three main barriers to high quality care 
were identified. These comprised (i) delayed specialist referral; (ii) limitations to 
routine follow up and (iii) accessing care in times of need. Examples of matters 
raised by patients, carers and healthcare professionals are summarised in Table 3.5  
  
Specialist Referral  
Patients and Carers  
Most patients (29/37) consulted their GPs when their symptoms started. Many 
(14/37) reported frustration at delays in specialist referral; only one patient 
commented on being referred early. Some patients (4/37) reported specialist referrals 
depended on positive blood tests, two of these patients had been diagnosed within the 
previous twelve months. Delayed referral was mentioned by two carers (2/11).  
  
Healthcare Professionals  
All rheumatology specialists in the focus group (3/3) commented on delayed 
referrals, noting variations in the timing and quality of referrals. This issue did not 
feature in interviews with individual specialists. Some GPs (4/13) emphasised the 
need for early referral but many (11/13) commonly waited for ‘positive blood tests’ 
for rheumatoid factor before referring. Some GPs (5/13) also waited for confirmatory 
responses to initial treatment with anti-inflammatory drugs and steroids. A number of 
GPs (5/13) were influenced by their perceived role as ‘gate keepers’ to specialist 
care. 
  
Limitations in Follow Up  
Patients and Carers  
Many patients (18/37) commented on the importance of monitoring their RA, 
highlighting the need for physical examinations together with explanations of disease 
progress and joint discussion of options of new treatments. They wanted the 
opportunity to participate in decisions about their care. Patients (12/37) focussed on 
the value of understanding approaches by staff and developing trusting relationship 




Some patients (8/37) commented critically about insufficient time during 
consultations with rheumatologists. By contrast there were many positive comments 
about interactions with rheumatology nurses (32/37). Patients felt more comfortable 
discussing matters with specialist nurses, who both understood their concerns and 
had more time (7/37).  
  
Patients reported organisational problems including long waiting times in clinic 
(13/37), blood sampling for disease modifying anti-rheumatic drugs (DMARDs) 
monitoring (9/37), between appointments (5/37) and clinic cancellations and 
postponements (2/37).  
  
They described mixed experiences with their GPs. On the one hand many (21/37) 
expressed criticisms about GPs’ perceived lack of knowledge of RA and its up-to 
date treatment (9/37). On the other hand a substantial number of patients reported 
positive experience in primary care (14/37), often mentioning sympathetic ongoing 
relationships (8/37). A minority preferred to receive most care in hospital (6/37).  
  
Carers also voiced concerns about waiting times in the clinic (5/11), perceived 
limited benefits from treatment (4/11) and difficulties with transport to the clinic 
(3/11). One carer was concerned about GPs limited knowledge. Most (6/11) 
commented on the importance of good interactions with outpatient clinic staff. 
Carers noted that RA had major impacts on themselves as well as on the patients they 
were caring for.  
  
Healthcare Professionals  
Specialists’ views (16/18) echoed patients’ experiences about the paucity of follow 
up appointments and lack of time during consultations; they found it difficult to 
adopt a holistic approach with patients. They noted that these pressures had resulted 
in appointments with rheumatologists being replaced by specialist nurse led clinics.  
  
Most GPs (10/13) commented on their role in providing repeat prescriptions after the 
initial referral of patients with RA, otherwise they are only marginally involved in 
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ongoing care. Only a minority (4/13) reported they regularly reviewed patients with 
RA.  
 
Few GPs (4/13) commented on the negative impact of the Quality and Outcomes 
Framework (QOF). They stated it influenced their approach to chronic disease 
management and, as RA falls outside this framework, they thought it reduced the 
priority given to RA patients in primary care.  
  
Access to Care in Times of Need  
Patients and Carers  
Patients emphasised the importance of immediate help and support during times of 
flare of their RA and/or emotional stress (14/37). They tend to approach 
rheumatology nurses first to gain access to specialists during flare ups. Carers did not 
comment on this topic.  
  
Healthcare Professionals  
Most specialists (11/18) agreed that patients need immediate access during an 
exacerbation of RA and that the service should respond quickly and effectively. 
However, such access increased pressure on appointments leading to overbooked 
clinics and long waiting times.  
  
Most GPs (8/13) considered an important pre-requisite for accessing secondary care 
was having a personal relationship with the consultant(s) and having knowledge 
about him or her. These professional links helped access to specialists during acute 
episodes of RA (9/13). When such links did not exist (4/13) it limited successful 
primary/secondary care integration. One GP thought this relationship was hindered 
by the ‘choose and book’ system as patients might be seen in hospitals unfamiliar to 
them. (Choose and Book is a national electronic referral service which gives patients 






Table 3:4 Summary of Key Themes 
 
Barriers Non-Professional Professional 
 Patients Carers Secondary Care Specialists General Practitioners 
Specialist Referral  Delay in referral from 
primary care 
 Delay in referral 
from primary care 
 Delay in referral from 
primary care 
 Quality of referral 
influences prioritisation 
 Role as gatekeepers to 
specialist care 
 Need for positive 
blood tests 
 Referral linked to 
personal confidence 
and role perception 
Routine follow up 
and DMARD 
monitoring 
 Lack of time with 
rheumatologist 
 Cancellation and 
postponement of 
appointments 
 Perceived lack of 








 Perceived lack of 




 Time pressures 
 Paucity of follow up 
appointments  
 Lack of monitoring by 
GPs 
 
 Lack of regular review  
 Lack of clarity of role 
in monitoring 
 
Access to care in 
times of need 
 Difficulty of access 
during a flare  
 No specific 
comments  
 Seeing patients urgently 
impeded by time 
pressures and paucity of 
appointments. 
 GPs not providing 
emergency care 
 Lack of knowledge of 
RA treatment 
 Preference for 
personal knowledge of 
rheumatologist to 




Quotations Exemplifying Issues in Specific Areas of Care 
Area Patient/Carer HealthCare Professional 
Specialist 
Referral 
I was diagnosed really soon because I put on a lot of weight 
and at the time I was on a tablet to stop smoking. I thought 
it was the tablets ….I went straight to the GP and he carried 
out the rheumatoid blood tests. So I was diagnosed pretty 
early so I felt quite lucky. (Patient 32) 
‘I used to go to the gym so it took my GP nearly a year and 
a half to find out that I had RA and it was only because I 
demanded an x-ray... (Patient 37) 
‘If they think it’s an inflammatory arthropathy, most GPs 
will send it to the appropriate people, maybe not quickly 
enough.’ ( Consultant Orthopaedic Surgeon) 
‘So initial diagnosis is key and quick referral putting the right 
things in the letter so that when we get the letter we can see 
what they [GP] think it is...there’s huge variation then in 
that.’ (Consultant Rheumatologist) 
‘If you don’t do the blood test the hospital would be 
absolutely overwhelmed. If everybody [patient] who thought 
they might have rheumatoid we refer to hospital, the system 
would grind to a halt… (GP1). 
‘So we normally do blood tests like RA Factor and 
antibodies and when they come back and yes the suspicion is 
that they might have RA, then we refer’ (GP2). 
Routine 
follow up 
‘Especially if it’s a period of time like 6 months [between 
appointments], you know that’s a long time…they should 
give you a thorough examination, send you for x-rays or 
god knows what, just to see how you’re coping.’ (Patient 
33)  
‘He tries to help me; he is a really understanding doctor. He 
understands how I feel. I can really talk to him. He knows 
how I feel. I tell him where I am having the pain. I relate to 
him.’ (Patient 22) 
‘I have to wait a long while to see the doctor when I got an 
appointment for a certain time. I have waited one hour and 
a half; you never go in at the appointment time’. (Patient 
15) 
‘I think sometimes the specialists haven’t got the time to 
‘It depends what they come in with. You don’t always have 
time…. I mean if they have everything at once it’s really 
difficult to address every issue in that time slot. ‘(Nurse 
Specialist) 
‘I think the follow-up in rheumatoid has changed a bit in the 
last of couple of years from our perspective in that with the 
pressure on follow up slots being so great, the interval 
between follow-ups is much longer and it will be pushed out 
to 6 months or a year’ (Consultant Rheumatologist) 
‘I’d like the GPs to take on blood monitoring, I think that is a 
complete waste of time for us to look at each single blood 
result for 100 of 100 of patients and so I would like to have 
blood monitoring with our support to be out in the 
community. Patients would prefer that as well’. 
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give you that long chat that you need, whereas the nurse 
will. You know, not that the specialist doesn’t want to…’ 
(Patient 31) 
 ‘My GP, I have… I think I have lost respect…he hasn’t 
really served me particularly well. I have to ‘play act’ when 
I see a GP. So I have to pretend that I am really ill and 
about to die before anything actually happens … I don’t 
have a lot of faith in them’. (Patient 24) 
‘Well my GPs quite good. If it wasn’t for my GP half the 
things he told [advised] me what to do. If you come to the 
hospital, you ask how you do this, nobody tells you.’ 
(Patient 30) 
“In the end I got so mad with them (GP) I started shouting 
and I said “you know, I’ve got to come up here and ask you 
for blood forms every month!”(Carer 8) 
‘Doctors… I think they get tired of me (carer) when I attend 
the consultation.’ (Carer 5) 
‘I mean obviously the waiting times can get on your 
nerves.’ (Carer 11) 
(Rheumatology Specialist Registrar) 
‘… so we sort of monitor them [RA patients] from the 
practice… just doing their bloods, seeing everything is in 
order and there is no sort of active flare up or anything and 
we are happy to do that if we get a sort of proper protocol 
and guidelines in which we can work’ (GP 10).  
‘…. there is no financial incentive and actually I don’t agree 
with the financial incentive, but if you suffer from an illness 
that is not included  in the QOF, I think there is a degree 
of neglect and ahm… there is no motivation of the practice to 





‘If the nurse thinks I am not all that good, she calls the 
doctor… and he will come and see me right away’ (Patient 
1) 
 
‘…..I like the patients to have better support…seeing 
someone in six months…is not very helpful…they [patients] 
just struggle on… I have no follow up appointments…the 
GPs don’t know what to do you see, so it is a dreadful 
situation… we are under-resourced. I don’t think that is the 
way to deliver it [health care]... knowing that we can’t 
actually do that [provide emergency cover]’. (Consultant 
Rheumatologist)  
‘Patients can now ‘choose and book’ any hospital which is 
extremely confusing for GPs, because I think it is extremely 
important that the patients go to local hospitals and I am 
familiar with the consultants and the system there.’ (GP 9). 
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3.3.5. Standards of Care 
Of the 100 respondents; 95 patients stated they had RA. Ninety-six patients gave 
information about disease duration; 84 patients had a disease duration of greater than 
2 years and 12 had the disease for less than 2 years. The mean age of respondents 
was 56 years. On first presentation to the GP with symptoms of inflammatory 
arthritis only 26 of 94 respondents (27.7%) of patients actually thought they had an 
inflammatory arthritis. However, 61 of the 90 respondents (67.8%) were given 
advice regarding pain control at their first visit. 
 
3.3.5.1. ARMA Standards 
Early Diagnosis and Treatment 
Patients were asked to answer questions about the treatment they received during the 
first six months after diagnosis. A total of 88 of the 100 respondents had seen a 
rheumatologist within six months of diagnosis, 43 had seen a nurse specialist, 5 had 
seen a podiatrist, 20 had seen a physiotherapist, 8 had seen an occupational therapist 
and only 3 had seen a dietician (Figure 3.1). 
 
When looking at those patients with early disease, defined as those with a disease 
duration of less than two years, all 12 patients had seen a rheumatologist within six 
months of diagnosis and 8 patients (66.7%) had seen a nurse specialist. However, 
only 4 patients (33.3%) had seen a physiotherapist, 1 patient (8.3%) had seen an 
occupational therapist and no one reported seeing a podiatrist or dietician within the 
first six months of diagnosis. 
 
At first diagnosis, 58 of the 100 respondents were offered a disease modifying anti-
rheumatic drug (DMARD), 56 patients were offered anti-inflammatories, half (50 
patients) were offered analgesics, 10 patients were offered oral steroid tablets and 35 
patients were offered a steroid injection (Figure 3.2). 
 
Again looking at patients with early disease a greater proportion were offered a 
DMARD; 11 patients (91.7%), 5 patients (41.7%) were offered anti-inflammatories, 
7 patients (58.3%) were offered analgesics, 2 patients (16.7%) were offered oral 
steroid tablets and 8 (66.7%) patients were offered a steroid injection. 
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Figure 3:1 Early Involvement: Access to Professional Advice 
 
 
Figure 3:2 Early Involvement: Range of Care Provided 
 
 
























Finally patients were asked if they were given the opportunity to discuss ongoing 
concerns at visits. Of the 88 respondents, 73 patients (83%) felt they were given an 
opportunity to discuss ongoing concerns and 15 patients (17%) felt they were not 
given an opportunity. 
 
Ongoing Treatment and Support 
The care patients receive from their GPs/practice nurses between visits to the 
rheumatology department is summarised in Figure 3.3.  
Despite the known increased cardiovascular risk in RA patients relatively few have 
their BP monitored.  
 
Figure 3:3 Integrated Management of Care: Treatments Offered 
 









Patients were asked how often their arthritis is assessed by the different healthcare 
professionals (annually, more often, less often, never, don’t know). The majority of 
patients have their arthritis assed annually or more often by both rheumatologists and 
specialist nurses, but rarely by other healthcare professionals. The results are 
summarised in Figure 3.4. 
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Figure 3:4 Annual Assessments by Healthcare Professionals 
 
Smoking and Exercise 
Ninety-seven patients answered the question relating to smoking status; 35 patients 
had never smoked, 21 patients were current smokers and 41 patients were ex-
smokers. A total of 14 (66.7%) of the 21 current smokers had been offered advice 
about how to give up, 1 patient didn’t answer the question. (Figure 3.5) 
 
Sixty-four patients responded to the question: Have you been offered advice about 
exercise programmes run at (or recommended by) the hospital? Of the 64 
respondents only 20 patients (31.25%) had been offered advice (Figure 3.5). 
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Figure 3:5 Smoking And Exercise 
Smoking












Involvement in Treatment 
Eighty-six patients (88.7%) felt that they have been involved in decisions about their 
treatment but only 19 patients (21.3%) have been given written care plans. Fifty 
patients (54.3%) had already been asked to provide feedback on the service and care 
they receive. Eighty-seven patients (91.6%) have been advised to contact the 
rheumatology team should their arthritis flare or become worse (Figure 3.6). 
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Figure 3:6 Involvement in Care 
0% 20% 40% 60% 80% 100%
Advised to contact rheumatology team
if arthritis flares
Involvement in treatment decisions
Feedback for service/care requested
Written plan about treatment
 
3.3.5.2. Satisfaction with Care 
Hill Satisfaction Questionnaire 
Patients were asked to give their overall opinion of the care they received in the 
rheumatology outpatients department. An overall satisfaction score was calculated 
for each patient as well as a mean and median for the whole group. One hundred 
patients completed the satisfaction questionnaire. The lowest score possible is 1 with 
a maximum of 5, the higher the number the greater the satisfaction. Scores above 3 
indicate satisfaction and below 3 indicate dissatisfaction. The mean scores and 
standard deviations for each subgroup are summarised in Figure 3.7. The mean score 
in each subcategory was above three, indicating satisfaction with the care provided. 
The mean scores were fairly similar across each subcategory; empathy with the 
patient and access and continuity having the lowest mean scores at 3.71 and technical 
quality and competence being rated highest at 4.17. The overall mean satisfaction 
score was 3.89 (range 2.08 - 4.92). 
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3.4.1. Standards of Care and Patient Satisfaction 
The standards of care audit in our population of patient shows that care is satisfactory 
in some areas but there are many aspects of care in which improvement is needed to 
meet ARMA standards. The majority of patients are seen and assessed frequently by 
rheumatologists and specialist nurses, and most patients have been offered written 
information about RA but clinicians are particularly poor at giving information about 
benefits and this most likely reflects the fact that nurse specialists and doctors often 
know very little about this subject themselves. The fact that all patients with early 
disease (less than 2 years) had been seen by a rheumatologist within six months of 
diagnosis would suggest an improvement in recognising inflammatory arthritis in 
primary care and an appreciation that patients should be referred early. The majority 
of patients feel they have been involved in decisions about their treatment but the 
majority have not been given written care plans. Clinicians are offering advice about 
cessation of smoking to over two thirds of smokers but less than a third had been 
offered advice about exercise programmes.  
 








In the last few years the focus of treatment in RA has changed to early aggressive 
treatment, with better treatments available and the department has also developed 
closer working relationships with occupational therapist and podiatrists. However, 
despite these changes only a third of patients with early disease had seen the 
physiotherapists, less than 10% reported seeing an occupational therapist and no-one 
reported seeing a podiatrist within six months of diagnosis. There may be some 
confusion about the terms OT and podiatrist which may account for the greater 
number claiming to have seen a physiotherapist, but even so, the numbers are small. 
One other possible explanation is recall bias and also in those with longstanding RA 
asking patients to recall events within the first 6 months of diagnosis has inherent 
difficulties.  
 
Most patients know to contact the rheumatology department should they experience a 
flare of their arthritis. However, between outpatients visits, although GPs frequently 
ask about blood tests, other possible signs and symptoms of co-morbidities are not 
being checked. One possible explanation for these findings is a lack of 
communication between primary and secondary care as rheumatologists often feel 
that management of blood pressure and cholesterol for example should be done by 
the GPs, but the GPs often think that this being undertaken in the rheumatology 
department as the patients are being seen frequently in secondary care. Another 
possible explanation of these findings is patient recall. This may also represent a lack 
of recognition by GPs of the association between RA and cardiovascular disease. 
[Bell et al. 2011] 
 
These findings suggest that for patients in south east London an integrated care 
pathway would be ideal which ensures that patients receive the information they 
require, as well as ensuring they are referred on appropriately to other health care 
professionals and ensuring that patients are screened for other co-morbidities and 
finally bridging the gap between primary and secondary care.  
 
Setting up the Lambeth and Southwark ARMA local network has been an important 
step. The ARMA network has brought together patients and the different 
stakeholders within secondary care who look after people with RA and has facilitated 
new important relationships. The ARMA network may also help to bridge the gap 
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between primary and secondary care and has already engaged with podiatry which is 
a primary care based specialty.  
 
Despite the shortfalls in the service provided as shown by the ARMA standards of 
care audit, patients overall are satisfied with the care they are receiving. The overall 
satisfaction was rated at 3.89. The possible range is 1-5 and any score over 3 is 
considered to show satisfaction. Technical quality scored highest (4.17) suggesting 
that patients feel that their doctors are competent, however, empathy scored lowest 
(3.71) suggesting there is some way to go in addressing all of the patients concerns. 
This has been born out to a degree in the qualitative work which shows that patients 
often feel that nurses address issues that doctors do not, such as exploring emotional 
issues and the effect on their everyday lives that doctors often do not enquire about. 
Although having a more empathic attitude towards patients may improve satisfaction 
rates, it may also be that it is important for patients to see both specialist nurses as 
well as doctors as there is no doubt that they often provide help with different aspects 
of the disease and that clinicians should be assessing satisfaction with the service as a 
whole and not just the service as provided by doctors or nurses. 
 
3.4.2. Focus Groups: Defining Patients Needs 
This qualitative study identified three key areas of importance to our RA patients and 
their needs. These are; the personal impact of RA, information needs, and health care 
delivery. The study aimed at looking at the needs of RA patients with regards to 
outpatient care. Despite the remit and the semi structured interview schedule patients 
talked quite extensively about the effect of RA on themselves and their everyday 
lives. They described vividly the pain they suffer as well as the emotional toll RA 
has on them. There was also a feeling of lack of understanding from work colleagues 
but also from members of their own families. These issues in some way mirror some 
of the findings in the satisfaction survey which showed that patients were least 
satisfied with the empathic attitude of doctors. It is important to understand and 
address patients’ emotional needs as well as physical needs. Rheumatology specialist 
nurses may be best placed to address these issues. 
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Despite the fact that most RA patients report that they had been given written 
information about RA in this study, most wanted more information about RA and its 
treatment. It seems that there is not a universal medium for delivery with which 
everyone is in agreement. While many prefer to use the internet to access their 
information not all are computer literate or have computers. Some patients prefer 
group meetings while others are put off by this suggestion. Although it is clear that 
clinicians need to provide more robust information about RA and its treatments, this 
will need to be provided in a variety of formats. Another aspect which was 
mentioned by the patients which was also picked up on the ARMA standards of care 
audit was the lack of information on social services and benefits. As stated 
previously this is likely due to the fact that doctors and nurse themselves may have 
little knowledge of these areas. Clearly further information about the services and 
benefits available at both a national and local level need to be provided.  
 
Most rheumatologists will agree that patients with RA should have immediate access 
in times of a flare of disease and this is something that patients felt strongly about, 
but they also commented on the difficulty of achieving this. Some patients use the 
relationship they have developed with specialist nurses to gain access to 
rheumatologists in times of need whereas a considerable number of patients will just 
‘grin and bear it’. It is important that patients do have access when needed and 
although a helpline number exists for these patients only a few knew about it. 
Patients need to be informed and reminded of how to access care between 
appointments should they experience a flare of disease and this access needs to be 
reliable so that they will use it appropriately. Relationships between staff and patients 
are clearly important and patients in this study described their relationships with 
specialist nurses more fondly. Continuity of care is important for patients as is being 
given time in an appointment and having an understanding and sympathetic attitude. 
Patients dislike waiting for long periods to be seen and then for the appointment to be 
rushed. These considerations need to taken into account when designing follow up 
clinics for RA patients, this will not necessarily be easy given the pressures on 
appointments but by ensuring that patients are seen by both specialist nurses and 
doctors will in some way alleviate this. Rheumatologists however, still need to 
appreciate that patients need to be given time to address their problems which may 
not just be related to their joints. 
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3.4.3. Perceived Barriers to Integrated Care in RA 
This qualitative study identified three key areas in which there were perceived 
barriers to seamless integrated care in RA from the perspective of patients, carers, 
specialists and GPs. These are early referral, limitations of ongoing care for 
established RA and management of acute flares. The study took place during a 
period in which NICE guidelines and other UK care strategies were being developed, 
and therefore helps place the findings in context. The results are relevant as there are 
few multi-perspective studies in rheumatology [Chard et al. 2002] and the 
multiperspective qualitative approach is very useful to capture the experiences of all 
stakeholders involved in the treatment and care [Kendall et al. 2009; Worth et al. 
2009; Black et al. 2009; Exley et al. 2005].  
 
This qualitative study was conducted in three out-patient clinics and three PCTs 
consisting of 79 participants of whom 37 were patients. It is difficult to assess how 
generalisable the findings of this study are, although patients were selected from two 
different clinics. The question over whether the emerging themes are general ones or 
merely represent local issues is difficult to answer although evidence from previous 
studies would suggest that similar issues occur more widely, examples include 
previous studies which showed delays in referral caused by the presence or absence 
of positive blood results [Suter et al. 2006; Robinson et al. 2010], the need for good 
access and working relationships with specialists [Bernatsky et al. 2010] and the lack 
of experience/knowledge of the primary care physician [Jacobi et al, 2004]. The lack 
of time with rheumatologists and lack of communication between primary and 
secondary care has also been noted in other parts of the world [Bernatsky et al. 
2010].  
 
Qualitative approaches allow patients to give first-hand accounts of their 
experiences, in this case their experience of the care provided in primary and 
secondary settings. By focusing on detailed descriptions and their meaning, such in-
depth accounts, from semi-structured interviews, may uncover aspects that cannot be 
readily captured by structured questionnaires and provide information that is helpful 
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when trying to re-organise services. To date little research has addressed the views of 
all stakeholders involved in the care of RA patients.  
 
Delay in referral, highlighted in the present study, has also been suggested in 
previous guidelines and observational studies from the UK [National Audit Office, 
2009; Steward et al. 2009] and Europe [Raza et al. 2011]. Experience with both the 
Norfolk Arthritis Register [Harrison et al. 2000] and the Steroids in Very Early 
Arthritis trial [Verstappen et al. 2010] have shown that it is possible to see UK 
patients with inflammatory arthritis in the early stages of their disease. The possible 
causes of delay in referral are complex and there may be several explanations, such 
as reflecting organisational aspects; however, alternate explanations may include 
patient issues such as the disparity between actual observed and perceived time to 
referral in those patients with long disease duration, who may find it difficult to 
accurately estimate any delays after such long periods. Patients may also take some 
time to identify their symptoms and hence achieve referral, which may be reflected 
in a perceived delay in referral. Finally it is not certain if many patients present with 
features that could be interpreted as leading to rheumatoid arthritis but, over time, 
melt away and do not progress. Other publications have suggested that people with 
inflammatory arthritis delay seeking medical advice [National Audit Office 2009] 
which could also impact on the time to referral to secondary care. In particular 
previous studies have shown that ethnicity may play a part in the delay in people 
seeking help [Kumar et al. 2010] as well as their willingness to accept aggressive 
treatment [Constantinescu et al. 2009]; these observations are pertinent given the 
multicultural population served by South London. However, the issue of people 
delaying seeking help was not discussed by patients or GPs. One clear message from 
research with GPs was that they are concerned about their role as “gatekeepers” to 
secondary care. This potentially creates reluctance to refer patients with possible 
inflammatory arthritis for specialist advice and is a barrier that needs to be removed.  
  
There are several limitations in the ongoing management of established RA that 
could be overcome by changes in the arrangements of the service. One major issue is 
insufficient time in secondary care appointments so that clinicians do not fully 
address major concerns for patients. The greater involvement of specialist nurses has 
been particularly helpful [Tijhuis et al. 2003], but is not enough by itself. The 
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evidence suggests that specialists should devote more time and resources to the 
follow up of patients with established RA [Lempp et al. 2006]. The NHS 
Musculoskeletal Framework should assist this goal by transferring stable 
musculoskeletal disorders to community based units and allowing specialists to focus 
on managing RA. This will require a re-evaluation of new to follow-up ratios as low 
ratios, often considered a mark of effective care, may actually indicate poor quality 
care in RA.  
  
A second important issue is the limited knowledge many GPs have about RA 
[Stewart et al. 2009; Bernatsky et al. 2010; Jacobi et al. 2004]. This reflects not only 
the absence of musculoskeletal disorders from the Quality and Outcomes Framework 
but also the dearth of rheumatology teaching in the postgraduate training of UK GPs 
[National Audit Office 2009]. Whilst some GPs provide high quality care, this is by 
no means universal [Stewart et al, 2009]. It is impractical to equip all GPs with 
enough expertise to make significant inputs into the management of RA patients, and 
the best solution may be to make better use of those GPs with particular expertise in 
the field. This has been utilised in some parts of the country by the establishment of 
so-called GPSIs (GPs’ with a specialist interest). Many of these GPs could be trained 
within rheumatology departments running clinics alongside consultants gaining 
greater insight and knowledge, which can then be transferred into the community 
setting.  
  
The final key issue is the need for close collaboration between primary and 
secondary care. Terminology may hinder improvements of service as the distinction 
actually lies between specialist and generalist. As RA is relatively uncommon and 
GPs have limited knowledge about the disease, much of its care needs to be managed 
by specialists. However, there needs to be better links between specialists and the 
community they serve and good working relationships between GPs and specialists 
and this might be better served by basing specialist services within the community. 
Better professional relationships could also be established by inviting community 
services into specialist centres to meet specialists and to organise teaching sessions. 
These ties would need to be continually maintained and would require commitment 
from both sides as it is unlikely that monetary resources would be available through 
the NHS although other sources could be sought. However, RA patients often need 
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direct access to X-rays and other specialist opinions. Exact solutions would have to 
be determined at a local level depending on issues such as travel for patients and 
local community facilities. This is a controversial matter that cannot be readily 
resolved. 
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CHAPTER 4.   OVERLOOKED AREAS: FATIGUE 
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4.1. INTRODUCTION 
Fatigue is common in rheumatoid arthritis (RA) and its absence characterises disease 
remission [Pinals et al. 1981]. Qualitative studies have highlighted the importance 
people with RA attribute to fatigue [Carr et al. 2003; Ahlman et al. 2005]. Between 
40-80% of RA patients attending specialist clinics have clinically relevant fatigue, 
which is a feature of active disease. [Belza 1995; Belza et al. 1993; Pinals et al. 1981; 
Wolfe et al. 1996] By contrast few cases (under 5%) are in remission [Balsa et al. 
2004], in which there is no fatigue. These observations suggest disease activity is one 
underlying factor, in the pathogenesis of fatigue in RA. Surprisingly the ways in 
which disease activity influence RA fatigue has not been investigated to any extent.  
 
In early RA, fatigue has been shown to be a dominant factor in determining quality 
of life and psychosocial aspects of daily living. The exact cause of fatigue in RA has 
not been established but several studies have shown that fatigue correlates most 
strongly with pain and depression [Jump et al. 2004, Huyser et al. 1998]. Wolfe 
coined the term "fibromyalgic RA" to describe the sub-set of patients with high 
levels of fatigue, pain and depression [Wolfe et al. 2004]. Previous studies have also 
shown that high fatigue scores are associated with greater levels of disability [van 
Hoogmoed et al. 2010]. This finding might be explained by fatigue being a marker of 
disease activity. Alternative explanations for the relationship of fatigue to disability 
include the interaction of fatigue with psychological symptoms or perhaps a more 
direct link to disability. 
 
The key aim of this study is to define the relative contribution of RA disease activity 
to fatigue in comparison to factors such as pain and depression in established RA. 
These inter-relationships were examined in two cross-sectional studies using 
different instruments to assess fatigue. They also evaluated the comparative effects 
of DMARDs and anti-TNF on RA fatigue in prospective observational cohorts in 
both early and established RA.   
 
A further study examined the relationship between fatigue and disability. Reducing 
disability is a key therapeutic aim in RA. The focus on improving disability by 
reducing synovial inflammation and joint damage has overshadowed treating other 
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potential drivers of disability. Fatigue exemplifies another treatable disability driver. 
RA patients find fatigue a troubling symptom and there is a growing consensus it 
should be a core RA outcome measure [Kirwan et al. 2007].  
 
Several measurement tools evaluate RA fatigue. The simplest is the unidimensional 
fatigue VAS; this is easy to score but only assesses overall severity. 
Multidimensional tools might be preferable as fatigue is likely to be multi-factorial. 
One multidimensional measure, the functional assessment of chronic illness therapy 
fatigue scale (FACIT-F), has been employed in many trials in RA [Cella et al. 2003]. 
Another measure, the multidimensional assessment of fatigue (MAF) questionnaire, 
was specifically designed for RA fatigue [Belza 1995]. A third measure, the 
Multidimensional Fatigue Symptom Inventory (MFSI), is a comprehensive tool 
[Stein et al. 1998].  
 
High fatigue scores are known to be associated with greater levels of disability 
[Pollard et al. 2006]. This relationship could be explained if fatigue is a marker of 
disease activity, or if it is associated with psychological symptoms that are driving 
disability or even if there is a direct link with disability. The associations between 
fatigue and RA disability were explored focusing on the different ways of measuring 
fatigue using either a visual analogue scale or multidimensional fatigue tools (MAF, 
MFSI and FACIT-F).  
 
Currently there is no agreed best measure of fatigue in RA. Therefore a further 
analysis of this second study aimed to determine whether it is best to measure fatigue 
in RA using a unidimensional or multidimensional tool. It also explored what the 
current fatigue tools are actually measuring by using exploratory factor analysis and 
a rotated factor matrix, which would allow us to determine the most useful questions 
to capture fatigue in RA. 
 
4.2. OUTLINE OF PATIENTS AND METHODS 
4.2.1. Patients 
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4.2.1.1.Clinical Association Studies 
The RA patients met the 1987 criteria of the American College of Rheumatology, 
and were attending outpatient clinics in south east London. There were two patient 
groups. The initial clinical association study assessed fatigue using a visual analogue 
scale (VAS); the second clinical association study (alternative measure study) also 
used the vitality scale of the SF-36 (Appendix 9) as an alternative measure of fatigue. 
Demographic details of the patients are summarised in Table 4.1. 
 









Female 189 (79%) 245 (76%) 
Male 49 (21%) 76 (24%) 
Age mean (range) 60 (26-85) 64 (24-91) 
Disease duration mean (range) 11 (0-37) 12 (1-52) 
Nodular Disease 49 (20.59%)  
Rheumatoid factor 199 (83.61%)  




4.2.2. Treatment Effects Studies 
4.2.2.1. Early RA 
Data collected from patients enrolled in the early rheumatoid arthritis network 
(ERAN) was used for the early rheumatoid arthritis study. ERAN is a national 
network of rheumatologists following outcomes in patients with RA for less than two 
years at enrolment. There are 19 centres across the UK and Ireland and standardised 
information is collected on case report forms at first presentation to secondary care, 
then again at 3 to 6 months, at 1 year and annually thereafter. The choice and 
intensity
 




4.2.2.2. Established RA 
Data were collected from 54 patients receiving DMARDS and 30 patients receiving 
anti-TNF therapy in one rheumatology outpatient department in south east London. 
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These patients met the 1987 criteria for RA. Data were collected prior to treatment 
and after 6 months of DMARD therapy and after 3 months of anti-TNF therapy. 
Patients who stopped treatment for any reason were excluded.  
 
4.2.2.3. Fatigue Measurements Study 
For the fatigue measurements study, data were collected from 105 patients with RA 
as defined by the 1987 ACR criteria, who were consecutive attendees in a routine 
outpatient clinic at King’s College Hospital. The sample comprised 80 females and 
25 males. Their mean age was 60 years (range 24-88); mean disease duration 13 
years (range 0.1-54) and 70% were rheumatoid factor positive. 20 patients were 
receiving biologics and 78 patients receiving single or combination disease 
modifying drugs. Their mean DAS28 was 4.53 (SD 1.44) and HAQ 1.49 (SD 0.8). 
At the time of assessment, the majority of patients (93 of 105, 89%) were taking 
DMARDs. Informed consent was obtained from each participant and the study was 
fully approved by the Research Ethics committee. 
 
4.2.3. Assessments 
4.2.3.1. Clinical Association Studies 
Fatigue was measured using a 100mm VAS and the vitality subscale of the SF-36 
questionnaire. Demographic data (age, sex and disease duration) was collected as 
well as information on treatment (current DMARDs and anti-TNF). Pain (100mm 
VAS), disease activity score (DAS) for 28 joint counts and its constituent 
components (28 tender joint counts, 28 swollen joint counts, patient-global 
assessment and ESR), early morning stiffness (EMS) in minutes, modified health 
assessment questionnaire (HAQ) score (Appendix 10) and physician global 
assessment score was recorded for each patient. Patients in the initial study were also 
assessed for the presence of erosive disease, nodules, rheumatoid factor, 
haemoglobin, creatinine, all concomitant medications and illnesses.  
 
4.2.4. Treatment Effects Studies 
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4.2.4.1. Early RA 
All ERAN patients completed baseline data at first presentation which includes 
demographic data including age, sex, ethnicity, concomitant diseases and any extra 
articular RA disease. At each visit disease activity measures including 28 tender and 
swollen joint counts, patient global assessment (visual analogue scale 0-100mm), 
physician global assessment and blood tests including ESR are undertaken, which 
also allows the DAS28 to be calculated for each patient. Patients are also asked to 
complete the HAQ and the short form 36 (SF-36) which is a generic health status 
measure at each visit. 
 
4.2.4.2. Established RA 
Demographic data including age, sex and disease duration were collected as was 
information on treatment comprising current DMARD therapy and anti-TNF. Pain 
(100mm visual analogue scale), disease activity score (DAS) for 28 joint counts and 
its constituent components, comprising 28 tender joint counts, 28 swollen joint 
counts, patient-global assessment (100mm visual analogue scale), ESR, early 
morning stiffness (EMS) in minutes, modified health assessment questionnaire 
(HAQ) score and physician global assessment score (100mm visual analogue scale) 
were recorded in all cases.  
 
4.2.4.3. Fatigue Measurements Study 
Fatigue was assessed using four measures: A double anchored 100mm visual 
analogue scale (VAS) and three fatigue questionnaires; the FACIT-F (Appendix 11), 
the MAF (Appendix 12) and the multidimensional fatigue symptom inventory 
(MFSI-Appendix 13)  
 
All questionnaires were self administered. The FACIT-F is a 13 item questionnaire 
and scores range from 0-52, it is an inverse scale, the higher the score the less the 
fatigue. The FACIT-F has four subscales; General fatigue, physical fatigue, mental 
fatigue and vigour. The MAF contains 16 items and scores range from 0 (no fatigue) 
to 50 (severe fatigue). The MAF has four subscales; Severity, distress, degree of 
interference of daily living and timing. The MFSI includes 30 items and scores range 
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from -24 to 96. The MFSI has five subscales; General fatigue, emotional fatigue, 
mental fatigue, vigour and physical fatigue.  
 
Anxiety and depression were assessed using the HADS (Appendix 14). This is a self 
completed questionnaire which has 14 items; seven items measure anxiety and 7 
items measure depression. [Zigmond et al. 1983] Anxiety and depression are 
measured separately with a range of scores between 0 and 21 for each subscale. 
Scores of 0-7 in respective subscales are considered normal, with 8-10 borderline and 
11 or over indicating clinical 'caseness'. 
 
Demographic data (age and disease duration), physician global assessment, pain 
VAS, early morning stiffness and the disease activity score (DAS) for 28 joints and 
its constituents (tender joint count, swollen joint count, erythrocyte sedimentation 
rate (ESR) and patient global assessment) were recorded in all cases. 
 
4.2.5. Analyses 
4.2.5.1. Clinical Association Studies 
Data analysis was done using the Statistical Package for the Social Sciences (SPSS 
for Windows 11). Fatigue was analysed in two ways. On a first approach, taking 
fatigue as a continuous variable, simple linear regressions were used to study the 
individual effects of continuous variables like age, pain, physical assessment, DAS, 
etc. The effects of binary variables were assessed with two sample t-tests. Bivariate 
correlations were also calculated for each variable with fatigue. 
To determine the key factors that contribute to fatigue in rheumatoid arthritis, these 
univariate analyses were followed by a multiple linear regression model fitted to all 
the variables in a stepwise manner, paying special attention to multi-collinearities, 
interactions and potential mediating relationships. 
 
4.2.6. Treatment Effects Studies 
4.2.6.1. Early RA 
Data analysis was done using the Statistical Package for the Social Sciences (SPSS 
for Windows 11). Simple descriptive analyses of baseline data were calculated. 
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Means for all 8 domains of the SF-36 were assessed. To investigate changes over 
time paired results at baseline and at 12 months were calculated and bivariate 
correlations and linear regression analyses were undertaken between different 
domains. Missing data were imputed using the standard method recommended for 
SF-36; whereby missing values were replaced by scale means where valid responses 
were available for at least half of the scale items. 
 
4.2.6.2. Established RA 
Data analysis was done using the Statistical Package for the Social Sciences (SPSS 
for Windows 11). To assess the effects of treatment two sample independent t-tests 
and bivariate Spearman’s correlations were used. 
 
4.2.6.3. Fatigue Measurement Study 
Simple descriptive analyses (including means and standard deviations) were applied 
to all the data. Bivariate Spearman’s correlations were carried out for each variable 
against HAQ and each measure of fatigue. Simple linear regression was undertaken; 
any variable which did not reach significance at this level was not included in any 
further analysis. Simple regression was followed by stepwise backward multiple 
regression using HAQ as the dependent variable. In the multiple regression model 
the DAS28 was used as the measure of disease activity, therefore, tender joint count, 
swollen joint count, ESR and patient global assessment were not used as the DAS28 
is a composite measure of these variables. A multiple regression model for each 
measure of fatigue was undertaken. Collinearity analysis was carried out for each 
final model. 
 
To explore the different dimensions captured in each fatigue questionnaire and also 
assess their relationship with anxiety and depression, simple descriptive analyses 
were applied to the data, as well as Spearman’s correlations. In this study, 
correlations of r≥0.6 are reported as strong correlations, r≥4 and <6 as moderate 
correlations and r<4 as weak correlations. Cronbach’s alpha was used to test the 
internal validity of the items in the fatigue questionnaires. Following this an 
exploratory factor analysis of the fatigue questionnaires was undertaken. Factor 
analysis can reduce complex interrelationships to a relatively simple linear 
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expression. A rotated factor matrix was performed with all the questions from each 
questionnaire as well as the fatigue VAS and the HADS scores. Unrotated factors 
define the most general patterns of relationship in the data and a rotated factor matrix 
can delineate the distinct clusters of relationships.  
 
4.3. RESULTS 
4.3.1. Fatigue and Its Clinical Associations 
4.3.1.1. Frequency and Distribution of Fatigue 
RA patients had high fatigue levels; 80% of patients had clinically relevant fatigue 
(VAS scores 20mm) and over 50% had high fatigue scores (VAS scores 50mm). 
The distribution of fatigue scores in this population is shown in Figure 4.1. Fatigue 
was also assessed by the SF-36 energy and vitality score (range 0-100). The lower 
the score the more severe the fatigue. The mean SF-36 energy and vitality score in 
the cohort was 51; which is substantially less than normal UK populations who have 
reported mean scores of 61-65. 
 
Figure 4:1 Fatigue Scores in Initial Study 
 
4.3.1.2. Correlations with Fatigue 
The initial clinical association study showed VAS fatigue scores were significantly 
correlated with disease activity measures including DAS and VAS pain and also 
HAQ and early morning stiffness (Table 4.2). In addition there were significant 
associations with some co morbidities (number of concomitant diseases, depression 
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(fatigue score 68.6 vs. 47.6, p=0.002) and a previous diagnosis of fibromyalgia 
(fatigue score 72.1 vs. 47.7, p=0.001) and some prescribed drugs (methotrexate, 
tramadol and paracetamol). Fatigue was not associated with other DMARDs 
(sulphasalazine, hydroxychloroquine, leflunomide, gold, azathioprine, cyclosporin, 
d-penicillamine), anti-TNF therapy (etanercept, adalimumab, infliximab) and 
steroids (Table 4.3). It was also unrelated to age, disease duration, sex, rheumatoid 
factor, rheumatoid nodules, anaemia, diabetes mellitus, and renal, respiratory or 
ischaemic heart disease. 
 
The second clinical association study (alternative measure study) showed similar 
significant correlations between VAS fatigue scores and both DAS and VAS pain 
scores. The SF-36 energy and vitality scores correlated (Spearman’s rank correlation) 
strongly with fatigue VAS scores (r= 0.58, p<0.001). Correlations with measures of 
disease activity were similar whether fatigue was measured using the VAS or the SF-
36 energy and vitality score; SF-36 energy and vitality score (DAS r=0.41, p<0.001; 
HAQ r=0.46, p<0.001), VAS fatigue (DAS r=0.47, p<0.001; HAQ r=0.46, p<0.001). 
SF-36 mental health scores also showed a significant relationship with SF-36 energy 
and vitality score (r=0.6, p<0.001) as well as VAS fatigue (r=0.46, p<0.001). 
 
4.3.1.3. Multiple Regression 
Multiple linear regression in the initial clinical association study showed five 
variables explained 53% of variation in VAS fatigue scores (Table 4.4). Pain had the 
strongest association, then HAQ and depression. Methotrexate and erosive disease 
had negative associations, indicating patients receiving methotrexate had less fatigue 
and those without erosions had more fatigue. 
 
Multiple linear regression in the second study showed three variables explained 53% 
of the variation in VAS fatigue scores (Table 4.4). Pain had the strongest positive 
association, followed by SF-36 mental health score (in an inverse scale a negative 
association indicates a positive relationship) and patient global assessment. Finally 
an ordinal regression model of the relationships of SF-36 energy and vitality scores 
showed three variables had significant associations: HAQ and pain had the strongest 
association followed by SF-mental health scores (Table 4.4). 
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Table 4:2 Linear Regression Analysis of Fatigue VAS (a) 
Continuous In Initial Study 
 
Variable Coefficient Significance 
Age -0.13 P=0.31 
Disease Duration -0.17 P=0.54 
Early Morning Stiffness 0.08 P<0.001 
Patient Global Assessment 0.64 P<0.001 
Pain 0.66 P<0.001 
Health Assessment Questionnaire 17.5 P<0.001 
Tender Joint Count 1.8 P<0.001 
Swollen Joint Count 1.7 P<0.001 
Physician Global Assessment 0.43 P<0.001 
ESR 0.18 P<0.01 
DAS28 7.6 P<0.001 
Haemoglobin -0.79 P=0.49 
Creatinine -0.09 P=0.21 




Table 4:3 Regression Analysis of Fatigue VAS (b) 
With Binary Variables 
 
Variable Coefficient Significance 
Sex (male) -5.3 p=0.22 
Rheumatoid Factor -3.8 p=0.41 
Erosive Disease -6.5 p=0.08 
Nodules -2.8 p=0.52 
Methotrexate -12.2 p<0.0001 
Adalimumab 4.2 p=0.69 
Etanercept 2.5 p=0.73 
Infliximab -9.7 p=0.43 
Corticosteroids 3.5 p=0.59 
Fibromyalgia 24.4 p<0.001 
Diabetes 7.6 p=0.27 
Depression 20.9 p=0.002 
Hypothyroidism 4.6 p=0.54 
Respiratory Disease 1.5 p=0.79 
Ischaemic Heart Disease 11.4 p=0.08 
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Table 4:4 Factors Contributing To Fatigue 
Fatigue Assessed Using VAS And SF-36 Vitality Scale. Analysis by Multiple Linear Regression 
 
Initial Clinical Association Study (n=238) Alternative Measure Clinical Association Study (n=274) 











   Lower Upper     Lower Upper  
Fatigue 
(VAS) * 
Pain (VAS) 0.50 0.39 0.61 0.0001 
Fatigue 
(VAS) ‡ 











 = 0.53 
Mental Health 
Score 
-0.39 -0.51 -0.27 0.0001 
 Depression 10.73 1.18 20.29 0.03  
Patient Global 
Assessment 
0.16 0.02 0.31 0.03 









-7.47 -12.62 -2.32 0.01 (SF-36) § Pain (VAS) 1.02 1.01 1.03 0.0001 
      Odds Ratio 
Mental Health 
Score 
0.95 0.94 0.97 0.0001 
 
* Excluded variables: DAS 28, TJC, SJC, physician global assessment, patient global assessment, ESR, EMS, age, disease duration, sex, seropositivity, rheumatoid 
nodules, Hb, Cr, diabetes mellitus, hypothyroidism, respiratory disease, ischaemic heart disease, number of concomitant diseases, fibromyalgia, tramadol, 
paracetamol, sulphasalazine, hydroxychloroquine, leflunomide, gold, azathioprine, cyclosporin, d-penicillamine, anti-TNF therapy, corticosteroids. 
‡ Excluded variables: DAS 28, TJC, SJC, physician global assessment, HAQ, EMS, CRP, ESR, age, sex, disease duration. 




4.3.2. Effects of Treatment on Fatigue in RA 
4.3.2.1. Early RA 
The sample was comprised of 265 females and 130 males. The mean age was 55 
years (range 18-88). The ethnic grouping of patients recruited into the study 
represented Caucasian, 96% and others 4%. At initiation into ERAN, 378 patients 
were on single or combination DMARD therapy, which comprised 17 patients on 
hydroxychloroquine, 148 on sulfasalazine, 173 on methotrexate, 11 on other 
monotherapy and 29 on combination DMARDs. At baseline the mean DAS28 was 
4.78 (SD 1.55), ESR 32(SD 25), tender joint count 8 (SD 7), swollen joint count 6 
(SD 6), CRP 25 (SD 33) and HAQ 1.1 (SD 0.8). 
 
The SF-36 showed substantial reductions in quality of life in patients with early RA, 
compared to reported general populations [Garratt et al. 2003]. There was major 
impact on physical function (mean 35.6, SE 0.6), general health (mean 44.3, SE 0.3), 
social function (mean 35.7, SE 0.2), mental health as well as vitality/fatigue (mean 
48.4, SE 0.3). (Table 4.5) 
 
After twelve months of treatment there were improvements in physical function 
(mean increase 2.5 (SD 11.8); p=0.01) and in role physical (mean increase 2.2 (SD 
12.1); p=0.03). However, there were no significant changes in vitality (fatigue), 
social function and mental health domains. (Figure 4.2) 
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Table 4:5 SF-36 in Early RA Patients 
 
 Mean Values 
SF-36 Measures Early RA Patients General Population 
 Baseline Visit 6 Months 12 Months [Garratt et al, 2003] 
Physical Functioning 35.6 37.6 38.5 79.2 
Role Physical 36.4 39.6 40.1 76.5 
Bodily Pain 41.1 37.9 38.0 76.9 
General Health 44.3 43.6 44.0 68.7 
Vitality 48.4 48.8 47.6 61.2 
Social Functioning 35.7 35.8 35.7 78.6 
Role Emotional 39.1 41.8 41.6 75.0 



























4.3.2.2. Established RA 
DMARDs: The sample comprised 54 patients with a mean age of 62 (range 33-82), 
mean disease duration of 10 years (range 1-42), mean fatigue VAS 56 (SD 27.2), 
mean pain VAS 61 (SD 25.2) and mean DAS28 5.7 (range 2.7-8.5) 
 
Over 6 months VAS fatigue scores fell from a mean of 56 to 49 (p=0.176). Pre-
treatment 34 (63%) of patients had high levels of fatigue (VAS scores 50mm); post 
treatment this fell to 26 (48%). The falls in VAS fatigue scores correlated with 
improvements in pain and DAS-28 (r=0.63, p<0.001 and r=0.69, p<0.001 
respectively). The effect sizes of DMARD therapy on DAS, pain and fatigue were 
79%, 66% and 42% respectively.  
 
Anti-TNF: The sample comprised 30 patients with a mean age of 53 (range 22-81), 
mean disease duration of 15 years (range 1-33), mean fatigue VAS 67 (SD 21.9), 
mean pain VAS 65 (SD 21.9) and mean DAS28 6.1 (range 3.7-7.8) 
 
Prior to treatment, the VAS fatigue score of anti-TNF treated patients were 
statistically significantly higher than DMARD treated patients (67 vs. 56, p=0.04) 
although post-treatment it was similar in both groups (50 vs. 49). Over 3 months 
there was a mean fall in VAS fatigue score of 67 to 50 (p=0.009). Pre-treatment 26 
(87%) of patients had high levels of fatigue (VAS scores 50mm); post treatment 
this fell to 15 (50%). The falls in VAS fatigue scores correlated with improvements 
in pain and DAS-28 (r=0.65, p<0.001 and r=0.43, p=0.019 respectively). The effect 
sizes of anti-TNF therapy on DAS, pain and fatigue were 128%, 80% and 73% 
respectively. 
 
4.3.3. Fatigue Measurement Study 
4.3.3.1. Fatigue and Disability 
Median scores for HAQ were 1.6 and for the fatigue measures were between 25 and 
54 (Table 4.6). Allowing for scaling differences by calculating median percent 
maximum scores showed they all assessed disability and fatigue at a similar level 
(HAQ 54%, MAF 56%, MRSI 58%, and FACIT 54%). 
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The different fatigue scores had varying relationships to HAQ when this was divided 
into 6 categories (Figure 4.3). VAS scores showed a straightforward linear 
relationship; it was equally sensitive at high and low levels of disability. The other 
three scores showed “ceiling” effects; so that once disability scores were more than 
1.50 (50% maximum score) there was very little change in the fatigue scores. 
Suggesting that fatigue scores increase with disability scores but once disability 
scores reach a certain level fatigue scores have already reached a maximum and can 
no longer increase with further increases in disability scores. The inverse nature of 
the FACIT score did not impact on this relationship. 
 
Simple linear regression showed significant associations between HAQ and all 
variables (disease duration, pain VAS, tender joint count, swollen joint count, ESR, 
patient and physician global assessment, DAS28, anxiety, depression and all fatigue 
measures) except age (p=0.18) and early morning stiffness (p=0.13); these two 
variables were therefore not included in the final multivariate analysis.  
 
Bivariate correlations showed significant correlations between HAQ and all variables 
except for age (r=0.13) (Table 4.6). HAQ showed moderate correlations with each 
fatigue measure (0.38 vs. Fatigue VAS, 0.32 vs. MAF, 0.38 vs. MFSI, -0.46 vs. 
FACIT-F) 
 
The various fatigue assessments were all inter-related. VAS fatigue scores showed 
moderate correlations with the other fatigue measures (Spearman’s R=0.52 vs. MAF, 
0.43 vs. MFSI and -0.54 vs. FACIT-F. Other fatigue scores showed moderate to high 
correlations with each other (0.77 MAF vs. MFSI; -0.77 MFSI vs. FACIT-F; -0.83 
MFSI vs. FACIT-F). 
 
The fatigue measures all showed moderate bivariate correlations with DAS28 (0.31-
0.54). The fatigue VAS had strong correlations with pain and was the only fatigue 
measure to correlate with the ESR (Table 4.6). MAF, MFSI and FACIT-F showed 
stronger correlations with HADS anxiety and depression scores. None of the fatigue 
measures showed significant correlations with age, disease duration, swollen joint 
counts or physician global assessment. 
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Table 4:6 HAQ and Fatigue Scores 
Medians (Interquartile Ranges) and Spearman’s Correlations are shown. 
 
 Range Median (IQR) 
Bivariate Correlation (Spearman’s) 







HAQ 0 − 2.75 1.62 (1.00, 2.12) 0.57 0.43 0.46 0.21 0.35 0.46 0.29 0.28 0.33 0.46 
Fatigue VAS 0 − 100 54 (35, 78) 0.54 0.59 0.45 0.13 0.24 0.51 0.25 -0.13 0.41 0.46 
MAF 0 − 50 28 (21, 35) 0.31 0.34 0.33 0.01 0.03 0.35 0.30 -0.15 0.58 0.67 
MFSI -24 − 96 25 (13, 43) 0.34 0.28 0.41 -0.08 0.01 0.35 0.29 -0.11 0.76 0.69 
FACIT-F 0 − 52 27 (19, 38) -0.40 -0.38 -0.39 -0.01 -0.10 -0.43 -0.29 0.13 -0.58 -0.70 
 
TJC – Tender Joint Count, SJC – Swollen Joint Count, PGA – Patient Global Assessment, EMS – Early Morning Stiffness 
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Figure 4:3 Fatigue Scores and HAQ Categories 









































0-0.49 0.50-0.99 1.00-1.49 1.50-1.99 2.00-2.49 2.50-3.00
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Fatigue scores were normally distributed and mean (range) fatigue scores comprised 
fatigue VAS 55 (0-100), MAF 27 (0-50), MFSI 26 (-14-75) and FACIT-F 28 (5-52). 
All fatigue scores correlated with HAQ: fatigue VAS (r=0.38, p<0.001), MAF 
(r=0.32, p<0.001), MFSI (r=0.38, p<0.001) and FACIT-F (r=-0.46, p<0.001). 
Backward stepwise regression analyses with HAQ as the dependent variable (Table 
4.7) showed MAF, MFSI and FACIT-F were all independent predictors of HAQ, but 
fatigue VAS was not. DAS28 and disease duration contributed to the variation in 
HAQ in all four regression models. Up to 50% of the variation in HAQ was 
explained by changes in DAS28, FACIT-F and disease duration (model 4). 
 











   Lower Upper  
Fatigue 
VAS 
DAS28 0.26 0.21 0.30 <0.001 
 Disease 
Duration 
0.02 0.02 0.03 <0.001 





MAF DAS28 0.25 0.21 0.29 <0.001 
 Disease 
Duration 
0.02 0.02 0.03 <0.001 





MFI DAS28 0.24 0.19 0.28 <0.001 
 Disease 
Duration 
0.02 0.02 0.03 <0.001 





FACIT-F DAS28 0.21 0.17 0.26 <0.001 
 FACIT-F -0.02 -0.03 -0.02 <0.001 
 Disease 
Duration 





4.3.4. Fatigue Measurement Study 
Simple descriptive statistics with means and standard deviations are shown in Table 
4.8. The fatigue questionnaires showed strong correlations with each other using 
Spearman’s correlation (MAF and MFSI r=0.78, p<0.001, MAF and FACIT-F r=-
0.76, p<0.001, MFSI and FACIT-F r=-0.80, p<0.001). They also showed strong 
correlations with the HADS anxiety and depression scores. In contrast the fatigue 
VAS was most strongly correlated with the pain VAS (r=0.59, p<0.001). The fatigue 
questionnaires had weaker correlations with pain VAS (Table 4.9). 
 
Table 4:8 Fatigue Questionnaires Descriptive Analysis 
 
 Patient Number* Mean (SD) 
Pain VAS 105 49.8 (29.1) 
Fatigue VAS 105 54.7 (27.5) 
HAQ 98 1.5 (0.8) 
HADS Anxiety 98 7.9 (4.3) 
HADS Depression 98 6.1 (3.8) 
MAF 98 26.8 (11.1) 
MFSI 97 26.4 (21.3) 
FACIT 97 28.4 (11.5) 
*Questionnaires with missing data were excluded from the analysis. 
 
Cronbach’s alpha was calculated for internal validity for all items in the fatigue 
questionnaires. This showed an overall Cronbach’s alpha of 0.82 (standardised 0.76), 











Table 4:9 Spearman’s Correlations with Different Fatigue Questionnaires 
 
 Pain VAS Fatigue VAS HAQ HADS Depression HADS Anxiety MAF MFSI 
Fatigue VAS 0.59
†


































































All questions from the fatigue multidimensional questionnaires were then entered 
into a factor analysis. Five dominant factors were identified that contributed to 
fatigue in RA. The five factors contributing to fatigue were: (1) psychological factors 
(anxiety/depression); (2) cognition; (3) fatigue severity; (4) physical interference; (5) 
social interference. The fatigue VAS did not load significantly into any category; its 
highest loading was severity (0.43). Of the 45 questions entered into the factor 
matrix, 12 questions loaded significantly (≥0.50) into factor 1 (psychological 
factors), 10 questions loaded significantly into factor 2 (cognition), with 4 questions 
loading into factor 3 (fatigue severity), 3 questions loading into factor 4 (physical 
interference) and 4 questions loading into factor 5 (social interference). There were 
12 questions which did not load significantly into any factor. (Table 4.10) 
 
Each questionnaire was examined separately to determine which were the major 
factors being measured by the individual multidimensional tools. For the FACIT-F 
the major contributing factor was cognition with 7 questions loading into that factor, 
there was a small contribution from severity with 1 question loading into that factor. 
For the MAF the questions loaded into 3 factors, the predominance was for 
measuring the impact of fatigue on daily living with 4 questions loading into factor 4 
(physical interference) and 4 questions loading into factor 5 (social interference), 
there was also a contribution from severity of fatigue with 3 questions loading into 
factor 3. For the MFSI questionnaire most questions loaded into 2 factors; the 
predominant factor was psychological factors with 11 questions loading into factor 1 
(psychological factors) and 3 questions loading into factor 2 (cognition). (Table 4.11) 
 
In order to identify the most appropriate questions, only items which loaded strongly 
into each dimension (loading >0.6) were included; this reduced the number of 
questions to 25. To further reduce this both clinical interpretation and statistics were 
employed to exclude any very similar questions; keeping the question with the 
highest loading. For example: I feel nervous and I feel tense were felt to be asking 
the same question. The loading into the factor analysis rotated factor analysis was 
0.889 for I feel nervous and 0.672 for I feel tense; therefore, I feel tense was 
excluded from the final model. Consideration was also made to ensure that each 
dimension was represented. This left us with 18 questions, which are shown in Table 
4.12.
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Table 4:10 Factor Analysis Using Rotated Matrix 
 









Fatigue-VAS 0.063 0.281 0.432 0.275 -0.091 
HADS anxiety score 0.715 0.326 0.119 0.228 0.053 
HADS depression score 0.335 0.538 0.232 0.330 0.126 
Individual Questions from Questionnaires 
Feel fatigued -0.134 -0.406 -0.682 -0.089 -0.046 
Feel listless (“washed out”) -0.233 -0.609 -0.303 -0.086 -0.261 
Feel tired -0.188 -0.592 -0.432 -0.024 -0.261 
Feel weak all over -0.182 -0.597 -0.350 -0.301 -0.132 
Have trouble starting things because I am tired -0.337 -0.706 -0.122 -0.154 -0.222 
Have trouble finishing things because I am tired -0.375 -0.647 -0.229 -0.034 -0.234 
Able to do my usual activities 0.010 -0.375 -0.177 -0.277 0.057 
Need to sleep during the day -0.307 -0.401 -0.080 -0.312 0.000 
Am too tired to eat -0.349 -0.386 -0.215 -0.090 0.016 
Have to limit social activity because tired -0.273 -0.706 -0.263 -0.287 -0.235 
Have energy -0.104 -0.274 -0.396 -0.061 -0.096 
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Frustrated by being too tired to do the things -0.370 -0.593 -0.172 -0.067 -0.260 
To what degree have you experienced fatigue? 0.169 0.287 0.869 0.205 0.115 
Severity of fatigue 0.185 0.193 0.848 0.289 0.150 
How often fatigued last week? 0.217 0.221 0.638 0.136 0.250 
Degree fatigue caused you distress 0.586 0.301 0.372 0.397 0.053 
Degree fatigue interfered with household chores 0.170 0.385 0.345 0.328 0.252 
Degree fatigue interfered with cooking 0.252 0.331 0.274 0.591 0.214 
Degree fatigue interfered with bathing/washing 0.251 0.277 0.192 0.823 0.124 
Degree fatigue interfered with dressing 0.330 0.314 0.169 0.791 0.136 
Degree fatigue interfered with working 0.129 0.037 0.087 0.331 0.365 
Degree fatigue interfered with socialising 0.099 0.40 0.268 0.366 0.40 
Degree fatigue interfered with sex 0.062 -0.030 0.111 0.086 0.717 
Degree fatigue interfered with leisure 0.032 0.023 0.004 -0.039 0.823 
Degree fatigue interfered with shopping/errands 0.019 0.154 -0.001 0.034 0.601 
Degree fatigue interfered with walking -0.031 0.219 0.131 -0.020 0.355 
Degree fatigue interfered with exercise -0.019 0.184 0.107 0.114 0.694 
Trouble remembering things 0.481 0.105 -0.002 0.105 -0.204 
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Confused 0.645 0.092 -0.016 0.147 -0.136 
Trouble paying attention 0.656 0.026 0.175 0.142 0.137 
Unable to concentrate 0.700 0.220 0.046 0.081 0.018 
More mistakes than usual 0.526 0.214 0.111 0.190 -0.022 
Forgetful. 0.625 0.103 0.007 -0.007 -0.178 
Muscles ache 0.175 0.637 0.175 0.313 0.005 
Legs feel weak 0.128 0.543 0.249 0.326 0.028 
Head feels heavy 0.328 0.190 0.115 0.244 0.107 
Arms feel weak 0.283 0.364 0.211 0.495 -0.103 
Ache all over 0.292 0.452 0.274 0.395 -0.100 
Body feels heavy all over 0.404 0.521 0.119 0.208 0.108 
Feel upset 0.889 0.096 0.146 0.084 0.077 
Feel nervous 0.864 0.164 0.073 0.074 0.092 
Feel sad 0.723 0.239 0.163 0.121 0.215 
Feel depressed 0.755 0.183 0.182 0.132 0.242 
Feel tense 0.672 0.289 0.191 0.083 0.113 
Distressed 0.762 0.103 0.144 0.125 0.196 
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Table 4:11 Dimensions In Fatigue Questionnaires 
 
 Fatigue Dimensions - Number of Questions Represented 
 1 2 3 4 5 
 Psychological Cognition Severity Physical Interference Social Interference 
FACIT-F 0 7 1 0 0 
MAF 0 0 3 4 4 
MFSI 11 3 0 0 0 
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Table 4:12 Proposed Questions for Final Fatigue Questionnaire 
 
Items Factors 
 1 2 3 4 5 
Psychological      
I am confused 0.645 0.092 -0.016 0.147 -0.136 
I am unable to concentrate 0.700 0.22 0.046 0.081 0.018 
I feel upset 0.889 0.096 0.146 0.084. 0.077 
I feel nervous 0.864 0.164 0.073 0.074 0.092 
I am distressed 0.762 0.103 0.144 0.125 0.196 
Cognition      
My muscles ache 0.175 0.637 0.175 0.313 0.005 
I feel listless (“washed out”) -0.233 -0.609 -0.303 -0.086 -0.261 
I have trouble starting things because I am tired -0.337 -0.706 -0.122 -0.154 -0.222 
I have trouble finishing things because I am tired -0.375 -0.647 -0.229 -0.034 -0.234 
I have to limit my social activity because I am tired -0.273 -0.706 -0.263 -0.287 -0.235 
Severity      
To what degree have you experienced fatigue? 0.169 0.287 0.869 0.205. 0.115 
How severe is the fatigue which you have been experiencing? 0.185 0.193 0.848 0.289 0.150 
Over the past week, how often have you been fatigued? 0.217 0.221 0.638 0.136 0.250 
Physical Interference      
To what degree has fatigue interfered with your ability to bathe or wash? 0.251 0.277 0.192 0.823 0.124 
To what degree has fatigue interfered with your ability to dress? 0.330 0.314 0.169 0.791 0.136 
Social Interference      
To what degree has fatigue interfered with your ability to engage in leisure and 
recreational activities? 
0.032 0.023 0.004 -0.039 0.823 
To what degree has fatigue interfered with your ability to shop and do errands? 0.019 0.154 -0.001 0.034 0.601 
To what degree has fatigue interfered with your ability to exercise, other than 
walking? 
-0.019 0.184 0.107 0.114 0.694 




4.4.1. Fatigue and Its Clinical Associations 
Fatigue is a dominant symptom in RA. In keeping with previous reports [Huyser et 
al. 1998; Riemsma et al. 1998; Rupp et al. 2004; Tack 1990; Fifield et al. 1998; 
Wolfe et al. 2004; Suurmeijer et al. 2001; Fifield et al. 2001; Crosby 1991; Jump et 
al. 2004] the results of this study showed it is strongly associated with pain. Patients 
with active RA had high levels of fatigue, but multiple regression analyses show this 
relationship was less important than the association with pain. Patients diagnosed 
with either fibromyalgia and/or depression have higher levels of fatigue. These 
conditions co aggregate and after adjustment with multivariate analysis, depression is 
the only co-morbidity invariably associated with fatigue. Other co-morbidities 
including cardiovascular and respiratory diseases were not directly related. Several 
other factors are associated with fatigue scores; HAQ scores were positively 
associated, indicating patients with high fatigue levels are markedly disabled. 
Methotrexate use and erosive disease had negative relationships. This suggests that 
methotrexate use is associated with lower levels of fatigue, which may have two 
explanations; firstly patients who are treated with methotrexate have a better 
outcome, secondly that the non-methotrexate treated patients represent a different 
subset of RA patients.  The association of non-erosive disease and higher fatigue 
scores may also represent a specific subset of RA patients in this population.  
Interestingly there were no association between fatigue and age or disease duration, 
indicating peripheral features like muscle mass, which decreases with age and 
disease duration are unimportant. One possible explanation for the lack of 
association between fatigue, disease duration and other peripheral features is that 
fatigue in RA may be central in origin. 
 
If fatigue is to be used as an RA outcome measure, it is crucial to identify the best 
assessment instrument. VAS fatigue scores are simple and reproducible; however, 
multidimensional assessments may provide a more complete picture and improve 
understanding of the clinical relationships of fatigue. There were similar results using 
VAS scores and SF-36 energy and vitality scores and when Wolfe [Wolfe 2004] 
compared VAS scores with three multidimensional fatigue scales he also found that 
the VAS fatigue performed favourably compared to more detailed scales. 
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Nevertheless other validated and detailed instruments that measure RA fatigue, such 
as the Multidimensional Assessment of Fatigue (MAF) [Belza et al. 1993] and 
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) [Cella et al. 
2005], may prove more valuable especially for studies which assess the mechanism 
of fatigue rather than using it simply as another outcome measure.  
 
In conclusion, high fatigue levels are common in RA and in this study are 
predominantly linked to pain and depression. In this cohort the association with 
disease activity appears to be secondary.  
 
4.4.2. The Effect of Treatment on Fatigue in RA 
RCTs provide some evidence that adalimumab [Weinblatt et al. 2003]; methotrexate 
and leflunomide [Strand et al. 2005] reduce fatigue. These falls in fatigue 
accompanied decreases in disease activity. The observational studies in established 
disease show that in routine practice fatigue decreases when active RA is treated with 
anti-TNF and to a lesser extent with DMARDs. These falls mirror decreases in DAS 
scores and pain. Although Wolfe and Michaud [Wolfe et al. 2004] found similar 
levels of fatigue in RA patients on anti-TNF therapy and those not receiving 
biologics, they did not measure fatigue levels prior to commencement of anti-TNF 
and their results are best explained by confounding by indication. Meaning that 
fatigue levels may have been higher initially in the patients who received anti-TNF 
but fatigue was only measured after they received treatment and fatigue levels were 
then similar to patients treated with DMARDs. It is then impossible to say whether 
anti-TNF had a greater effect on fatigue than DMARDs as fatigue may have been 
significantly higher in the patients who went on to receive anti-TNF compared to 
those who received DMARDs.  Indeed the data from this study indicates that patients 
started on anti-TNF therapy had higher fatigue scores at baseline.  
 
TNF receptors have been identified on neurons [Pollock et al. 2002] and chronic 
inflammation is associated with upregulation of these TNF receptors [Inglis et al. 
2005]. TNF has also been implicated in pain pathways [Empl et al. 2001] and thus in 
conditions such as RA the increase in TNF levels may contribute to chronic 
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inflammatory pain. The improvement in pain and fatigue with anti-TNF therapy may 
be due to a direct central effect through interaction with sensory neurons. 
 
The early RA study highlights the impact of early RA across most aspects of health. 
The SF-36 showed substantial overall reductions in quality of life, compared to 
normal populations [Garratt et al. 2003]. Although treatment over twelve months 
showed improvements in the physical domains of the SF-36 (physical function and 
role physical) there were no significant changes in vitality, social function and 
mental health domains. This would suggest that a broader range of treatment 
approaches would benefit early RA patients, focusing on mental as well as physical 
health. One reason for not demonstrating an improvement in fatigue with treatment 
in this group of patients may be in part related to the way in which fatigue was 
measured in these patients. There is no agreed best method of measuring fatigue in 
RA and there are disease specific questionnaires such as the MAF and generic 
measures such as the SF-36. Although there is some evidence of validation for 
measuring fatigue in RA with the SF-36 vitality scale, Hewlett et al [Hewlett et al. 
2007] felt that the scale would benefit from further research, particularly concerning 
content validity for patients with RA and sensitivity to change. Further work using 
different measures of fatigue in RA are recommended to clarify this point. 
 
4.4.3. Fatigue and Disability 
RA disability is influenced by disease activity, joint damage, co morbidities, 
psychosocial factors and depression [Pollard et al. 2006; Esclante et al. 1999; Sokka 
et al. 2000; Wolfe 2000; Rupp et al. 2006; Gettings et al. 2010; Hazes et al. 2010]. 
Many of these factors have cultural contexts [Ravindran et al. 2008; Griffiths et al. 
2000; Bruce et al. 2007]. The results from our study confirm that fatigue is another 
important contributor to disability in RA. The relationship between fatigue and 
disability depends on how fatigue is measured. It is only when multidimensional 
tools are used (MAF, MFSI and FACIT-F) that the effects of fatigue on disability 
become apparent. The multidimensional fatigue measurements incorporate 
psychological factors, and were strongly correlated with HADS depression and 
anxiety scores; however, multivariate analyses took these relationships into account 
and still showed the multidimensional fatigue questionnaires had stronger 
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associations with disability. The results suggest while fatigue seems to be strongly 
associated with psychological factors when measured by multidimensional tools it 
independently contributes to disability in RA, suggesting that it is measuring 
something more than just anxiety and depression. 
 
The findings have several limitations. The patient sample was relatively small and 
came from one centre with an ethnically diverse population. The patients were 
receiving different treatments and were at different stages of their disease. Changes 
over time were not evaluated. Finally, it is not possible to determine causality from 
these results; they cannot differentiate fatigue being disabling from disabled patients 
being more fatigued. However, they show there is a complex interaction between 
fatigue, psychological factors and disability, and this interaction explains why 
multidimensional tools perform better than the unidimensional VAS in predicting 
disability. 
 
Effective RA management involves reducing disease activity but also targeting 
factors like fatigue. The findings in this study suggest it is better to assess fatigue 
using multidimensional tools. The wide use and simplicity of the FACIT-F make it 
the current multidimensional instrument of choice. 
 
4.4.4. Fatigue Questionnaires: What Is Actually Being Measured? 
One of the difficulties of studying fatigue in RA is the lack of agreement over which 
is the best measure of fatigue in RA. Different studies often use different fatigue 
tools meaning that comparison between studies is difficult. There is also a lack of 
agreement by what is actually meant by fatigue and what it is actually measured with 
current questionnaires and the important dimensions that should be measured. 
[Nikolaus et al. 2012] The present study used a simple visual analogue scale for 
fatigue which has the advantage of being quick and easy to administer and score as 
well as three different fatigue questionnaires. The MAF was designed specifically for 
RA patients so has the advantage of being disease specific, the FACIT-F has been 
widely used and seems to be the fatigue questionnaire of choice in many drug trials. 
The MFSI is one of the more comprehensive tools. 
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There was strong correlation between all three questionnaires but less so with the 
fatigue VAS, this correlated most strongly with the pain VAS. The reason for the 
strong correlations between pain and fatigue VAS may in part be related to the way 
in which they are measured, as they are both measured using a visual analogue scale. 
When factor analysis was applied to the questions from all the questionnaires five 
factors or dimensions were identified. These were psychological distress/cognition, 
severity, physical and social interference. These five factors/dimensions are very 
similar to the dimensions described by the Bristol research group who have recently 
designed a new fatigue measure for RA (BRAF-MDQ) [Nicklin et al. 2010]. Their 
dimensions included Living (questions on physical and social interference), 
cognition, emotion and physical (questions on physical interference and severity). 
Although five important dimensions were identified none of the established 
questionnaires in the study measured all five dimensions. Questionnaires were often 
heavily weighted to one domain over another. The FACIT-F was predominantly 
measuring cognition; MFSI was predominantly measuring psychological factors and 
the MAF was predominantly measuring the impact of fatigue (physical and social 
interference).  
 
As five important factors/dimensions of fatigue have been identified in this study, as 
in the Bristol study [Nicklin et al. 2010], an ideal fatigue questionnaire for RA 
should include all five dimensions/factors. In this study using statistics and clinical 
judgement we identified 18 questions which covered all dimensions which could 
make an appropriate questionnaire. Interestingly, there is significant overlap in the 
questions suggested in this study and the questions in the BRAF-MDQ with nine of 
the questions being identical or very similar. To determine the usefulness of the 
suggested items; the proposed questionnaire would need to be subject to test and 
retest as well as checks for internal consistency and validity. This requires further 
research.  
 
When deciding which measure to use in future studies, of the currently widely used 
questionnaires the FACIT-F compares well to other questionnaires and is quick and 
easy to use. However, it has limitations as described above. The BRAF-MDQ has yet 
to be widely used but may prove to be the preferred multidimensional fatigue tool. 
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CHAPTER 5.   CLINICAL SUBTYPES: FIBROMYALGIC DISEASE 
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5.1. INTRODUCTION 
5.1.1. Fibromyalgic Rheumatoid 
Rheumatoid arthritis (RA) spans several distinct clinical phenotypes. One of these 
includes coexisting fibromyalgic features; this phenotype has been termed 
“fibromyalgic RA” [Scott et al. 2007]. Its importance has been highlighted by Wolfe 
and colleagues who described its characteristic high levels of pain, fatigue and 
disability [Wolfe et al. 1984; Wolfe et al. 2004]. It is estimated that approximately 
10%-20% of RA patients have the subtype fibromyalgic RA.  
 
The high pain and disability scores that are seen in fibromyalgic RA suggest that 
these patients will also have high scores using summative assessments such as the 
Disease Activity Score for twenty-eight joints (DAS28) which includes assessments 
of tender joint counts, swollen joint counts, ESR and patient’s global assessments. 
This perception is supported by previous research that shows DAS scores are often 
high in patients with fibromyalgia without RA [Leeb et al. 2004]. In this context 
DAS28 scores of 5.1 or more are considered indicative of active disease. DAS scores 
are particularly important in treatment decisions about disease modifying anti-
rheumatic drugs (DMARDs) and biologics [Meyer et al. 2007; Fautrel et al. 2008]. If 
DAS scores are disproportionately high in relation to the level of inflammatory 
synovitis in fibromyalgic RA, the value of DAS assessments in these patients is open 
to question. This is a particularly cogent issue as a recent study of fibromyalgic RA 
by Coury et al suggested DAS28 over-estimated disease activity in these patients 
[Coury et al. 2009]. 
 
Patients with fibromyalgic RA were studied with three aims. Firstly to confirm that 
its prevalence and clinical impact in UK RA patients reflects the experience of other 
countries. Secondly to determine if the conventional core data set of clinical 
assessments in RA such as tender and swollen joint counts and ESR can be used to 
identify patients with fibromyalgic RA. Finally to examine the influence of 
fibromyalgic RA on the identification of active disease using DAS28 scores and 
ascertain the limitations of DAS28 in this setting. 
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5.1.2. Pain Thresholds in RA and Their Associations 
Pain remains a dominant problem for many patients with RA, despite new treatment 
approaches using disease modifying drugs and biologics. Both local and central 
factors are likely to contribute to RA pain. Studies in experimental models of 
inflammatory arthritis show peripheral sensitisation induced by activation of the 
nocioceptive system in the joints are important [Woolf et al. 1997; Inglis et al. 2005]. 
In addition to inflammation induced sensitisation of peripheral nocioception, 
hyperexcitability in the spinal cord, attributed to continued stimulation by 
nocioceptive receptors, has also been implicated [Scaible et al. 1993; Neugebauer et 
al. 1990]. This hyperexcitability may lead to central sensitisation [Kunz et al. 2005; 
Telleria-Diaz 2010]. In RA patients, increased severity of pain and reduced pressure 
pain thresholds are one potential consequence of central sensitisation of pain. They 
have previously been reported in observational studies of RA patients [Huskisson et 
al. 1972; Gerecz-Simon et al. 1989; Lee et al. 2009].  
 
Central pain sensitisation is most likely in long-standing RA. It was therefore 
hypothesised that disease duration may affect pain thresholds. Several other potential 
factors could contribute to reduced pain thresholds in RA. These include high disease 
activity and coexistent fibromyalgia. The variability of pain thresholds in RA and the 
possible factors which influence them was evaluated using a cross-sectional 
observational study design. 
 
5.2. OUTLINE OF PATIENTS AND METHODS 
5.2.1. Patients in Initial Fibromyalgic RA and Pain Threshold Study 
For the first part of the study to confirm there is evidence of fibromyalgic RA, and to 
define pain thresholds, prospective data was collected from 105 patients with RA as 
defined by the ACR criteria who were consecutive attendees in a routine outpatient 
clinic at King’s College Hospital. All patients signed an informed consent form 












Female 80 (76%) 245 (76%) 
Male 25 (24%) 76 (24%) 
Age, mean years (range) 60 (24-88) 60 (20-87) 
Disease duration, mean years (range) 13 (0.08-54) 9 (0-48) 
Ethnicity Caucasian 84 (80%) 281 (88%) 
 Afro-Caribbean 16 (15%) 31 (10%) 
 Asian 3 (3%) 7 (2%) 
 Oriental 2 (2%) 2 (0.6%) 
DMARD Therapy 89 (85%) 239 (74%) 
Biologics 20 (19%) 13 (4%) 
Steroid 16 (15%) 72 (22%) 
NSAIDs 56 (53%) 132 (41%) 
Analgesics 56 (53%) 81 (25%) 
 
The sample comprised 80 females and 25 males. Mean age was 60 years and mean 
disease duration 13 years. The ethnic grouping of patients recruited into the study 
represented Caucasian, 80%, Afro-Caribbean, 15%, Asian, 3% and Oriental, 2%. At 
the time of assessment, the majority of patients (93 of 105, 89%) were on second line 
therapy. Within this group of 93 patients, twenty patients were on biologic therapy, 
namely adalimumab, etanercept and infliximab. There were 78 patients on single, 
combination and triple DMARD therapy, which comprised 49 on methotrexate, 21 
on sulphasalazine, 7 on hydroxychloroquine, 17 on leflunomide, 1 on IM-gold and 
16 on prednisolone. In total 85 patients were either on NSAIDs or analgesics or both. 
 
5.2.2. Patients in Replicate Fibromyalgic RA Study (Established RA) 
Data collected from patients for a previous study was used in the replicate study. 
These patients were part of a study to design a patient derived disease activity score. 
The patients were attending outpatient clinics at four hospitals in South London. The 
sample comprised 245 females and 76 males.  Mean age was 60 years and mean 
disease duration 9 years. The ethnic grouping of patients recruited into the study 
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represented Caucasian, 88%, Afro-Caribbean, 10%, Asian, 7% and Oriental, 0.6%. 
At the time of assessment, the majority of patients (244 of 321, 76%) were on second 
line therapy. Within this group of 244 patients, thirteen patients were on biologic 
therapy, namely adalimumab, etanercept and infliximab. There were 231 patients on 
single, combination or triple DMARD therapy, which comprised 151 on 
methotrexate, 44 on sulphasalazine, 17 on hydroxychloroquine, 12 on leflunomide, 
15 on IM-gold, 10 on azathioprine, 9 on ciclosporin, 12 on D-penicillamine and 42 
on oral corticosteroids. Thirty patients had been given either intra articular or 
intramuscular depomedrone. In total 245 patients were either on NSAIDs or 
analgesics or both.  
 
5.2.3. Patients in Fibromyalgic Early RA Study 
Data collected from patients enrolled in the early rheumatoid arthritis network 
(ERAN) was used for the early rheumatoid arthritis study. ERAN is a national 
network of rheumatologists following outcomes in patients with RA for less than two 
years at enrolment. The sample comprised 265 females and 130 males. Mean age 
was 55 years (range 18-88). The ethnic grouping of patients recruited into the study 
represented Caucasian, 96%, others 4%. At initiation into ERAN, 378 patients were 
on single or combination DMARD therapy, which comprised 17 patients on 
hydroxychloroquine, 148 on sulfasalazine, 173 on methotrexate, 11 on other 
monotherapy and 29 on combination DMARDs.   
 
5.2.4. Assessments 
5.2.4.1. Initial Study 
Disease activity measures based on the EULAR/OMERACT core data set which 
comprises 28 tender and swollen joint counts, pain score (visual analogue scale 0-
100mm), patient and physician global assessment (visual analogue scale 0-100mm), 
erythrocyte sedimentation rate (ESR) and health assessment questionnaire (HAQ 
scores, were collected. In addition fatigue was measured using a visual analogue 
scale (0-100mm), duration of early morning stiffness and tender point counts (based 
on the ACR 18 fibromyalgic tender points). Anxiety and depression were assessed 
using the Hospital Anxiety and Depression Scale (HADS).  
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Pain thresholds were measured using a handheld digital algometer. There have been 
numerous studies that evaluated the reliability and validity of this instrument in 
determining the pressure-pain threshold of different body tissues both in patients and 
controls. [Kinser et al. 2009; Wylde et al. 2011] The measurements were all done by 
the same investigator, minimising inter-observer error. Two measurements were 
taken and the mean of the two measurements was used. The algometer was applied to 
the right thumb nail, away from any involved joints and taking care to avoid the nail 
bed.  
 
5.2.4.2. Replicate Study (Established RA) 
Disease activity measures based on the EULAR/OMERACT core data set which 
comprises 28 tender and swollen joint counts, pain score (visual analogue scale 0-
100mm), patient and physician global assessment (visual analogue scale 0-100mm), 
erythrocyte sedimentation rate (ESR) and health assessment questionnaire (HAQ) 
scores, were collected. In addition fatigue was measured using a visual analogue 
scale (0-100mm), duration of early morning stiffness and C-reactive protein (CRP). 
Quality of live was measured using the SF-36 and NHP questionnaires. 
 
5.2.4.3. Early RA Study 
The DAS28 and its constituents (28 tender and swollen joints, patient global 
assessment and ESR) were measured. In addition CRP, haemoglobin and the HAQ 
were collected at 3, 6, 12 and 24 months. 
 
5.2.5. Analyses 
5.2.5.1. Initial Study 
All analyses used the Statistical Package for the Social Sciences (SPSS® 14 for 
Windows). Group data were reported using means (standard deviations) and ranges.  
The inter relationships between tender points and measures of disease activity were 
assessed using bivariate Spearman’s correlations. To determine the factors 
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influencing tender points, simple regression was followed by backwards stepwise 
multiple regression using tender points as the dependent variable. 
To determine the impact of tender points on patient outcomes, the patients were 
divided into two groups according to the number of positive tender points used in the 
diagnosis of fibromyalgia; those with 11 or more positive tender points and those 
with 10 or less positive tender points.  
 
To determine if tender minus swollen joint counts could identify fibromyalgic RA as 
accurately as tender points, Receiver Operator Characteristic analysis was employed. 
Sub-groups were compared using Students t-test and frequencies using the odds 
ratio. 
 
To assess the factors associated with pain threshold univariate and multivariate 
Ordinal logistic regression models were performed using STATA version 10 
(StataCorp, Texas, 2007). As the distribution of pain thresholds was not linear, they 
were divided into tertiles for analysis. All continuous measures were entered into the 
models as continuous variables.  For these analyses the crude and adjusted odds 
ratios with 95% confidence interval are presented, p-values are two-tailed 
throughout. Any variables that had a p value ≤0.05 in the univariate analysis were 
carried forward into multivariate analysis. Factors showing significant collinearity 
were excluded from the final model.  
 
5.2.5.2. Replicate Study (Established RA) 
To determine if the tender minus swollen joint count formula could identify 
fibromyalgic RA patients, the formula was applied to data from a group of patients 
with established disease and they were divided into two groups. The impact of 
‘tender minus swollen joints’ was assessed by calculating means with 95% 
confidence intervals for the outcome measures assessed. To determine the effect of 
fibromyalgic RA on response to treatment, mean DAS28 scores after 6 months of 
treatment were compared in the two groups using independent T-test. 
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5.2.5.3. Early RA Study 
To determine if the tender minus swollen joint count formula could identify 
fibromyalgic RA patients, the formula was applied to data from a group of patients 
with early disease and they were divided into two groups. The impact of ‘tender 
minus swollen joints’ was assessed by calculating means with 95% confidence 
intervals for the outcome measures assessed. To determine the effect of fibromyalgic 
RA on response to treatment, mean DAS28 scores after 24 months of treatment were 
compared in the two groups using independent T-test. 
 
5.3. RESULTS 
5.3.1. Tender Point Counts and Subtypes of Rheumatoid Arthritis Patients 
The 105 patients assessed in the initial cohort study had a mean tender joint count 
(TJC) of 7.5 (SE 0.7), mean swollen joint count (SJC) of 3.6 (SE 0.3), mean patient 
global assessment (PGA) of 44.2mm (SE 2.5), mean DAS28 of 4.53 (SE 0.15), mean 
HAQ of 1.49 (SE 0.08), mean ESR of 29.6mm/hr (SE 2.2), mean early morning 
stiffness (EMS) of 82.4 minutes (SE 20.2), mean physician global assessment 
(PhysGA) of 23.1mm (SE 1.5), mean pain VAS of 49.8mm (SE 2.8), mean fatigue 
VAS of 54.7mm (SE 2.7), mean tender points of 4.4 (0.5) and mean pain threshold of 
331.8 KPa (SE 18.8). 
 
Tender point counts showed correlations of moderate significance with tender joint 
counts (0.71), DAS28 (0.64), fatigue (0.52), patient global assessments (0.49), pain 
(0.47), HADS depression (0.48), pain threshold (-0.55), HAQ (0.51), early morning 
stiffness (0.33) and HADS anxiety (0.39); p<0.01 in all cases. They also showed 
correlations of minimal significance with physicians global assessments (0.22; 
p<0.05). They were not correlated with ESR (0.11), swollen joint counts 0.18), age 
(0.04) and disease duration (-0.004).  
 
Stepwise backwards multiple regression analysis using tender point counts as the 
dependent variable showed three variables explained 61% of the variation. Tender 
joint counts had the strongest association, and these were followed by pain threshold 
(negative association) and the HADS depression score (Table 5.2).  
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Table 5:2 Regression Analysis of Factors Influencing Tender Point Counts 
Initial Study 
 
Tender Point Counts (R
2
 = 0.61) 
Variable Coefficients (95% CI) Significance 
Tender joint counts 0.38 (0.273, 0.483) p=0.001 
Pain Threshold -0.005 (-0.009, -0.002) p=0.005 
HADS Depression 0.23 (0.04, 0.42) p=0.016 
Excluded variables 
HADS Anxiety, HAQ, Pain, PGA, ESR, Fatigue, Physician Global Assessment 
 
5.3.1.1. Prevalence of Fibromyalgic RA 
18/105 (17%) of patients in the initial cohort and 12/100 (12%) of patients in the 
replicate cohort had 11 or more tender points and met the criteria for fibromyalgic 
RA. 
 
5.3.1.2. Identifying Fibromyalgic RA Using Tender Joint Counts 
In the initial cohort tender point counts correlated strongly with tender joint counts 
(Pearson’s correlation r=0.74) and tender minus swollen joints (r=0.70); 
tender/swollen joints could not be used as it would mean dividing by zero in patients 
with no swollen joints. To take into account patients with very active synovitis 
having high numbers of both tender and swollen joints tender minus swollen joints 
were evaluated in more detail. 
 
Receiver operator characteristic (ROC) analysis showed the area under the curve 
using tender minus swollen joints to identify fibromyalgic RA patients defined by 
tender point count scores was 0.86. Tender minus swollen joint counts of 7 
predicted the presence of 11 tender points with 83% sensitivity and 80% specificity. 
(Figure 5.1) The number of patients with 11 or more tender point counts who also 
had tender minus swollen joint counts of 7 was 15 (83%), meaning 3 patients had 
11 or more tender point counts but less than 7 tender minus swollen joint counts. Of 
the 87 patients who had less than 11 tender point counts 17 (19.5%) had 7 or more 
tender minus swollen joint counts. Thirteen of the 17 patients who had 7 or more 
tender minus swollen joint counts had 5 or more tender points and 5 had 9 or 10 
 180 
tender points. This gave the tender minus swollen joints count a negative predictive 
value of 96%. 
 
In the replicate cohort tender point counts correlated with tender joint counts (r=0.78) 
and tender-swollen joint counts (r=0.77 in both cases). ROC analysis showed the 
area under the curve using tender minus swollen joints to identify fibromyalgic RA 
patients defined by tender point count scores was 0.94. Tender minus swollen joint 
counts of 7 predicted the presence of 11 tender points with 72% sensitivity and 
98% specificity.  
 
Figure 5:1 ROC of “Tender Minus Swollen Joint Counts” 


















“Tender minus swollen joint counts” 7 and tender point counts 11 
Sensitivity = 83% (95% CI 58%, 96%), Specificity = 80% (95% CI 71%, 88%, 
Efficiency = 81% (95% CI 72%, 0.88%) 
 
5.3.1.3. Clinical Impact of Fibromyalgic RA 
Patients with fibromyalgic RA identified by high tender point scores (initial cohort) 
or high tender minus swollen joint counts (initial cohort and clinical practice cohort) 
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had higher tender joint counts, patient global assessments, DAS28 scores, pain 
scores, fatigue and HAQ (Table 5.3). However, their swollen joint counts were 
similar to those of other RA patients. 
 
5.3.1.4. Fibromyalgic RA and Active Disease 
The impact of fibromyalgic RA, assessed by tender point counts of 11 or more on the 
definition of active disease was evaluated by combining data from the initial and 
replicated cohorts.  
 
Most patients with fibromyalgic RA had DAS28 scores of 5.1 or more compared to 
only a minority of other patients; the odds ratio (OR) and 95% confidence intervals 
(CI) for having active disease by DAS28 criteria with fibromyalgic RA was 14.3 
(5.5, 37.1). The same situation occurred if the DAS28 was replaced by CDAI, taking 
22 or more as being active disease with fibromyalgic RA patients having an 
increased likelihood of being classified as active (OR 17.2; 95% CI 6.1, 48.5).  
 
By contrast using more conventional assessments based on reaching predefined 
numbers of tender and swollen joints and a high ESR showed fewer patients with 
fibromyalgic RA patients had active disease. Using ≥3 or more tender and swollen 
joints and an ESR of ≥28 showed a non-significant increase in active disease in 
patients with fibromyalgic RA (OR 1.75; 95%CI 0.72, 4.3). This difference is shown 
in the Figure 5.2. There were similar findings with ≥6 or more tender and swollen 
joints and an ESR of ≥28 (OR 2.6; 95% CI 0.88, 7.6).  
 
5.3.2. Comparison of Different Groups of Rheumatoid Arthritis Patients 
5.3.2.1. Early Rheumatoid Arthritis  
The same criteria were applied to a cohort of patients with early disease, to determine 
if the formula could be applied to RA patients at different stages of disease duration 
to identify this specific subset of patients. Data that had been collected for the ERAN 
study was used. The patients were collected from various centres across the UK, 
provided they had a disease duration of 2 years or less.  
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After applying the tender minus swollen joint formula to this cohort of patients, 
similar results were obtained. Of the 394 patients studied, 67 patients had tender joint 
minus swollen joint counts of 7 or more and 327 patients with less than 7. The 
patients with tender joints minus swollen joints ≥ 7 had significantly higher tender 
joints (17), DAS28 scores (5.9) and HAQ scores (1.5). There was no difference in 




Table 5:3 High Tender Point Counts and Tender Minus Swollen Joint Counts 
 






















Pain VAS  71 (61, 82) 45 (39, 51) 71 (63, 78) 41 (34, 47) 63 (58, 68) 43 (40, 46) 
Fatigue VAS  82 (72, 91) 50 (44, 56) 72 (63, 80) 47 (41, 53) 62 (56, 68) 46 (43, 50) 
Tender joints 17 (14, 21) 6 (4, 7) 16 (14, 18) 4 (3, 5) 18 (16, 19) 5 (4, 5) 
Swollen joints 4 (2, 6) 4 (3, 4) 3 (2, 4) 4 (3, 4) 6 (5, 7) 5 (4, 5) 
ESR  39 (22, 55) 27 (23, 32) 33 (22, 43) 28 (24, 32) 32 (27, 38) 33 (30, 36) 
Patient global VAS  66 (55, 77) 40 (34, 46) 61 (53, 68) 37 (31, 42) 63 (58, 69) 46 (43, 40) 
DAS28  6.0 (5.5, 6.5) 4.3 (3.9, 4.6) 5.7 (5.3, 6.1) 4.0 (3.7, 4.3) 6.1 (5.8, 6.3) 4.4 (4.2, 4.5) 
HAQ  2.0 (1.8, 2.3) 1.4 (1.2, 1.5) 1.9 (1.6, 2.1) 1.3 (1.2, 1.5) 1.9 (1.7, 2.1) 1.4 (1.3, 1.5) 
 




Figure 5:2 Fibromyalgic RA and Assessments of Active Disease 
















Table 5:4 High “Tender Minus Swollen Joint Counts” In Early RA  
 
 
Tender joints minus swollen 
joints ≥7 
(n=67) 
Tender joints minus swollen 
joints <7 
(n=327) 
Tender joints 17 (16, 18) 6 (6, 7) 
Swollen joints 5 (4, 6) 6 (6, 7) 
ESR 37 (30, 44) 31 (28, 34) 
DAS28 5.9 (5.6, 6.2) 4.6 (4.4, 4.8) 
HAQ 1.5 (1.3, 1.7) 1.0 (0.9, 1.1) 
 
5.3.2.2. Treatment Effects 
To determine if patients with fibromyalgic RA as defined by tender minus swollen 
joint counts of 7 or more respond to treatment in a similar fashion to other patients 
changes in DAS28, tender joints, swollen joints and ESR following treatment were 
examined in patients with established disease and also patients with early disease. 
 
5.3.2.3. Established Rheumatoid Arthritis 
Patients in the established RA study who had assessments following six months of 
treatment with either DMARDs or biologics were included. A total of 62 patients had 
data before and after six months of treatment. The tender minus swollen joint count 
formula was again applied to this group and 16 patients had tender minus swollen 
joint counts of 7 or more and 46 patients had less than 7. Following treatment for 6 
months there was no significant difference in mean improvements of tender joints, 
swollen joints, ESR or DAS28 between the two groups. Although there were greater 
numerical improvements in tender joints in the patients with tender minus swollen 
joints of 7 or more and greater numerical improvements in ESR in the tender minus 
swollen joints of less than 7. (Table 5.5) However, the mean DAS28 score for the 
patients with tender minus swollen joint counts of 7 or more was still significantly 
higher than those with less than 7 tender minus swollen joints (5.64 SD 1.56 vs. 4.44 




Table 5:5 High “Tender Minus Swollen Joint Counts” and Treatment Changes 
DMARDS or Biologics in Established Disease; Mean Improvement (95% CI) 
 
 
Tender joints minus 
swollen joints ≥7 
(n=16) 
Tender joints minus 
swollen joints <7 
(n=46) 
Tender joints 7 (2, 12) 1 (0, 3) 
Swollen joints 2 (0, 4) 3 (1, 5) 
ESR 6 (8, 20) 22 (13, 32) 
DAS28 1.2 (0.5, 2.0) 1.2 (0.7, 1.7) 
 
 
5.3.2.4. Early Rheumatoid Arthritis (ERAN) 
All the patients in the ERAN study had assessments at 6, 12 and 24 months 
following treatment with DMARDS or biologics. As stated previously, 67 patients in 
this data set had tender joint minus swollen joint counts of 7 or more. After 24 
months of treatment, there was a significantly greater improvement in the number of 
tender joints in the group with tender joint minus swollen joint counts of 7 or more, 
otherwise there was no significant difference in improvement in swollen joints, ESR 
or DAS28 between the two groups. (Table 5.6) However, after 24 months of 
treatment the mean DAS28 score for the patients with tender minus swollen joint 
counts of 7 or more was still significantly higher than those with less than 7 tender 
minus swollen joints (4.37 SD 1.52 vs. 3.64 SD 1.55, p=0.012). 
 
Table 5:6 High “Tender Minus Swollen Joint Counts” on Treatment Changes 
DMARDS in Early Disease 
 
 
Tender joints minus 
swollen joints ≥7 
(n=67) 
Tender joints minus 
swollen joints <7 
(n=327) 
Tender joints 7 (6, 9) 2 (1, 2) 
Swollen joints 2 (1, 3) 3 (2, 4) 
ESR 14 (8, 20) 9 (7, 12) 
DAS28 1.3 (0.9, 1.7) 0.9 (0.7, 1.1) 
 
To compare the change in DAS28 and HAQ scores between the two groups of 
patients with similar treatment regimes, patients who were treated with either 
methotrexate or sulphasalazine only were included in the analysis. There were 
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improvements in DAS28 scores in both groups of patients at 6, 12 and 24 months, 
although mean DAS28 scores at 24 months remained higher in the group with 7 or 
more tender minus swollen joint counts (4.56 SD1.52 vs. 3.64 SD 1.42, p=0.002). 
There were minor but significant improvements in HAQ after 24 months of treatment 
in both groups but HAQ remained significantly higher in the group with 7 or more 
tender minus swollen joint counts (1.44 SD 0.75 vs. 0.98 SD 0.73, p=0.002). 
(Figures 5.3 and 5.4) 
 
Figure 5:3 “Tender Minus Swollen Joint Counts”, DAS28 and HAQ Scores 
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Figure 5:4 “Tender Minus Swollen Joint Counts” DAS28 and HAQ Levels 
Early RA Patients who Initially had DAS28≥5.1 after 24 Months of Treatment 
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5.3.3. Pain Thresholds and its Associations 
5.3.3.1. Distribution of Pain Thresholds 
The median pain threshold was 289 with an interquartile range of 189-434 and upper 
and lower levels of 67 and 1123 kPa. The distribution of pain thresholds (Figure 5.5) 
showed a broad range with a substantial upper “tail” of high pain thresholds 
Chi Squared=7.6 df=2 p<0.03 
Chi Squared=7.3 df=2 p<0.03 
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Figure 5:5 Distribution of Pain Thresholds in RA 
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5.3.3.2. Relationship to Disease Activity and Associated Clinical Variables 
The relationships to disease activity and demographic assessments were evaluated 
using Spearman’s correlations (Table 5.7). Pain threshold showed high correlations 
(R>0.4) with tender point counts, tender joint counts, fatigue (VAS) and HAQ; 
moderate correlations (R=0.2-0.4) with pain (VAS), HADS depression and anxiety, 
patient global assessments, disease duration and age; and no correlation (R<0.2) with 
swollen joint counts, physician global assessment, ESR and early morning stiffness. 
 
Table 5:7 Pain Thresholds and Clinical and Demographic Variables 
 
Variable Spearman's Correlation Significance 
Age -0.19 0.046 
Disease Duration -0.21 0.031 
Early Morning Stiffness -0.18 0.071 
ESR -0.61 0.504 
FACIT 0.31 0.002 
Fatigue (VAS) -0.44 0.000 
HADs-A -0.32 0.002 
HADS-D -0.35 0.000 
HAQ -0.44 0.000 
Pain VAS -0.34 0.000 
Patient Global Assessment (VAS) -0.33 0.001 
Physicians Global Assessment (VAS) -0.10 0.328 
Sex -0.15 0.116 
Swollen Joint Counts -0.04 0.698 
Tender Joint Counts -0.44 0.000 




The relationship of tender point counts and disease duration to pain thresholds were 
evaluated in detail (Figure 5.6). Pain thresholds were lower in patients with tender 
point scores of 11 (p<0.001 Mann Whitney test). They were also lower in patients 
with disease durations 10 years (p=0.027 Mann Whitney test). 
 
5.3.3.3. Regression Analysis 
Ordinal logistic regression evaluated pain threshold tertiles to disease activity and 
other clinical measures. Adjusted odds ratios showed tender point counts and disease 
duration were independently associated with pain thresholds (Table 5.8). In the 
adjusted model age did not retain significance suggesting that it is disease duration 
and not age that is the dominant factor. Tender joint counts and patient global 
assessments showed significant collinearity with tender point counts and pain and 
were excluded from the adjusted model. In the multivariable model fatigue (VAS or 
FACIT-F), anxiety, depression and disability (HAQ) were not associated with pain 
thresholds. 
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Figure 5:6 Pain Thresholds, Tender Points and Disease Duration 




Table 5:8 Regression Analysis of Factors Associated with Pain Threshold 









Age 0.97 (0.94,0.99) 0.015 0.97 (0.94, 1.01) 0.16 
Disease Duration 0.97 (0.94,1.00) 0.037 0.95 (0.91, 1.00) 0.04 
Pain (VAS) 0.98 (0.97,0.99) 0.002 0.99 (0.97, 1.01) 0.38 
Number Of Tender Points 0.78 (0.71,0.86) <0.001 0.75 (0.65, 0.86) <0.001 
Fatigue (VAS) 0.97 (0.96,0.99) <0.001 0.98 (0.96, 1.00) 0.15 
Health Assessment Questionnaire 0.39 (0.23,0.69) 0.001 1.19 (0.56, 2.56) 0.64 
Erythrocyte Sedimentation Rate (ESR) 0.98 (0.96, 1.00) 0.035 1.00 (0.98, 1.03) 0.83 
FACIT-F 1.04 (1.01,1.08) 0.011 - - 
Tender Joint Count 0.88 (0.82,0.93) <0.001 - - 
Patient Global Assessment (VAS) 0.98 (0.96,0.99) 0.003 - - 
HADS Depression 0.89 (0.81,0.99) 0.028 - - 
HADS Anxiety 0.92 (0.83,1.01) 0.064 - - 
Duration of Morning Stiffness (mins) 1.00 (0.99,1.00) 0.076 - - 
White vs. Other Ethnic Groups 1.52 (0.62,3.74) 0.360 - - 
Swollen Joint Count 0.96 (0.86,1.07) 0.428 - - 
Male vs. Female 0.67 (0.28,1.61) 0.373 - - 
 
Explanatory Note: The adjusted odds ratio excluded EMS, HADS anxiety, ethnicity, 
swollen joint count and gender as they showed no significant relationship with pain 
thresholds at the 0.05 level. HADS Depression, tender joint count, patient global 
assessment, fatigue VAS, FACIT-F and HAQ were all significantly correlated with 
pain threshold. However, many were also highly correlated with each other (eg 
tender point counts and tender joint counts r=0.71). Those variables which showed 
strong collinearity with each other were excluded. Where strong collinearity existed 
statistical and clinical assessments were used to decide which variables to include 





These findings confirm previous reports that 10–20% of RA patients attending 
specialist units have fibromyalgic RA. All
 
centres evaluating fibromyalgic RA report 
similar frequencies
 
in patients attending specialist centres. Bliddal and Danneskiold-
Samsøe
 
[Bliddal et al. 2007] have highlighted the importance of chronic widespread 
pain
 
in rheumatic diseases including RA, pointing out that not all
 
patients meet 
accepted diagnostic tender point criteria of 11
 
for diagnosing fibromyalgia. Recent 
work from Ranzolin et al,
 
[Ranzolin et al. 2009] also showed that high DAS28 scores 
are common in patients
 
with fibromyalgia and RA, and Wolfe [Wolfe 2009] 
suggested the term
 ‘fibromyalgianess’ applied to such patients whom he considered 
to have polysymptomatic distress. The balance
 
of evidence suggests that there is a 
subset of RA patients with
 
a fibromyalgic phenotype who have high pain levels 
unrelated
 
to synovial inflammation, high fatigue scores and more disability
 
with high 
HAQ scores. In other rheumatic diseases, particularly
 
connective tissue disorders 
such as SLE, some studies report
 
limited evidence of an increase in fibromyalgic 
symptoms [Wolfe et al. 2009] whereas other studies show that fibromyalgic features 
are
 
commonplace [Gladman et al. 1997].
 
When interpreting these data it must be 
remembered that this is based on relatively small numbers of patients from one 
department although estimates are similar to other studies from different centres and 
patient characteristics are similar. [Wolfe et al. 1983; Wolfe et al. 1984; Wolfe et al. 
2011; Kapoor et al. 2011] Nevertheless it is important not to simply label these 
patients as there is evidence from previous studies that disease severity is similar to 
non-fibromyalgic RA patients [Wolfe et al. 1984] and disease activity should be 
treated appropriately; however, identifying these patients with apparently worse 
outcomes may be beneficial to ensure that all aspects of their care are optimised. 
 
In order to identify these RA patients with apparent worse outomes we devised a way 
to screen for these patients using a conventional core data set. In our study these 
patients had disproportionately high tender joint counts, and could
 
be identified by 
examining tender minus swollen joint counts. A subsequent study has used our 
suggestions for identifying fibromyalgic RA using tender minus swollen joint counts 
[Kapoor et al. 2011] and using this method found that 15% of patients had 
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fibromyalgic RA as defined using tender minus swollen joint counts but only 6& of 
patients had fibromyalgic RA as defined using conventional tender points. It is 
possible that using tender minus swollen joint counts may overestimate the 
prevalence of fibromyalgic RA. Research from Wolfe and Michaud [Wolf et al. 
2009] suggests that fibromyalgia
 
and by implication fibromyalgic RA are one end of 
a spectrum.
 
Consequently using cut-off points of 11 tender points or tender
 
minus 
swollen joint count of 7 over simplifies a complex situation.
 
One crucial question is 
whether it is appropriate to divide
 
patients into those with or without fibromyalgic 
RA—the evidence suggests that it is better to consider fibromyalgic features as a 
continuum rather than a diagnosis that is either
 
present or absent. Indeed Wolfe et al 
[Wolfe et al. 2011] showed that up to approximately 20% of RA patients may 
develop fibromyalgic symptoms at some point during their disease. A second related 
question is whether in this
 
context fibromyalgia is a separate associated disease or a 
symptom
 
complex; the latter approach is favoured. However, irrespective
 
of these 
questions, patients with high tender
 
joint counts but few swollen joints seem to differ 
from the majority
 
of patients with relatively equal numbers of tender and swollen
 
joints. Such patients with a pattern of fibromyalgic RA will still need conventional 
treatment with DMARDs to suppress inflammation but are likely to need other 




Using DAS-28 5.1 to define active RA has the benefits of simplicity
 
and 
reproducibility. However, these results show that it may overestimate
 
the activity of 
patients with fibromyalgic RA [Atzeni et al. 2011]. Using CDAI, which has been 
shown to perform in a similar fashion in RA as the DAS28, [Dejaco et al. 2011] as
 
an 
alternative does not change this over-representation.
 
The explanation for this effect is 
the way in which these indices
 
handle joint counts with equal weighting given to the 
numbers
 
of tender joints no matter how high these are. The classic entry
 
criteria for 
trials involve patients having high swollen joint
 
counts [Kingsley et al. 2005] and 
therefore avoid entering patients with a purely
 
fibromyalgic pattern of disease. These 
results suggest that there
 
are strong arguments in favour of using conventional trial 
entry
 
criteria, such as having three or more tender and swollen joints
 
and an elevated 
ESR, rather than only concentrating on DAS28
 
scores. Some patients with many 
tender points and
 




DAS-28 5.1 also have evidence of synovial inflammation with
 
high swollen joint 
counts. Assessing disease activity in fibromyalgic
 
RA is clearly challenging and 
complex [Mäkinen et al. 2009]. However, using DAS28 5.1 as the sole criterion to 
define active
 
RA is too simple and will misclassify a substantial number of
 
patients. 
Such summary measurements need to be tempered with
 
additional clinical 
assessments to enable patients to receive
 
the optimal treatment they need [Deighton 
et al. 2008; Ton et al. 2012]. 
 
When looking at the effect of treatment on patients with fibromyalgic RA both 
patients with early and established disease had improvements across most variables 
of the DAS28, however, despite treatment these patients still had significantly higher 
DAS28 scores following treatment compared to those patients who did not have 
fibromyalgic RA. The changes in DAS28 with treatment are mirrored by the changes 
in HAQ with treatment in the same group of patients. Again like the DAS28 scores, 
HAQ scores remain higher in those patients with fibromyalgic RA compared to those 
without fibromyalgic RA despite treatment with conventional DMARDs. These 
findings add weight to the argument that other treatments besides conventional 
treatments are needed in order to reduce DAS28 scores and disability as measured by 
the HAQ. 
 
Pain thresholds vary substantially in RA patients and are affected by many clinical 
variables. The dominant factors are high tender point counts, reflecting the presence 
of fibromyalgic RA [Wolfe et al. 2004; Ranzolin et al. 2009], and prolonged disease 
duration, which probably reflects central sensitisation. Lee et al, [Lee et al. 2009] 
highlighted the importance of sleep, although they found no link to disease duration, 
in the patients they studied. 
 
“Fibromyalgic RA”, defined by 11 tender points, affects 10-20% of RA patients; 
most of these patients had low pain thresholds. The association of low pain threshold 
with disease duration is likely to have a different explanation. It was particularly 
marked in patients with RA of more than ten years duration. This finding suggests 
that over time the burden of inflammation in RA causes not only progressive joint 
damage and functional decline but also can lead to persistence of pain. It implies that 
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chronic RA inflammation results in persisting nocioceptive stimulation, resulting in 
central sensitisation and reduced pain thresholds.  
 
This study has a number of limitations. It was relatively small, it was at a single time 
point and the impact of treatment was not investigated. Nevertheless, the results in 
this thesis highlight a potentially important factor in the perpetuation of RA pain.  
 
Early and intensive treatment which minimises inflammation is likely to reduce 
central sensitisation and minimise long-term RA pain. Traditional analgesics may 
have limited value in patients for whom pain remains a problem despite apparent 
control of their synovitis. Their pain management should focus on treatments that are 
effective in the presence of central sensitisation. 
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CHAPTER 6.   UNDERSTANDING TREATMENT DECISIONS 
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6.1. INTRODUCTION 
In the UK and Europe the DAS28 score is the most widely used measure of disease 
activity although it is not widely used in the US, where there is no agreed gold 
standard for assessing disease activity in clinical practice. [Furst et al. 2007] 
Treatment strategies that are currently advocated in RA are to treat the disease early 
and aggressively with either combination drugs or rapid escalation of monotherapy to 
try and achieve good control of disease activity and prevent long term damage and 
disability. [NICE, CG79. 2009; Haraoui et al. 2011; Smolen et al. 2010; Bykerk et al. 
2011] The DAS28 is of particular importance in the UK as to qualify for biologic 
therapy on the NHS you must have active disease as defined by a DAS28 score of 
5.1 or greater on two occasions as well as failing at least two DMARDs. [NICE, 
TA130. 2007] 
 
As treatments have improved over the years with the introduction of early and 
combination therapies and biologics, it is reasonable to assume that disease activity 
in RA has fallen over time. There are also studies which have suggested that RA 
itself may becoming a milder disease [Welsing et al. 2005], although it is not clear if 
this is the case and that the improvements seen coincide with different treatment 
strategies.  
 
Despite clear recommendations regarding treatment in RA; patients continue to have 
active disease and only a relatively small proportion of patients receive combination 
therapies despite having evidence of active disease [Kiely et al. 2011]. This study by 
Kiely et al for ERAN, (Early Rheumatoid Arthritis Network) of routine practice in 
the UK of an inception cohort of early RA patients followed over time showed that if 
you had a DAS28 score indicating moderate disease (DAS28 3.2 to 5.1) at the end of 
the first year of treatment following diagnosis, then the likelihood of achieving a low 
disease activity score (<3.2) at years 2 and 3 is poor.  
 
It is unclear what prompts treatment changes for some patients who have active 
disease and not for others. There may be other factors which influence DAS28 scores 
such as fibromyalgic RA [Pollard et al. 2010] that affect treatment decisions and 
clinicians may use clinical judgement in these situations rather than specifically 
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relying on the DAS28. A recent study has suggested that the decisions which lead to 
an escalation in treatment differ between patients and physicians. [vn Hulst et al. 
2011] 
 
This study looked at disease activity over a 13 year period between 1997 and 2010 at 
five different time points. There were five different cohorts of patients undergoing 
routine clinical care. It assessed whether there was evidence of a change in disease 
activity over time and also looked at changes in DMARD therapy in line with 
treatment guidelines as they were produced. It also looked at the impact of 
fibromyalgic RA over time. Secondly it looked at a further cohort of patients 
undergoing routine clinical care to explore the treatment changes that were instituted 
according to DAS28 score and evaluated the effect of fibromyalgic RA on the 
DAS28 as well as treatment decisions. 
 
6.2. OUTLINE OF PATIENTS AND METHODS 
6.2.1. Patients 
6.2.1.1. Temporal Changes Study 
All patients met the 1987 ACR criteria for RA. They comprised in total 987 patients. 
Data were collected from five different time points; 1997, 2003, 2006, 2008 and 
2010. There were five separate cohorts of patients. All patients were attending 
rheumatology outpatient departments from two hospitals within South East London, 
either a large teaching hospital or a district general hospital. These patients were 
receiving routine clinical care. 
 
6.2.1.2. Treatment Changes Study 
The patients in the treatment changes study all met the 1987 ACR criteria for RA and 
were attending outpatient departments in South East London in either a large 
teaching hospital or a district general hospital. Patients were consecutive attendees at 
the rheumatology departments in each hospital. This was a cross-sectional study with 





6.2.2.1. Temporal Changes Study 
Demographic data was collected for each patient, including age, sex, and disease 
duration. All patients had measures of disease activity documented, including the 
DAS28 and its constituents (tender joint count, swollen joint count, ESR and patient 
global assessment). All DMARDs, biological therapies, steroids and NSAIDs being 
taken by each patient were documented. Patients with fibromyalgic RA were 
identified by the methods recommended by Pollard et al in 2010; patients who had 
≥7 tender minus swollen joints. 
 
6.2.2.2. Treatment Changes Study 
Demographic data were collected for each patient, including age, sex, ethnicity and 
disease duration. All patients had measures of disease activity documented, including 
the DAS28 and its constituents (tender joint count, swollen joint count, ESR and 
patient global assessment). Note was made of each patient’s current DMARD 
therapy. At each visit note was made of any treatment change, including whether it 
was a new DMARD that was given or an increase in current DMARD, biological 
therapy was commenced or if steroids were given (oral or intramuscular). Patients 
with fibromyalgic RA were identified by the methods recommended by Pollard et al 
in 2010; patients who had ≥7 tender minus swollen joints. 
 
6.2.3. Analyses 
6.2.3.1. Temporal Changes Study 
Data analysis was done by the Statistical Package for the Social Sciences (SPSS for 
Windows 16). Simple descriptive analyses were applied to all data (Table 6.1). Mean 
DAS28 scores with standard deviations and standard errors were calculated for each 
time period. This was repeated for all the DAS28 constituents (tender joint count, 
swollen joint count, patient global assessment and ESR). Patients were divided by 
DAS28 categories into four groups: Remission (DAS28<2.6), low disease activity 
(DAS28 2.6 to <3.2), moderate disease activity (DAS28 3.2 to <5.1) and high disease 
activity (DAS28 ≥5.1). The percentage of patients in each DAS28 category was 
calculated for each time point. The patients were also grouped into fibromyalgic and 
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non-fibromyalgic RA. Mean DAS28 scores for fibromyalgic and non-fibromyalgic 
patients were calculated including standard deviation and standard errors. 
 
6.2.3.2. Treatment Changes Study 
Data analysis was done using the Statistical Package for the Social Sciences (SPSS 
for Windows 16). Simple descriptive analyses were applied to all data. Patients were 
divided by DAS28 categories into four groups: Remission (DAS28<2.6), low disease 
activity (DAS28 2.6 to <3.2), moderate disease activity (DAS28 3.2 to <5.1) and 
high disease activity (DAS28 ≥5.1). For each category the percentage of patients 
who had a treatment change was calculated. In those with high disease activity 
(DAS28≥5.1) the rate of treatment change was examined further and patients were 
divided further into five groups according to DAS28. These groups comprised 
DAS28 of 5.1-5.5, DAS28 of 5.5 to 6.0, DAS28 of 6.0-6.5, DAS28 of 6.5-7.0 and 
those with a DAS28 of over 7.0. Again percentages of patients who had a treatment 
change were calculated for each group. The percentage for each type of treatment 
change was also calculated for each DAS28 category. 
 
To determine what influenced treatment changes binary regression was performed 
for each variable (univariate analysis) and reported as odds ratios (as there were 
categorical and continuous variables). Any variable which showed significance 
(p≤0.05) at this level was carried forward into the multivariate analysis and the odds 
ratios are reported. Two models were analysed, firstly DAS28 was used as a measure 
of disease activity and its constituents were excluded. In the second model the four 
constituents of the DAS28 (tender joint count, swollen joint count, ESR and patient 
global assessment) were included and the DAS28 composite measure was excluded. 
 
Patients were categorised as fibromyalgic and non-fibromyalgic RA (tender minus 
swollen joint counts of ≥7) to explore the effect of fibromyalgic RA on treatment 
decisions. Chi-squared testing was then used to determine if there were differences 
between groups in treatment changes and also the kind of treatment change that was 
initiated. 
 
To explore the effect of age on treatment decisions, patients were placed into three 
categories; under 45 years, 45-65 years and over 65 years. It also looked at the effect 
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of age of onset of RA on treatment decisions and patients were again placed into 
three categories depending on age at onset of disease; under 45 years, 45-65 years 
and over 65 years at onset of disease. Chi-squared testing was then used to determine 
if there were differences between groups in treatment changes and also the kind of 
treatment change that was initiated. 
 
6.3. RESULTS 
6.3.1. Temporal Changes Study 
A total of 987 patients were included in the study. There were 202 patients from 
1997, 300 patients from 2003, 105 patients from 2006, 71 patients from 2008 and 
309 patients from 2010. Females predominated at 76% overall, this was similar in 
each year with 72% in 1997, 76% in 2003, 2006 and 2008 and 81% in 2010. Disease 
duration did not change significantly over time with an overall mean of 10.4 years 
(SD 10), with a range of 0 to 61 years. The mean disease duration in 1997 was 11 
years (SD 10), in 2003 was 9 years (SD 10), in 2006 was 13 years (SD 11), in 2008 
was 8 years (SD 8) and in 2010 was 11 years (SD10). The mean age overall was 59 
years (range 18-89 years). In 1997 the mean age was 59 years (SD 13), in 2002 the 
mean age was 61 years (SD 13), in 2006 the mean age was 60 years (SD 14), in 2008 
the mean age was 56 years (SD 15) and in 2010 the mean age was 59 years (SD 14).  
 
Table 6:1 Patients Studied 
 
 Temporal Changes Study Treatment Changes Study 
Disease Characteristics Mean (Standard Deviation) 
Disease Duration (years) 10.4 (10) 9.5 (9.0) 
Tender Joint Count 6.6 (7.5) 4.4 (5.9) 
Swollen Joint Count 4.4 (4.6) 3 (3.9) 
Patient Global Assessment 45.7 (26.6) 38.2 (24.6) 
ESR 30.5 (24.6) 29.4 (23.3) 
DAS28 4.41 (1.63) 3.89 (1.50) 
Treatments Percent 
DMARDs 74 80 
Biologics 10 16 
Steroids 15 11 
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In total there were 182 patients (18%) who fit the criteria (≥7 tender minus swollen 
joints) for fibromyalgic RA. This number varies over time but overall seems to have 
reduced (27% in 1997 to 9% in 2010). (Figure 6.1) 
 

























The mean DAS28 overall was 4.41 (SD 1.63). The mean DAS28 score fell 
significantly over time; the mean DAS28 in 1997 was 5.01 (SD 1.64), in 2002 the 
mean DAS28 was 4.72 (SD 1.55), in 2006 the mean DAS28 was 4.53 (SD 1.44), in 
2008 the mean DAS28 was 3.81 (SD 1.55) and in 2010 the mean DAS28 was 3.77 
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The number of patients classified as having high disease activity (DAS28 >5.1) also 
decreased over time (47% in 1997 to 20% in 2010), although this reduction seem to 
plateau after 2008. Equally the number of patients who achieved DAS28 remission 
(DAS28 <2.6) rose over the years (8% in 1997 to 22% in 2010), again a plateau 
effect is seen from 2008. (Figure 6.3) 
 























Overall 11% of patients had fibromyalgic RA. Comparing mean DAS28 scores in 
fibromyalgic and non-fibromyalgic patients at each time point shows a gradual and 
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significant improvement over time in the non-fibromyalgic RA patients (4.62 (SD 
1.50) in 1997 to 3.60 (SD 1.44) in 2010). However, fibromyalgic RA patients have 
mean DAS28 scores of over 5.1 at every time point measured with no sustained 
reduction in DAS28 over time. (6.56 (SD 0.92) in 1997 to 5.47 (SD1.13) in 2010). 
(Figure 6.4)  
 




The mean scores for tender joint counts and swollen joint counts, as well as patient 
global assessment and ESR were calculated for each year and showed a reduction in 
all constituents of the DAS28 over time, although there was less if any reduction in 
values between 2008 and 2010. The overall mean tender joint count was 6.6 (SD 
7.5), falling from 9.9 (SD 9.4) in 1997 to 3.4 (SD 5.1) in 2008 and 4.0 (SD 5.5) in 
2010. (Figure 6.5) The overall mean swollen joint count was 4.4 (SD 4.6), falling 
from 6.5 (SD 5.6) in 1997 to 2.9 (SD 4.2) in 2010. (Figure 6.6) Overall mean score 
for patient global assessment was 45.7 (SD 26.6), falling from 49.1 (SD 25) in 1997 
to 39.7 (SD 25) in 2010. (Figure 6.7) The overall mean ESR was 30.5 (SD 24.6), 
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The number of patients taking NSAIDs has fallen over time, with an overall 40% of 
patients on NSAIDs; falling from 47% in 1997, increasing slightly in 2006 to 53% 
but falling to 26% in 2010. (Figure 6.9) The number of patients taking steroids 
increased from 11% in 1997 to 23% in 2002 but then fell over the next three time 
points to 10% in 2010. (Figure 6.10) There was an increase in the number of patients 
receiving DMARDs from only 58% in 1997, increasing to 86% in 2006 and then 
remaining stable at 80% in 2008 and 2010. (Figure 6.9) There was also an increase in 
the number of patients receiving combinations of DMARDs with only 1% of patients 
in 1997 receiving combination therapy, increasing to 21% in 2010. Likewise there 
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was an increase in the number of patients receiving biological therapy with no 
patients receiving biologics in 1997, increasing to 19% in 2006 and remaining stable 
at 18% and 17% in 2008 and 2010 respectively. (Figure 6.10) 
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6.3.2. Treatment Changes Study 
A total of 482 patients from two sites were included in the study. The majority of 
patients were female (79%), 70% of patients were Caucasian, 19% of patients were 
of Black origin and 11% were from other ethnic backgrounds. The mean age was 59 
years (range 24-89 years), with 38% of patients being over the age of 65 years, with 
a mean disease duration of 9.5 years (range 0-61 years), mean tender joint count of 
4.4 (SD 5.9), mean swollen joint count of 3 (SD 3.9), mean patient global assessment 
of 38.2 (SD 24.6), mean ESR of 29.4 (SD 23.3) and a mean DAS28 of 3.89 (SD 
1.50). Of the 482 patients, 80% were on a DMARD, 11% were on steroids and 16% 
were on biologic therapy (Table 6.1). 
 
In total 34% of patients had a change to their treatment initiated at the clinic visit. 
The most common change in treatment was steroid (13%), 11% of patients had an 
increase in their current DMARD and 12% were given a new DMARD. The least 
common change was the initiation of a biologic therapy at 2.5%. Less than 1% of 
patients had a combination of changes to treatment; in every case this was the 
addition of steroid with a change to DMARD or biologic therapy.  
 
6.3.2.1. The Effect of DAS28 on Treatment Decisions  
Twenty percent of patients were in remission according to DAS28 scores 
(DAS29<2.6), 14% of patients were in the low disease activity category (DAS28 2.6 
to <3.2), 45% of patients were in the intermediate disease activity group (DAS28 3.2 
to <5.1) and 22% were in the high disease activity category (DAS28≥5.1). In those 
with DAS28 scores above 5.1, 24 patients had a DAS28 score of 5.1 to 5.5, 41 
patients had a DAS28 score between 5.5 and 6.0, 13 patients had a DAS28 score 
between 6.0 and 6.5, 12 patients had a DAS28 score between 6.5 and 7.0 and 14 
patients had a DAS28 score of over 7.0. 
 
When comparing the number of changes within each DAS28 category most changes 
in treatment were seen in patients with high disease activity; 72% of these patients 
had a treatment change, meaning 28% had no treatment change despite DAS28 
scores≥5.1. In contrast 86% of patients received no additional treatment if they were 
in remission according to DAS28 scores, which means that 14% of patients 
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categorised as in remission received an escalation in treatment. Only 31% of patients 
with moderate disease activity in the intermediate group had a change in treatment 
and 12% of patients in the low disease activity group had a change in treatment. 
(Figure 6.11) 
 
Figure 6:11 Treatment Changes and DAS28 Category 
 
 
Looking at very active patients more closely, in those with DAS28 scores ≥5.1, as 
the DAS28 score increases so does the likelihood of a change in treatment, ranging 
from a 50% chance of a change in treatment change if the DAS28 is between 5.1 and 
5.5 to a 93% chance of a change in treatment if the DAS28 score is over 7.0. (Figure 
6.12) 
 
The changes for each disease activity category, according to the type of treatment 
change is summarised in Table 6.2. This showed that the most common treatment 
change in patients with high disease activity was the addition of steroids (35%) and 
the most common change of treatment for those in the remission and low disease 
categories was an increase in DMARD (11% and 6%, respectively), for those in the 
intermediate disease activity group the most common change to treatment was the 








Table 6:2 Treatment Changes and DAS28 Categories 
 
DAS Categories Remission Low Intermediate High 
No change 86% 88% 69% 28% 
Increase DMARD 11% 6% 11% 15% 
New DMARD 3% 5% 12% 26% 
Oral/IM Steroids 2% 2% 10% 35% 
Biologics 0% 0% 1% 10% 
 
6.3.2.2. The Effect of Fibromyalgic RA on Treatment Changes 
Patients with fibromyalgic RA had significantly higher DAS28 scores than non-
fibromyalgic RA (5.54 (SD 1.12) vs. 3.68 (SD 1.41) p=0.04). Fibromyalgic RA 
patients also had a significantly higher chance of having a treatment change overall 
(56% fibromyalgic RA vs. 31% non-fibromyalgic RA, p=0.001). This trend was not 
seen across all types of treatment change. There was no significant difference in the 
chance of being prescribed a new DMARD or having your current DMARD 
increased in dose whether patients did or did not have fibromyalgic RA. However, if 
patients had fibromyalgic RA they were more likely to be given steroids (27% 
fibromyalgic RA vs. 11% non-fibromyalgic RA, p=0.003) or biologics (10% 
fibromyalgic RA vs. 2% non-fibromyalgic RA, p=0.005). (Figure 6.13) 
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6.3.2.3. What Influences Changes in Treatment? 
Univariate Analysis 
Univariate analysis using odds ratios, showed significant associations between the 
chance of a change in treatment and age (0.98, p=0.003), ethnicity (1.34, p=0.035), 
DAS28 (2.25, p<0.001), fibromyalgic RA (2.81, p0.001) and being on a biologic 
therapy (0.58 p=0.05). Disease duration only just failed to gain significance at the 
0.05 level (0.98, p=0.07). No association was found between change in treatment and 
gender, current DMARD or steroid use. (Table 6.3) There were also significant 
associations between the chance of having a treatment change and each component 
of the DAS28 when they were substituted instead of the DAS28: Tender joint count 
1.16 p<0.001, swollen joint count 1.31 p<0.001, ESR 1.03 p<0.001 and patient 
global assessment 1.03 p<0.001. 
 
Multivariate Analysis 
Multivariate analysis was then used to determine the most important factors 
influencing treatment change in RA. Those variables which had significance at the 
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univariate level were included in the multivariate level and disease duration was also 
included in the final model. In the first model DAS28 was used as the measure of 
disease activity. This showed that only two factors retained significance at the 
multivariate level; age (odds ratio 0.97, p=0.002) and DAS28 (odds ratio 2.45, 
p<0.001). Ethnicity, disease duration, fibromyalgic RA and current biologic therapy 
showed no significant association in the multivariate analysis. (Table 6.3)  
 
In the second model the components of the DAS28 were included which all had 
significance at the univariate level and excluded DAS28. This showed again that age 
retained significance (odds ratio 0.97, p=0.003), of the components of the DAS28 the 
only component which did not retain significance in the multivariate analysis was 
tender joint count. Swollen joint count had an odds ratio of 1.18 (p<0.001), ESR 1.02 
(p<0.001) and patient global assessment 1.02 (p=0.002). As in the first model 
ethnicity, disease duration, fibromyalgic RA and current biologic therapy showed no 
significant association in the multivariate analysis. (Table 6.4) 
 
Table 6:3 Factors Influencing Treatment Changes with DAS28 
 
 Univariate Multivariate 
 Odds Ratio (95%CI) Signif Odds Ratio (95%CI) Signif 
Age 0.98 (0.97, 0.99) 0.003 0.97 (0.96, 0.99) 0.002 
Gender 1.06 (0.67, 1.68) NS - - 
Ethnicity 1.34 (1.02, 1.75) 0.035 0.87 (0.63, 1.25) NS 
Disease Duration 0.98 (0.96, 1.00) 0.07 0.98 (0.96, 1.01) NS 
DAS28 2.25 (1.90, 2.68) <0.001 2.45 (2.00, 3.00) <0.001 
Fibromyalgic RA 2.81 (1.57, 5.01) 0.001 0.72 (0.35, 1.48) NS 
Biologics 0.58 (0.33, 1.00) 0.05 0.55 (0.29, 1.06) NS 
DMARD 0.86 (0.54, 1.36) NS - - 
Oral Steroids 0.90 (0.49, 1.62) NS - - 
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Table 6:4 Factors Influencing Treatment Changes with DAS28 Components 
 








Age 0.98 (0.97, 0.99) 0.003 0.97 (0.96, 0.99) 0.003 
Gender 1.06 (0.67, 1.68) NS - - 
Ethnicity 1.34 (1.02, 1.75) 0.035 0.93 (0.6, 1.32) NS 
Disease Duration 0.98 (0.96, 1.00) 0.07 0.99 (0.96, 1.01) NS 
Tender Joint Count 1.16 (1.12, 1.21) <0.001 1.07 (0.99, 1.15) NS 
Swollen Joint Count 1.31 (1.22, 1.41) <0.001 1.18 (1.10, 1.29) <0.001 
ESR 1.03 (1.02, 1.04) <0.001 1.02 (1.01, 1.03) <0.001 
Patient Global 1.03 (1.02, 1.04) <0.001 1.02 (1.01, 1.03) 0.002 
Fibromyalgic RA 2.81 (1.57, 5.01) 0.001 0.96 (0.32, 2.88) NS 
Biologics 0.58 (0.33, 1.00) 0.05 0.61 (0.31, 1.19) NS 
DMARD 0.86 (0.54, 1.36) NS - - 
Oral Steroids 0.90 (0.49, 1.62) NS - - 
 
 
6.3.2.4. The Effect of Age on Treatment Decisions 
As age was shown to be important in treatment decisions using a multivariate model 
this variable was looked at more closely. Patients were divided into three groups 
according to age; under 45 years (17%), 45 to 65 years (45%), and over 65years 
(38%). The relationship of treatment change with age of onset of disease was 
explored. Patients were grouped into the same three categories; under 45 years at 
onset of disease (39%), 45-65 years at onset of disease (42%) and over the age of 65 
years at onset of disease (16%).  
 
The different age groups were applied to each DAS28 category and chi-squared 
testing showed that there were no significant differences in treatment changes 
between age groups in the remission, low disease activity and high disease activity 
categories. However, age had a significant impact on the chance of having a 
treatment change in those patients with moderate disease activity in the intermediate 
group (53% in patients under 45 years, 35% in patients 45-65 years and 15% in 
patients over 65 years, p<0.001).(Figure 6.14) 
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Although there was a significant difference in treatment changes overall depending 
on current age (under 45 years 45%, 45-65 years 36%, over 65 years 25%, p=0.003), 
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there was no significance in changes to treatments with age at onset of disease. 
(Figure 6.15)  
 
There was also no significant difference in the use of steroids or DMARDs between 
age groups or in age at onset. (Figures 6.16 and 6.17) There was however, a 
significant difference in the use of biologics, with no difference seen with current age 
but a reduced number of patients who developed RA when they were over the age of 
65 years receiving biological therapy. Of the patients who were under the age of 45 
years at onset of disease, 22% of patients were given biological therapy, 16% of 
patients who developed RA between the ages of 45 and 65 years, and only 7% of 
patients who developed RA after the age of 65 years were given biological therapy 
(p=0.012). (Figure 6.18) 
 
 















6.4.1. Temporal Changes Study 
The study showed that the DAS28 has fallen significantly over the years from a 
mean of 5.01 in 1997 to a mean of 3.77 in 2010. The fall in DAS28 however, does 
seem to have plateaued over the last few years. There was gradual reduction in 
DAS28 until 2008, with no significant fall between 2008 and 2010. The individual 
components of the DAS28 also saw significant reductions over time but again most 
plateaued from 2006 (swollen joint count, patient global assessment) or 2008 (tender 
joint count, ESR) onwards. These improvements in DAS28 could be explained by 
the change in treatment strategies which have been advocated in the last few years. 
The focus of treatment has very much shifted to treating early and attaining tight 
control of disease. [NICE CG79 2009] Why improvements in disease activity seem 
to have plateaued over the last few years is not clear.  
 
The prevalence of fibromyalgic RA does seem to have decreased over time and 
whether this reflects the effects of better treatment is unclear. Those patients with 
fibromyalgic RA continue to have high DAS28 scores which have not changed over 
time, as opposed to non-fibromyalgic RA patients who showed a gradual and 
significant reduction in DAS28 over time. This would suggest that for these patients 
other treatment strategies are needed other than just targeting disease activity as their 
DAS28 scores may be falsely elevated by a large contribution from patient global 
assessment and tender joint counts. 
 
The improvements in DAS28 are mirrored by the increase in the use of combination 
therapies with a large increase seen between the 1997 and the subsequent cohorts. 
There was a non-sustained increase in the use of steroids between 1997 and 2003. 
This in part may be explained by publications of studies around this time influencing 
prescribing practice. Kirwan et al published data on the effect of low dose 
prednisolone in RA in 1995 and then the COBRA study which looked at 
combinations of prednisolone with DMARDs versus monotherapy in early RA was 
published in August 1997 [Boers et al. 1997]. Further influential studies were 
published in 2004 and 2005 which may have changed prescribing habits as both 
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came out in favour of combination therapies; the TICORA (Tight Control for RA) 
study [Grigor et al. 2004] and the BeSt  study [Goekoop-Ruiterman et al. 2005].  
 
The only drugs which saw a reduction over time were non steroidal anti-
inflammatories. There are likely to be two main reasons for the decline in use of 
NSAIDs; the withdrawal of rofecoxib in 2004 saw a decline in prescription because 
of the concern of the increase in cardiovascular risk with the use of rofecoxib and 
whether it was a class effect. Secondly there has been a lot of work looking at 
cardiovascular risk in RA in the last few years with a particular focus on NSAIDs 
[Scott et al. 2007] and the prescription of NSAIDs seems to have fallen even further. 
 
The study also showed an increase in biologic use since 2003, which would fit with 
the approval and guidance from NICE (National Institute for Health and Clinical 
Excellence) in 2002 [NICE TA36]. Again the use of biologics has not changed 
significantly since 2006. The plateau in use of biologics in the cohorts may reflect 
the fact that, although more treatments are available for RA, these drugs remain 
expensive and are currently only used under guidance from NICE in the UK and in 
the current economic climate there is likely to be pressure on the prescription of 
these expensive drugs. It is therefore important to focus more closely on the use of 
combination therapies and although the number of patients having combination 
DMARDs has increased over time there were still only 21% of patients receiving this 
type of treatment. This number of patients on combination DMARDs was similar to 
those seen in the ERAN cohort who reported 26% of patients on combination therapy 
[Kiely et al. 2010] and slightly higher than the 15.6% on multiple DMARDs seen 
between 2005 and 2007 in a Canadian cohort [Tavares et al. 2011]. There are current 
studies underway looking at the efficacy of combination therapy versus biologic 
therapy which may have important economical impacts. 
 
6.4.2. Treatment Changes Study 
The previous study showed that disease activity scores have improved significantly 
over the last 15 years. However, there are still a significant number of patients with 
active disease as defined by the DAS28. Only 20% of patients in this study of 482 
RA patients were classified as being in remission (DAS28<2.6). Overall however, 
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only 34% of patients had a change in treatment, although the higher the DAS28 the 
more likely a patient was to have a change in treatment. Those patients with high 
disease activity (DAS28 ≥5.1) had their treatment changed 72% of the time. Those 
patients with even higher DAS28 scores were more likely to have a change in 
treatment and the chance of having a treatment change approaches 100% when the 
DAS28 is over 7.0. This still means that there are a considerable number of patients 
not having an increase in treatment despite having high disease activity. Perhaps 
more concerning is the lack of treatment change in those patients with 
moderate/intermediate disease activity. Only 31% of patients with moderate disease 
had a change in treatment.   
 
There may be several reasons behind this apparent lack of treatment changes, 
including patient choice, concomitant disease limiting DMARD use or intolerance to 
DMARDs. The effect of fibromyalgic RA is slightly more complex. The results 
show that if a patient has fibromyalgic RA there is a greater chance overall of having 
a change in treatment, although this effect is only seen with changes in treatments 
involving steroids and biologics. The fibromyalgic RA patients had higher DAS28 
scores compared to non-fibromyalgic RA and the increased chance of having a 
change in treatment may be explained by this observation. The fibromyalgic RA 
patients had a mean DAS28 of 5.54, putting them in the high disease activity 
category and this also may mean they are eligible for biologic therapy. If treatment 
changes are led only by DAS28 then it would not be surprising to see an increase in 
the number of fibromyalgic patients given biologics. Some clinicians however, may 
use clinical judgment rather than DAS28 to solely determine treatment changes and 
may explain why some patients with apparent active disease do not have their 
treatment changed.  
 
The DAS28 did have a strong influence on treatment decisions in this cohort and 
treatment decisions are swayed more by objective signs of inflammation (swollen 
joint count and ESR) and also patient global assessment but not by tender joint 
counts. The multivariate analysis showed that age has an effect on treatment 
decisions and retained significance in the multivariate analysis. This suggests that the 
older you are the less likely you are to have change in treatment. The effect of age on 
whether you have a change in treatment is most apparent in the intermediate 
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category, with no apparent differences seen in the remission and low disease activity 
categories and no difference once you develop a high disease activity state. The 
possible reasons for this may be that clinicians are willing to accept a degree of 
disease activity in the older population, as they feel that the burden of disease 
progression and disability will be less than a younger patient who is likely to have a 
longer life span. Older patients are likely to have more co-morbidities than younger 
counterparts, and this may influence our treatment decisions although if this is the 
case clinicians do not seem to be concerned about this when disease activity becomes 
high as there is no difference in treatment changes with age for this category. These 
possible reasons may explain the other observation that if you develop RA after the 
age of 65 years you are less likely to be given a biologic therapy although there is no 
difference in the prescription of DMARDs or steroids. One final reason which may 
explain this phenomenon is patient choice which was not explored in this study. 
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CHAPTER 7.   DISCUSSION 
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7.1. SUMMARY OF FINDINGS 
7.1.1. Key Issues 
The conclusions in this thesis are based on data collected predominantly in South 
East London and must be assessed within this context; as organisation of provision of 
care can vary within different parts of the UK. The results in this thesis also clearly 
reflect an inner city population which has a diverse ethnic mix. The ethnic mix seen 
within South East London means a higher number of patients with Afro-Caribbean 
and Asian backgrounds were represented and therefore the findings may not be 
generalisable to the rest of the UK. However, similar findings have been found in 
other parts of the UK and are discussed in detail below. Despite these caveats the 
research in this thesis has identified a number of limitations to care, which are 
particularly important in relation to the provision of high quality care for patients 
with RA. These fall into three broad areas, as follows: 
 
Firstly, it showed that current care is not optimal. Particular problems care included 
the following: 
 It is not sufficiently patient centred 
 Management is not integrated across the primary/secondary care divide 
 The focus of care over-emphasises drug treatment and overlooks care of the 
whole person. 
 
Secondly, care does not deal with a number of crucially important areas to patients 
with RA. These include the following: 
 Fatigue, which is a key problem for patients, receives little attention 
 Pain, which is a dominant symptom of RA, is often not directly addressed 
 Patients with the fibromyalgic rheumatoid clinical phenotype do not receive 
treatment that is specifically tailored to their needs. 
 
Finally, by using patient-centred outcomes treatment decisions will be improved as 
follows: 
 There should be a greater understanding of the need to increase adherence with 
treatment  
 The potential for treatment decisions to be influenced by age will be identified  
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 The delivery of targeted treatments involving patients’ views will be attainable. 
 
Looking at these three broad areas it is clear that with regard to patients concerns two 
main themes emerge. Firstly, many patients concerns are related predominantly to 
environment, society and care delivery. These findings will be influenced by the 
organisation of medical provision within the institution in which the research was 
conducted. Secondly, the symptomatic concerns of pain and fatigue and the 
psychological impacts may be inherent to the disease process but the expression of 
these symptoms may have a cultural setting as ethnicity has been found to be a 
predictor of depression in RA [Margaretten et al. 2009] and therefore the findings in 
our ethnically diverse population need to be considered. Although pain is a symptom 
that is common in RA and accompanies active disease; chronic pain and fatigue as 
well as psychological distress are symptoms that are often seen in other chronic 
diseases such as chronic obstructive pulmonary disease, multiple sclerosis and 
diabetes [Bentsen et al. 2013; Yamout et al. 2013; Flachenecker et al. 2002; Sudore 
et al. 2012] and as such these findings may not be disease specific but may reflect in 
part the consequence of chronic disease. 
 
The issues raised by these studies are considered in more detail in the subsequent 
sections. 
 
7.1.2. Current Care 
7.1.2.1. Standards of Care  
The standards of care audit shows many areas need to be improved before care meets 
the ARMA standards. Those areas in which there is room for improvement include 
giving information, providing written care plans and giving advice about exercise 
programmes. In patients with a new diagnosis of RA only a third had seen a 
physiotherapist, less than 10% had seen an occupational therapist and no-one had see 
a podiatrist within six months of diagnosis. Co-morbidities are also not being 
routinely checked including blood pressure and cholesterol assessments; both these 
need to be addressed to deal with the increased risk of heart disease in RA patients.  
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Despite relative shortfalls in the service provided, patients are satisfied with the care 
they receive, with an overall satisfaction rate of 3.89. Technical quality scored 
highest. As there were low empathy scores it is likely there is some way to go in 
addressing patients' concerns.  
 
7.1.2.2. Patients Needs 
The qualitative study identified three key areas of importance to RA patients: the 
personal impact of RA, information needs and health care delivery. Although most 
RA patients receive some written information about their disease, many wanted to 
know more about RA and its treatment. Further information is needed about the 
disease, its treatment and services and benefits available at both a national and local 
level. 
 
Most rheumatologists agree RA patients should have immediate access to specialist 
advice when their RA is flaring. Patients have the same view but have commented on 
the difficulty in achieving it. Some patients use the relationship they have developed 
with specialist nurses to gain access to rheumatologists in times of need whereas as a 
considerable number of patients will just ‘grin and bear it’. Continuity of care is 
important for patients as is being given time in an appointment and having an 
understanding and sympathetic attitude. Patients dislike waiting for long periods to 
be seen and then for the appointment to be rushed. These considerations need to 
taken into account when designing follow up clinics for RA patients, this will not 
necessarily be easy given the pressures on appointments but ensuring that patients 
are seen by both specialist nurse and doctors appears essential. 
 
7.1.2.3. Barriers to Integrated Care 
The qualitative study identified three areas in which there were perceived barriers to 
seamless integrated care in RA from the perspective of patients, carers, specialists 
and GPs. These are early referral, limitations of ongoing care for established RA and 
management of acute flares. The study took place when NICE guidelines and other 
UK care strategies were being developed; these help place the findings in context. 
These themes could either be general ones or represent local issues which are not 
generalisable. It is impractical to provide an answer from a single centre study and 
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national audits are needed to find out; there are moves to start these in the near 
future.  
 
Delay in referral, highlighted in the present study, has also been suggested in 
previous guidelines and UK observational studies [National Audit Office; King’s 
Fund]. The Norfolk Arthritis Register [Harrison et al. 2000] and the Steroids in Very 
Early Arthritis trial [Verstappen et al. 2010] have shown it is possible to see patients 
with inflammatory arthritis in the early stages of their disease. Delay in referral 
reflects several complex factors including both organisational issues and patient 
issues. There may be disparities between observed and perceived time to referral in 
patients with long disease durations who find it difficult to accurately estimate delays 
retrospectively. Patients may also take time to identify their symptoms and hence 
achieve referral, which may be reflected in a perceived delay in referral. One clear 
message from research with GPs was their concerns about their role as “gatekeepers” 
to secondary care. This potentially creates reluctance to refer patients with possible 
inflammatory arthritis, which can create a barrier to seeking specialist advice which 
needs to be removed.  
  
Several limitations in the management of established RA could be overcome by 
changes in the arrangements of the service. One issue is insufficient time in 
secondary care appointments so that clinicians do not fully address major concerns 
for patients. Greater involvement of specialist nurses has been helpful [Tijhuis et al. 
2003], but is not enough by itself. Specialists need to devote more time and resources 
to the follow up of patients with established RA [Lempp et al. 2006]. The NHS 
Musculoskeletal Framework may help by transferring stable musculoskeletal 
disorders to community based units and allowing specialists to focus on managing 
RA. This will require a re-evaluation of new to follow-up ratios as low ratios, often 
considered a mark of effective care, may indicate poor quality care in RA.  
  
Another issue is the limited knowledge many GPs have about RA [Stewart et al. 
2009; Bernatsky et al. 2010; Jacobi et al. 2004]. This reflects the absence of 
musculoskeletal disorders from the Quality and Outcomes Framework and the dearth 
of rheumatology teaching in the postgraduate training of UK GPs [National Audit 
Office 2009]. It is impractical to equip all GPs with enough expertise to make 
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significant inputs into the management of RA patients; the best solution may be to 
make better use of those GPs with expertise in the field. 
 
A final issue is the need for close collaboration between primary and secondary care. 
As RA is relatively uncommon, GPs have limited knowledge about the disease; 
much of its care needs to be managed by specialists. There also need to be better 
links between specialists and the community they serve. The best way to achieve this 
goal will need to be determined locally as it will depend on issues like travel for 
patients and local community facilities.  
 
Although we have discussed the barriers to care within our local area and how these 
might be addressed new guidelines have subsequently been produced by NICE 
regarding management of RA. [NICE Clinical Guideline 79, 2009] Patient centred 
care is an essential part of the guidelines and they have set out what they feel is best 
patient care for RA patients and should be achievable on a national level. From our 
study it is clear that not all standards are being met at least within this population, 
particularly with reference to monitoring, review and access to a multidisciplinary 
team. As new guidance is issued such as the Best Practice Tariff for early 
inflammatory arthritis where financial incentives are given to provide best quality 
care; [Department of Health 2012] it will be important for rheumatologists to assess 
their services to ensure that best care is provided as set out by national organisations 
such as NICE.   
 
 
7.1.3. Patient Centred Outcomes 
7.1.3.1. Fatigue and Its Clinical Associations 
Fatigue is a dominant symptom in RA. In keeping with previous reports [Huyser et 
al. 1998; Riemsma et al. 1998; Rupp et al. 2004; Tack 1990; Fifield et al. 1998; 
Wolfe et al. 2004; Suurmeijer et al. 2001; Fifield et al. 2001; Crosby 1991; Jump et 
al. 2004] the studies in this thesis show it is strongly associated with pain. Patients 
with active RA had high levels of fatigue; however regression analysis showed this 
relationship was less important than the association with pain. Patients diagnosed 
with either fibromyalgia and/or depression also had higher levels of fatigue. As these 
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conditions co-aggregate, after appropriate adjustment, depression was the only co-
morbidity invariably associated with fatigue. Fatigue was also influenced by 
disability; HAQ scores were positively associated, suggesting patients with high 
fatigue levels are more disabled. 
 
If fatigue is widely adopted as an RA outcome measure, it is crucial to identify the 
best instrument to assess it. Although VAS fatigue scores are simple and 
reproducible, multidimensional assessments provide a more complete picture and 
improve our understanding of the clinical relationships of fatigue. Validated 
instruments that measure RA fatigue like the Multidimensional Assessment of 
Fatigue (MAF) [Belza et al. 1993] and Functional Assessment of Chronic Illness 
Therapy-Fatigue (FACIT-F) [Cella et al. 2005] may prove valuable, especially in 
assessing the mechanism of fatigue. 
 
7.1.3.2. Treatment and Fatigue  
RCTs show adalimumab [Weinblatt et al. 2003] methotrexate and leflunomide 
[Strand et al. 2005] reduce fatigue. These falls in fatigue are accompanied by 
decreases in disease activity. Observational studies in established disease show that 
in routine practice, fatigue decreases when active RA is treated with anti-TNF and to 
a lesser extent with DMARDs. These falls mirror decreases in DAS scores and pain. 
TNF receptors have been identified on neurons [Pollock et al. 2002] and chronic 
inflammation is associated with upregulation of these TNF receptors [Inglis et al. 
2005]. TNF has also been implicated in pain pathways [Empl et al. 2001] and thus in 
conditions such as RA the increase in TNF levels may contribute to chronic 
inflammatory pain. The improvement in pain and fatigue with anti-TNF therapy may 
be due to a direct central effect through interaction with sensory neurons. 
 
The early RA study highlights the impact of early RA across most aspects of health. 
The SF-36 showed substantial overall reductions in quality of life, compared to 
normal populations [Garratt et al. 2003]. Although treatment over twelve months 
showed improvements in the physical domains of the SF-36 (physical function and 
role physical) there were no significant changes in vitality, social function and 
mental health domains. This would suggest that a broader range of treatment 
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approaches would benefit early RA patients, focusing on mental as well as physical 
health.  
 
7.1.3.3. Fatigue and Disability 
RA disability is influenced by disease activity, joint damage, co morbidities, 
psychosocial factors and depression [Pollard et al. 2006; Esclante et al. 1999; Sokka 
et al. 2000; Wolfe 2000; Rupp et al. 2006; Gettings et al. 2010; Hazes et al. 2010]. 
Many of these factors have cultural contexts [Ravindran et al. 2008; Griffiths et al. 
2000; Bruce et al. 2007]. Our results confirm fatigue is another important driver of 
RA disability. The relationship between fatigue and disability depends on how 
fatigue is measured. It is only when multidimensional tools are used (MAF, MFSI 
and FACIT-F) that the effects of fatigue on disability become apparent. The 
multidimensional fatigue measurements incorporate psychological factors, and had 
strong correlations with HADS depression and anxiety scores; however, multivariate 
analyses took these relationships into account and still showed the multidimensional 
fatigue questionnaires had stronger associations with disability. The results in this 
thesis suggest fatigue contributes to disability in RA rather than just reflecting 
psychological factors. 
 
However, it is impossible to determine causality from these results; they cannot 
differentiate fatigue being disabling from disabled patients being more fatigued. 
However, there is a complex interaction between fatigue, psychological factors and 
disability, and this interaction explains why multidimensional tools perform better 
than the unidimensional VAS in predicting disability. 
 
7.1.3.4. Fatigue Questionnaires 
One of the difficulties of studying fatigue in RA is the lack of agreement over which 
is the best measure of fatigue in RA. Different studies often use different fatigue 
tools meaning that comparison between studies is difficult. There is also a lack of 
agreement by what is actually meant by fatigue and what it is that is actually 
measured using current questionnaires. Many of the studies in this thesis used a 
simple visual analogue scale for fatigue which has the advantage of being quick and 
easy to administer and score as well as three different fatigue questionnaires. The 
 231 
MAF was designed specifically for RA patients so has the advantage of being disease 
specific, the FACIT-F has been widely used and seems to be the fatigue 
questionnaire of choice in many drug trials. The MFSI is one of the more 
comprehensive tools. 
 
There was a strong correlation between all three multidimensional questionnaires; 
however, the link was less strong with the fatigue VAS. Factor analysis showed 
fatigue involved five factors or dimensions. These comprised psychological, 
distress/cognition, severity, physical and social interference. These five 
factors/dimensions are similar to the dimensions described by the Bristol research 
group who have recently designed a new fatigue measure for RA [Nicklin et al. 
2010]. Their dimensions included living (questions on physical and social 
interference), cognition, emotion and physical (questions on physical interference 
and severity). Although five important dimensions were identified none of the 
questionnaires measured all of them. Questionnaires were often heavily weighted to 
one domain over another. The FACIT-F was predominantly measuring cognition; 
MFSI was predominantly measuring psychological factors and the MAF was 
predominantly measuring the impact of fatigue (physical and social interference).  
 
As five important factors/dimensions of fatigue have been identified an ideal fatigue 
questionnaire for RA should include all five dimensions/factors. Using statistics and 
clinical judgement 18 questions were compiled which cover all dimensions which 
would make an appropriate questionnaire. To determine the usefulness of the 
suggested items; the questionnaire would need to be subject to test and retest as well 
as checks for internal consistency and validity. Further research is needed in this 
area. 
 
7.1.3.5. Fibromyalgic RA 
The research in this thesis confirms previous reports that 10–20% of RA patients 
attending specialist units have fibromyalgic RA. All
 
centres evaluating fibromyalgic 
RA report similar frequencies
 
in patients attending specialist centres. Recent work 
from Ranzolin et al,
 
[2009] also showed that high DAS-28 scores are common in 
patients
 
with fibromyalgia and RA, and Wolfe [Wolfe 2009] suggested the term
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‘fibromyalgianess’ applied to such patients whom he considered to have 
polysymptomatic distress. The balance
 
of evidence suggests that there is a subset of 
RA patients with
 
a fibromyalgic phenotype who have high pain levels unrelated
 
to 
synovial inflammation, high fatigue scores and more disability
 




Conventional core data set measures can be
 
used to identify patients with 
fibromyalgic RA. Such patients
 
have disproportionately high tender joint counts, and 
can readily
 
be identified by examining tender minus swollen joint counts.
 
A related 
question is whether in this
 
context fibromyalgia is a separate associated disease or a 
symptom
 
complex; there is much in favour of the latter approach. Overall patients 
with high tender
 
joint counts but few swollen joints differ from the majority
 
of 
patients with relatively equal numbers of tender and swollen
 
joints. Such patients 
with a pattern of fibromyalgic RA may
 
need a different approach to symptom control 
and may require
 
a greater emphasis on exercise and psychological treatment and
 
less 




Using DAS-28 5.1 to define active RA has the benefits of simplicity
 
and 
reproducibility. However, these results show that it may overestimate
 
the activity of 
patients with fibromyalgic RA. The classic entry
 
criteria for trials involve patients 
having high swollen joint
 
counts [Kingsley et al. 2005] and therefore avoid entering 
patients with a purely
 
fibromyalgic pattern of disease.  
 
Some patients with many tender points and
 
high tender joint counts who have 
features of fibromyalgic RA
 
and DAS-28 5.1 also have evidence of synovial 
inflammation with
 
high swollen joint counts. Assessing disease activity in 
fibromyalgic
 
RA is clearly challenging and complex [Mäkinen et al. 2009]. However, 
using DAS-28 5.1 as the sole criterion to define active
 
RA is too simple and will 




When looking at the effect of treatment on patients with fibromyalgic RA both 
patients with early and established disease had improvements across most variables 
of the DAS28, however, despite treatment these patients still had significantly higher 
DAS28 and HAQ scores following treatment compared to those patients who did not 
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have fibromyalgic RA. These findings add weight to the argument that other 
treatments besides conventional treatments are needed in order to reduce DAS28 
scores and disability as measured by the HAQ. 
 
7.1.3.6. Pain in RA 
Pain thresholds vary substantially in RA patients and are affected by many clinical 
variables. The dominant factors are high tender point counts, reflecting the presence 
of fibromyalgic RA [Wolfe et al. 2004; Ranzolin et al. 2009], and prolonged disease 
duration, which probably reflects central sensitisation. 
 
The association of low pain threshold with disease duration was particularly marked 
in patients with RA of more than ten years duration and was not just associated with 
age. This finding suggests that over time the burden of inflammation in RA causes 
not only progressive joint damage and functional decline but also can lead to 
persistence of pain. It implies that chronic RA inflammation results in persisting 
nocioceptive stimulation, resulting in central sensitisation and reduced pain 
thresholds.  
 
Early and intensive treatment which minimises inflammation is likely to reduce 
central sensitisation and minimise long-term RA pain. Traditional analgesics may 
have limited value in patients for whom pain remains a problem despite apparent 
control of their synovitis. Their pain management should focus on treatments that are 
effective in the presence of central sensitisation. 
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7.1.4. Treatment Changes 
7.1.4.1. Temporal Changes in RA 
DAS28 has fallen significantly over the years from a mean of 5.01 in 1997 to a mean 
of 3.77 in 2010. Individual components of the DAS28 also showed reductions over 
time though most plateaued from 2006 (swollen joint count, patient global 
assessment) or 2008 (tender joint count, ESR) onwards. These improvements in 
DAS28 could be explained by the change in treatment strategies which have very 
much shifted to treating early and attaining tight control of disease.  
 
Fibromyalgic RA does seem to have decreased over time and whether this reflects 
the effects of better treatment is unclear. Those patients with fibromyalgic RA 
continue to have high DAS28 scores which have not changed over time, as opposed 
to non-fibromyalgic RA patients who showed a gradual and significant reduction in 
DAS28 over time.  
 
The improvements in DAS28 are mirrored by the increase in the use of combination 
therapies. There was a non sustained increase in the use of steroids between 1997 and 
2003; both of these findings likely reflect studies published around this time. The 
only drugs which saw a reduction over time were anti-inflammatory drugs, the 
reason for which is likely due to the withdrawal of Vioxx (rofecoxib) and the 
concern over their association with increased cardiovascular disease.  
 
The study also showed an increase in biologic use since 2003, although it has not 
changed significantly since 2006, which would fit with the approval and guidance 
from NICE in 2002 [NICE TA36]. The plateau in use of biologics in our cohorts may 
reflect the fact that although there are more treatments available in RA these drugs 
remain expensive and are currently only used under guidance from NICE in the UK 
and in the current economic climate there is likely to be pressure on the prescription 
of these expensive drugs. It is therefore essential to focus more closely on the use of 
combination therapies and there are current studies underway looking at the efficacy 




7.1.4.2. Treatment Decisions 
Despite improvements in disease activity scores over the last 15 years, many patients 
still have active disease. The treatment decisions study showed that only 34% of 
patients had a change in treatment when seen in the clinic. Although patients with 
higher DAS28 were more likely to have changes in treatment, the chance of having a 
treatment change only approached 100% when the DAS28 was over 7.0. More 
concerning was the lack of treatment change in patients with moderate/intermediate 
disease activity; only 31% of patients with moderate disease had a change in 
treatment.  
 
Several reasons might explain the apparent lack of treatment changes, including 
patient choice, concomitant disease limiting DMARD use or intolerance to 
DMARDs. The effect of fibromyalgic RA is complex. The results show that if a 
patient has fibromyalgic RA there is a greater chance overall of having a change in 
treatment, but this effect is only seen with changes in treatments involving steroids 
and biologics. Fibromyalgic RA patients had higher DAS28 scores compared to non-
fibromyalgic RA and the increased chance of having a change in treatment may be 
explained by this observation. If treatment changes are led only by DAS28 then it 
would not be surprising to see an increase in the number of fibromyalgic patients 
given biologics. Some clinicians however, may use clinical judgment rather than 
DAS28 to solely determine treatment changes and this may explain why some 
patients with apparently active disease as measured using a DAS28 do not have their 
treatment changed.  
 
Treatment decisions were influenced more by objective signs of inflammation 
(swollen joint count and ESR) and also patient global assessment than by tender joint 
counts. The multivariate analysis also showed that age has an effect on treatment 
decisions which retained significance in the multivariate analysis. This suggests that 
older patients were less likely to have changes in treatment. The possible reasons for 
this may be that clinicians are willing to accept a degree of disease activity in the 
older population, and feel that the burden of disease progression and disability will 
be less than a younger patient. In addition older patients are likely to have more co-
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morbidities. Another potential reason is patient choice, which was not explored in 
this study. 
 
7.2. STRENGTHS AND WEAKNESSES 
7.2.1. Strengths 
The research in this thesis considered the problems involved in delivering high 
quality care from a range of perspectives, including those of the patients and the 
different clinicians involved in care. It also combined qualitative and quantitative 
research studies and involved many different stakeholders. Finally it looked at the 
same set of problems using a range of different research methods, which all gave 
broadly similar findings. These are substantial strengths and they all mean that the 
conclusions reached are likely to be both robust and reliable.  
 
7.2.2. Weaknesses 
Inevitably, the research also has a number of potential weaknesses. Firstly, there was 
no single hypothesis. Each study had its own hypothesis, or explored a specific 
theme or set of themes. However the absence of a single hypothesis is intellectually 
regrettable, even though the very nature of the problem being investigated meant that 
a unified single question was inappropriate. 
 
Secondly, only limited longitudinal data were collected in the thesis. In research 
undertaken primarily by the candidate it is impractical to collect data over 3-5 years 
or longer and data collected from patients followed for shorter periods of time is of 
less value. Nevertheless, longitudinal data is always helpful in assessing long-term 
diseases in which there are temporal variations due to the impact of treatment. In the 
standards of care study and the qualitative studies patients were asked to recall events 
from the past which inevitability may lead to recall bias. 
 
Thirdly, the findings are regionally focused, and reflect experience in South East 
London which has a diverse ethnic mix. National data might give a somewhat 
different perspective and is inevitably preferable as a basis for national 
recommendations, even though it cannot be collected by a single investigator.  
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Fourthly, the data is observational and does not include evidence from clinical trials. 
This reflects the nature of the research questions, which could not be addressed in 
randomised controlled trials. However, the results have generated hypotheses that 
can be tested in trials, as outlined below. 
 
Fifthly, there is always a question of representativeness. Although large numbers of 
patients were used in most parts of the study there were small numbers in the 
qualitative studies as is often the case in these types of studies and patient selection 
strived to produce an appropriate and representative cohort. In the fibromyalgic RA 
studies only the initial cohort had an assessment for the ACR tender points, although 
the formula to identify patients using standard RA assessments was developed from 
this cohort. Clearly the tender minus swollen joint counts formula is not a perfect 
measure but may aid clinicians to identify some of these patients with worse 
outcomes and perhaps go on to formally assess for fibromyalgic tender points as well 
as think about possible psychological issues. 
 
Finally, the views on much of the research findings are based on the judgement of 
the researcher and collaborators, and are not based on absolute measures. Questions 
such as how much fatigue is too much and the point at which to divide patients into 
fibromyalgic and non-fibromyalgic RA reflect the views of the researcher rather that 
any absolute divisions that would be inevitably agreed by all experts in the field. 
Again, this reflects the nature of the research questions, which all involve relative 
judgments. 
 
7.3. FUTURE RESEARCH 
As most issues discussed in this thesis are not RA pathogenesis related and may in 
fact be inherent in many other chronic diseases; collaborative work with other 
researchers looking into the provision of care and whether symptoms such as fatigue 
are similar in RA and other diseases such as chronic obstructive pulmonary disease 
or diabetes is something that may be worth addressing in future studies. These 
studies could also assess differences in provision and expectations of care in different 
settings such as private health care compared to the NHS.  
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7.3.1. Better Treatment of Fatigue and Pain 
From our research it is clear that fatigue remains a major issue for RA patients. 
Currently there are no treatments that specifically target fatigue in RA. There is some 
evidence that DMARDS and biologics have some effect on fatigue in RA [Chauffier 
et al. 2012] but they are specifically targeting inflammation in RA. Cognitive 
behavioural therapy (CBT) has been used with effect in other diseases where fatigue 
is a prominent symptom such as multiple sclerosis [van Kessel et al. 2008]. In 
chronic fatigue syndrome, where fatigue is the dominant feature CBT and graded 
exercise have been shown to improve fatigue [White et al. 2011].  
 
A recent study by Hewlett et al [Hewlett et al. 2011; Dures et al. 2011]; used group 
CBT to target fatigue in RA patients. Patients with high fatigue (VAS >60mm) were 
randomised into one of two groups; group CBT for six sessions weekly and a 
consolidation session or the control group who received fatigue self management 
information in a one hour didactic group session. At 18 weeks significant 
improvements were seen in fatigue measured by the MAF and VAS in the active 
group compared to the control group.  In addition, there were significant 
improvements in disability, depression, helplessness, self-efficacy and sleep scores. 
 
Following on from this research, a proposal has been put together for a trial designed 
to improve fatigue and disability in RA. The CEFRAD Trial (Cognitive Behavioural 
Therapy and Exercise to Improve Fatigue and Rheumatoid Arthritis Disability); is 
designed to develop and evaluate a treatment programme consisting of cognitive 
behavioural therapy and exercise advice that can be provided within the 
rheumatology outpatient department by trained rheumatology specialist nurses. The 
aim of the study will be to reduce fatigue levels in RA patients with high levels of 
fatigue and also reduce disability as measured by the HAQ. The study duration is for 
six months and patients will be randomised into one of two arms. The active arm of 
the study will involve individual CBT and exercise advice and the control arm will 
consist of standard treatment as defined by NICE guidance. The outline proposal for 




Table 7:1 Outline Proposal for Fatigue Trial 
 
Proposed Research 
Cognitive Behavioural Therapy And Exercise To Improve Fatigue and 
Rheumatoid Arthritis Disability: The CEFRAD Trial 
Goal 
To develop and evaluate a treatment programme of cognitive behavioural therapy 
(CBT) with advice about exercise given by rheumatology nurses in routine care 
which treats high fatigue levels in patients with rheumatoid arthritis (RA) 
Rationale 
a. CBT and exercise reduce fatigue and disability in many long-term disorders  
(eg chronic fatigue syndrome and systemic lupus erythematosus) 
b. Many RA patients have high fatigue levels which are associated with high 
pain and disability scores 
c. Few RA patients currently receive treatment designed to specifically reduce 
fatigue 
Hypothesis 
CBT with exercise advice given by rheumatology nurses will minimise fatigue 
and gives sustained, clinically important improvements in disability in RA 
patients with high levels of fatigue 
Objectives 
Experience from observational studies and clinical trials to improve fatigue will 
be used to develop a treatment for RA fatigue which combines CBT with advice 
on exercise which delivered by specialist nurses. A large clinical trial will 
establish its effectiveness by showing it: 
a. Gives clinically relevant reductions in fatigue and disability 
b. Achieves improvements sustained for 6 months 
c. Delivers cost-effective improvements 
Design And Setting 
6-month individually-randomised 2-arm pragmatic multicentre trial based in 
rheumatology out-patients 
Target Population 
a. Included: RA by current criteria; high fatigue (FACIT F <15); stable 
drug/biologics therapy; willing/able to participate 
a. b. Excluded: remission; major co-morbidities, pregnancy; irreversible 
disability (>20 years RA) 
Health Technologies Assessed 
a. Active: CBT and exercise advice from specialist nurses to individual RA 
patients 
b. "Standard Care": NICE 2009 guidelines 
Measurement Of Cost And Outcomes 
a. Co-primary Outcomes: Fatigue on multidimensional instrument (FACIT-F) 
and disability assessment health assessment questionnaire (HAQ) 
b. Clinical: pain (visual analogue score), disease activity score for 28 joints, 
hospital anxiety and depression score 
c. Quality of life: SF-36 and EuroQol 
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d. Costs: Client Service Receipt Inventory 
Sample Size And Analysis 
The hypothesis (CBT/exercise reduce fatigue and improve disability) requires 
improvements in HAQ levels of 0.22 (smallest clinically detectable change) at 6 
months (published SD for change 0.55). Showing this with 5% significance and 
90% power means recruiting 133 patients per group (266 in total); allowing for 
20% drop-outs means recruiting 320 patients. Analysis will involve linear 
regression adjusted for age, gender and initial scores 
 
7.3.2. Adherence to Guidance and Developing Clinical Pathways 
The research shows that patients with active disease (DAS28≥5.1) more often than 
not have a change in their treatment, however, there is a large group of patients with 
disease activity that falls into the intermediate category of disease activity that don’t 
have a change in treatment. The reason for this apparent lack of treatment change is 
not apparent and may be due to patient choice, concomitant diseases or other factors 
such as fatigue or psychological factors which may be contributing to the DAS28.  
 
The work has been used to develop a new research programme (Treatment Intensities 
and Targets in RA Therapy Integrating Patients' and Clinicians' Views – The 
TITRATE Programme). This programme includes a randomised trial which 
specifically targets patients with intermediate disease activity to provide an intensive 
management strategy that includes not only increases in drug therapy but also 
employs self –management as well as ‘motivational interviewing’ techniques. 
Patients will be involved in each step to improve compliance and a written care plan 
provided. Psychosocial aspects, quality of life and fatigue will also be assessed. The 






Table 7:2 Treatment Intensities and Targets in RA Therapy 
Integrating Patients' and Clinicians' Views – The TITRATE Programme 
 
Objectives 
The overall objective is a patient-led implementation of an effective intensive 
management strategy for RA patients with intermediate disease activity. The aims 
comprise: 
a. Equipping patients to benefit from intensive management 
b. Understanding patients’ views about it 
c. Implementing it in routine care in partnership with patients 
Goals 
As intensive management will be challenging for RA patients, its effectiveness will 
depend on equipping them to benefit from receiving it. This will involve the 
following: 
a. Developing information that enables patients understand intensive management 
b. Establishing shared care plans which involve patients in planning their treatment 
(“no decision about me without me”). These will build on Joint Crisis Plans, 
which help patients with major mental health disorders choose treatments and the 
National Rheumatoid Arthritis Society (NRAS) Members' Care Plan developed 
by patients for patients. The shared treatment plans for RA will involve 
agreements about drugs, dosages and therapeutic sequences. 
c. Training specialist nurses to support patients. One part will involve 
understanding psychosocial issues - illness beliefs, self-efficacy, adherence, 
beliefs about medicine, fatigue and anxiety and depression. The other part will 
involve improving adherence.  
 
Design And Setting 
12-month pragmatic open label multicentre trial with individual randomisation based 
in specialist rheumatology clinics in England. 
Hypothesis 
Patients with RA for at least 6 months who have intermediate disease activity 
(DAS28 3.2-5.1) after receiving at least one DMARD will be more likely to achieve 
remission over 12 months if they receive intensive management (combination 
DMARDs with or without biologics) than standard care (NICE guidelines 2009). 
Target Population 
a. Inclusion Criteria: RA by current classification criteria; received ≥1 DMARD(s) 
for ≥6 months; intermediate disease activity (DAS28 3.2-5.1); willing and able to 
follow intensive management programme 
b. Exclusion Criteria: major co-morbidities making intensive treatment inadvisable 
(eg heart failure); previously failed multiple DMARDs (≥5 treatments) or having 
received biologics; irreversible disability from extensive joint damage (disease 
duration ≥20 years); pregnancy, breast-feeding and women at risk of conceiving 
Intensive Management 
a. Approach: patients will be seen monthly by trained specialist nurses who will 
assess their RA, evaluate treatments, modify therapy, and give supportive care 
outlined above in “Equipping Patients To Benefit From Intensive Management” 
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b. Screening: Eligibility will be checked and disease activity assessed 
c. Supportive information: this will be provided after screening through the patient 
handbook and psychosocial factors measured using self-assessment instruments 
for illness beliefs, self-efficacy and adherence and anxiety and depression. 
Advice will also be given on how to self-manage pain by optimising analgesics 
and NSAIDs. 
d. Initial visit (within 2 weeks): disease activity will be assessed, a “Shared Care 
Plan” agreed between patients and specialist nurses, and the first treatment 
change initiated using the DMARD/Steroid treatment algorithm. This will 
involve starting another DMARD with additional IM steroids if relevant. 
e. Visits 2-5: disease activity will be assessed and treatment stepped up following 
the agreed treatment algorithm. Patients will be encouraged to self manage pain. 
Adherence will also be encouraged using “Motivational Interviewing” 
approaches. 
f. Patients in remission (DAS28<2.6) after visit 1: treatment will be sustained at its 
present level until month 12 unless there is a subsequent increase in activity. 
g. Patients with major flare (DAS28>5.1) after visit 1: considered for biologic 
therapy with TNF inhibitor, which requires safety screen and second visit one 
month later to ensure flare persists.  
h. Visit 6: “intermediate assessment” on basis of assessment of disease activity will 
divide patients into 3 groups: good response (DAS28 fell by >1.2) - maintain 
approach and increase current DMARDs; partial response (DAS28 fell by 0.6-
1.2) - initiate new DMARDs; no response (DAS28 fell by <0.6 and ≥3 
swollen/tender joints - initiate TNF inhibitor after safety screen 
i. Visits 7-11: disease activity will be assessed and treatment stepped up using 
agreed treatment algorithm 
j. Final visit: on the basis of assessments of disease activity patients will be divided 
into three groups – remission/low disease activity, ongoing intermediate disease 
activity, or flare requiring biologics. Self-assessment instruments for illness 
beliefs, self-efficacy and adherence and anxiety and depression will also be 
recorded 
k. The patients in remission/ low disease activity will be offered treatment tapering 
in a pilot trial. Other patients will thereafter receive standard care, with patients 
on biologics due to flare remaining on these treatments (current NICE guidance) 
"Standard Care" (based on NICE 2009 guidelines) 
a. Maintain suppressive treatment with DMARDs and steroids  
b. Maintain symptomatic therapy (analgesics/non-steroidal anti-inflammatory 
drugs) 
c. Annual specialist reviews 
d. Urgent specialist review and treatment modification for flares (DAS28 ≥5.1) or 
clinically significant adverse events 
Assessments 
Baseline assessments will comprise: 
a. Demographic data (age, gender, ethnicity, Townsend score) 
b. Current and previous treatments for RA 
c. Features of RA (disease duration, rheumatoid factor positivity, erosions) 
d. Extra-articular RA 
e. Co-morbidities 
f. Relevant psychosocial factors: health belief (revised RA specific Illness 
Perception Questionnaire) and depression and anxiety (Hospital Anxiety and 
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Depression Score) 
g. Adherence by Medication Adherence Rating Scale (MARS) and fatigue by the 
FACIT-F. 
Co-primary outcomes will comprise: 
a. The number of patients achieving remission by DAS28 ≤2.6 
b. The number of patients achieving remission by SDAI≤3.3 
Secondary outcomes will comprise: 
a. Tender/swollen joint counts (28 joints), patient/assessor global assessment, ESR 
and CRP used to calculate DAS28, SDAI and CDAI 
b. HAQ 
c. SF36 and EuroQol 
d. Erosive damage: x-rays of hands and feet read by modified Larsen’s score 
e. Adverse events 
f. Health resource use questionnaire 
Sample Size 
The most relevant UK trial (TICORA) compared tight control versus standard 
treatment in patients with RA for less than 5 years. It reported 16% of patients 
receiving standard care achieved DAS remission at the end of the trial. Patients 
receiving standard treatment showed decreases in DAS until 12 months but no 
further falls from 12-18 months. Analysis of routine care patients from the King’s 
Health Partners database showed 16% of those patients with initial intermediate 
disease activity treated with DMARDs were in remission at their second visit 
between 9-15 months. We have also analysed all similar RA trials that reported 
remission, including our early RA CARDERA trial. These show that overall with 
standard care 16% of patients will have achieved DAS remission at 1 year follow-up. 
We also anticipate intensive treatment should almost double the rate of remission 
(increase rates by at least 15%). 
 
We will reject the null hypothesis (RA patients with intermediate disease activity 
(DAS28 3.2-5.1) despite DMARDs will not have no more remissions with intensive 
management for 12 months) if the difference in remission rates at 12 months between 
the intensive management arm and the standard care arm is 15% or greater. 
Demonstrating such a difference with 5% significance and 90% power requires 
randomising 358 patients in total, under 1:1 allocation (i.e. 179 patients per group). 
After allowance is made for a 10% drop-out overall, the required total sample size 
increases to 398 patients. Although the CARDERA trial suggests DAS28 and SDAI 
remissions occur with similar frequencies, there is limited comparative data for 
SDAI remission; we therefore based sample size calculations on DAS28 remissions. 
Analysis 
An intention-to-treat analysis will be used to determine whether there is a difference 
in remission rates between arms of this pragmatic randomised trial. Missing data will 
be dealt with primarily through use of multiple imputation, though other approaches 
to assess the impact of “missingness” may be adopted for additional sensitivity 
analyses. The primary outcome – remission at 12 months – will be modelled using 
logistic regression methods. Adjustment for a centre effect in all analyses will be 













7.3.3. Other Approaches 
The treatment of RA has changed dramatically in the last two decades and the speed of 
change has, if anything increased. In the UK the new regulatory environment and the 
existence of standards of care such as the new NICE guidelines for RA have been of 
crucial importance [Deighton et al. 2009; Deighton et al. 2010a; Deighton et al. 2010b]. 
There is a growing recognition that non-drug therapy is equally as important as drug 
therapy, though this area is far less researched. Other areas which need developing 
include understanding the importance of exercise [Bearne et al. 2002], promoting sleep 
for arthritis [Ulus et al. 2011], focusing on regional problems such as foot disease [Otter 
et al. 2011; Otter et al. 2012], and moving from hospital based care to care in the 
community [Symmons et al. 2005; Davies et al. 2007]. The research in this thesis 
contributes to setting this new agenda for ongoing change. Although RA care has 
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Appendix 1: Patients focus group consent form 
 
CONSENT FORM FOR PARTICIPATION IN RESEARCH PROJECTS AND 
CLINICAL TRIALS 
 
Principal Investigator: Dr L. Pollard  BSc MSc MRCP  
King's College Hospital 
Denmark Hill 
London 




Title of Project:  Standards Of Care For People With Inflammatory Arthritis:  
Establishing A Local Framework To Deliver National Standards - Defining 
Patients Needs. 
 
Name of Researcher: Dr L. Pollard BSc MSc MRCP 
 
         Please initial box 
 
1. I confirm that I have read and understand the information    
 sheet dated July 17
th
, 2006 (version 1) for the above study  
 and have had the opportunity to ask questions without my 
  medical care or legal rights being affected. 
 
2. I understand that my participation is voluntary and that     
 I am free to withdraw at any time, without giving any reason, 
 
3. I understand that sections of any of my medical notes may   
 be looked at by responsible individuals from King’s College 
 Hospital, and/or from regulatory authorities where it is relevant  
 to my taking part in research. I give permission for these  
 individuals to have access to my records. 
 
4. I agree to take part in the above study.      
 
_____________________ ________________ ______________ 
Name of Patient Date Signature 
 
_____________________ ________________ ______________ 




Appendix 2: Patients focus group interview schedule 
 
INTERVIEW SCHEDULE (Patients) 
 
There are three main themes to be discussed in the focus group, firstly what 
information you feel should be provided about your illness and its management, 
secondly how you access medical services and finally what assessments you feel 
should be done in the outpatient clinic  
At the end I would welcome any further information you may feel is relevant to your 
experience in the outpatient department, including your thoughts on taking part in the 
study. The focus groups will last for approximately one hour but can go on longer if 
needed. The discussion will be recorded on tape and can be paused at any time. If 
you provide any information you do not wish to have recorded, the tape recorder can 





1. How do you get information about your illness? 
- eg by whom 
- eg via internet/leaflets 
- eg patient groups 
 
2. What information do you need to help you manage your own illness? 
- eg staying active 
- eg identifying symptoms and signs of inflammatory arthritis 
- eg  managing pain  
- eg information on new drugs 
- eg help back to work 
- eg Benefits available 
 
3. How would you like this information to be delivered? 
- eg website/leaflet 
 
4. What type of information would you like on a website? 




Access to Care 
 
1. In your opinion who should decide when and how often you attend 
outpatients?  
- eg how often do you think you should be seen 
-  
2. How important is continuity of care to you? 
- eg Do you usually see the same doctor? Is this important to you? 
-  
3. What do you think is the role of your rheumatologist in your care? 
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4. What do you think is the role of your GP in your care? 
eg who do you think should monitor your other medical problems 
such as blood pressure, cholesterol etc. 
- eg where should you have your blood monitoring done? 
 
5. How to you access care during a flare of your arthritis? 
- eg how easy is it to be seen at GP/rheumatology outpatients 
- eg telephone hotlines. 
 
6. What other healthcare professionals have you seen about you arthritis? 
- eg hand therapists/OT/physio/podiatry  
- how important is it to see them 





1. What questions are you currently asked when you attend the outpatient 
department? 
 
2. What questions do you feel should be asked? 
a. eg fatigue, pain, sleep 
 
3. What examinations do you expect to be carried out in your outpatient 
appointment? 
eg joint examination 
eg check feet 
eg blood pressure  





Appendix 3: Health professionals focus group consent form 
 
 




Principal Investigator: Dr L. Pollard  BSc MSc MRCP   
King's College Hospital 
Denmark Hill 
London 




Title of Project:  Standards Of Care For People With Inflammatory Arthritis: 




Name of Researcher: Dr L. Pollard BSc MSc MRCP 
  
 
         Please initial box 
 
1. I confirm that I have read and understand the information    
 sheet dated July 17
th
, 2006 (version 1) for the above study  
 and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that     
 I am free to withdraw at any time, without giving any reason, 
 
3. I agree to take part in the above study.      
 
 
_____________________ ________________ ______________ 
Name of Patient Date Signature 
 
_____________________ ________________ ______________ 
Researcher Date Signature 
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Appendix 4: Health professionals focus group interview schedule 
 
 
INTERVIEW SCHEDULE (Health Care Professionals) 
 
There are two main themes to be discussed in the focus group, firstly what 
information you feel should be collected during the routine care of patients with 
rheumatoid arthritis and secondly, to define the optimal interaction of the 
multidisciplinary team as well as between primary and secondary care. 
At the end I would welcome any further information you may feel is relevant to the 
multidisciplinary care provided to patients with rheumatoid arthritis and also your 
thoughts on taking part in the study. The focus groups will last for approximately one 
hour but can go on longer if needed. The discussion will be recorded on tape and can 
be paused at any time. If you provide any information you do not wish to have 




1. What questions do you routinely ask a patient with RA when you see them in 
your clinic? 
- eg pain and fatigue levels, general questions about arthritis 
- eg Difficulty at work/home 
- eg Other general health questions 
 
2. What questions do feel we should be asking routinely? 
 
3. What information do you give out routinely to patients with RA? 
- eg Benefits available 
- eg Help in getting back to work if appropriate 
- eg self- management 
 
4. What assessments do you currently undertake when you see a patient with 
RA? 
- eg Joint assessments, pain and fatigue assessments 
- eg Examine feet 
- eg General examination 
- eg BP 
- eg Cardiovascular risk factor assessments 
 
5. What assessments do you think should be done in a routine appointment? 
 
Interaction between Primary and Secondary Care 
 
1. What do you think is the role of the rheumatologist in the care of patients 
with RA? 
- eg Regular follow-ups 
- eg Prescribing and monitoring of drugs 
- eg Coordinating care across multidisciplinary team 
 
 275 
2. What do you think is the role of the General Practitioner in the care of 
patients with RA? 
- eg Prescribing and monitoring of drugs 
- eg Monitoring of cardiovascular risk factors 
- eg Help with social support 
 
3. How can we improve the interaction between primary and secondary care to 
improve the care provided for patients with RA? 
- eg Shared care record, electronic/paper form held by patient 
 
 
Interaction of the Multidisciplinary Team 
 
1. What do you think are the role of the allied health professionals and when 
should their care be accessed by patients with RA? 
- eg OT, Physio, Podiatry 
- eg Rheumatology nurse specialists 
- eg on diagnosis, regular sessions 
 
2. How can we improve the access and referral to allied professionals for 
patients with RA? 
- eg Primary or secondary care referrals 
- eg community or hospital care  
 
 276 



































Thinking of the care you have received in the rheumatology department at King’s 
College Hospital, please indicate how much you agree with the following statements 










The care providers did not 
know what each other was 
doing 
0 1 2 3 4 
While under care, I found the 
quality of the different 
facilities such as the waiting 
room the surgery and the 
treatment room was good 
0 1 2 3 4 
In such a devastating disease as 
RA, the care providers could 
have shown more 
understanding 
0 1 2 3 4 
I was kept well informed about 
the reasons of investigations 
and care 
0 1 2 3 4 
The care had a favourable 
effect on my RA 
0 1 2 3 4 
It was difficult to reach the 
care providers 
0 1 2 3 4 
In general, per group of care 
providers (eg occupational 
therapists or physiotherapists), 
I was treated by the same carer 
0 1 2 3 4 
The information I received 
about RA and its treatment was 
clear 
0 1 2 3 4 
After the start of treatment, it 
took a lot of time before the 
different care providers could 
see me. 
0 1 2 3 4 
I underwent investigations and 
treatments that appeared 
irrelevant 
0 1 2 3 4 
There was not much 
information available about 
RA and its treatment. 
 










I had the impression that the 
care providers knew a great 
deal about RA 
0 1 2 3 4 
The care providers respected 
my own wishes and ideas 
concerning the care 
0 1 2 3 4 
The end-results of the care 
were disappointing 
0 1 2 3 4 
The care providers were 
perceptive of what having RA 
means to me 
0 1 2 3 4 
Per group of care providers (eg 
physiotherapists or 
rheumatologists), I was treated 
by many different carers 
0 1 2 3 4 
The information I received 
about RA was difficult to 
understand 
0 1 2 3 4 
The carers provided a lot of 
verbal information about RA 
and its treatment. 
0 1 2 3 4 
The treatment rooms and other 
facilities that were used during 
my care could have been much 
better. 
0 1 2 3 4 
The collaboration among the 
care providers was good. 
0 1 2 3 4 
The care was quick and good; 
No inappropriate investigations 
or treatments were performed 
0 1 2 3 4 
After referral by the 
rheumatologist, the care started 
promptly 
0 1 2 3 4 
There was always someone to 
confer with if I had problems 
or questions 
0 1 2 3 4 
During the care, I was seen 
promptly by different care 
providers 
0 1 2 3 4 

















The care providers decided 
which treatment was the best 
for me; I could not influence 
this decision 
0 1 2 3 4 
A considerable amount of time 
elapsed between the referral by 
the rheumatologist and the 
commencement of other 
treatments 
0 1 2 3 4 
I was repeatedly surprised; I 
was not informed about what 
was going on with regard to 
investigations and care 
0 1 2 3 4 
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SATISFACTION WITH CARE 
 
 
This questionnaire has been devised to tell us about your overall opinion of your care 
in the rheumatology out-patients clinic.  It is not a test and there are no right or 
wrong answers.  We are interested in your opinions and impressions, whether they 
are GOOD or BAD. 
 
The questionnaire consists of a number of statements about your care in the clinic.  
Some statements may look the same but they are different so please read each one 
very carefully before filling it in. 
 
Please place a tick in the column which resembles your opinions most closely. 
 
 
ONLY TICK ONE BOX FOR EACH STATEMENT 
 
 








      
The seats in the waiting area  
are very comfortable 
     
      
There are always a lot of people 
attending the clinic 
     
 
 
Please keep in mind that what we are trying to find out are YOUR opinions and not 
those of your husband, wife or neighbour, so please complete the questionnaire by 
yourself. 
 
Please try to think about the care that you are receiving at the PRESENT TIME and 
give us your opinions about that. 
 
 






Agree Not sure Disagree Strongly 
disagree 
      
They don’t seem to listen to anything I tell 
them during my consultation 
     
      
I feel that I’m in good hands when I come to 
the clinic 
     
      
The person I see in clinic takes an interest 
in my family 
     
      
I’m always given a clean explanation          
of why I am having tests done. 
     
      
There are some things about my care in the 
clinic which could be improved. 
     
      
I’m told everything I want to know about my 
arthritis drugs. 
     
      
During my consultation I’m given little or no 
medical explanation about my arthritis. 
     
      
Side effects of tablets are rarely discussed 
during my consultation. 
     
      
The person I see in clinic really knows what 
he/she is talking about. 
     
      
Visiting the clinic is not a stressful occasion.      
      
I am given good advice on how to cope with 
my arthritis. 
     
      
No matter how long you have to wait in 
clinic, it’s worth it. 






Agree Not sure Disagree Strongly 
disagree 
      
I’m satisfied with the care I receive in the 
clinic. 
     
      
There’s no one to get in touch with at the 
clinic if I have a problem. 
     
      
I’m rarely told why I need tests such as 
bloods and x-rays. 
     
      
My questions are answered in words that I 
find hard to understand. 
     
      
I find it difficult to talk about things that 
concern me when I’m in the clinic. 
     
      
The person I see in clinic has no interest in 
the effect my disease has on my family. 
     
      
It’s easy to get an appointment if I need to 
come back to the clinic. 
     
      
I’m given as much time as I need for my 
consultation. 
     
      
The person I see in clinic sometimes 
appears uncertain about what they are 
doing. 
     
      
The person I see in the clinic is not as 
thorough as he/she should be. 
     
      
I am given very little information on how to 
cope with my arthritis. 
     
      
The person I see in clinic doesn’t 
understand what its like to have arthritis. 
     







Agree Not sure Disagree Strongly 
disagree 
      
The person I see in clinic seems to know 
how it feels to have arthritis. 
     
      
I feel that I’m treated as a person rather 
than a disease. 
     
      
I’ve no confidence in the person who is 
treating me. 
     
      
I am encouraged to ask questions about my 
arthritis. 
     
      
If I had a problem it would be difficult to get 
someone to speak to over the phone. 
     
      
I’m rarely asked which treatments I would 
prefer. 
     
      
If I had a problem with my arthritis I would 
find it easy to get advice over the phone. 
     
      
My feelings about my treatment are taken 
into consideration. 
     
      
If I had a medical problem I feel sure it 
would be checked out when I came to the 
clinic. 
     
      
Prescriptions for new tablets are given 
without any explanation. 
     
      
I’m usually told what the possible side 
effects of the tablets could be. 
     
      
I’m encouraged to contact the person I see 
in clinic if I have a problem with my arthritis. 
     






Agree Not sure Disagree Strongly 
disagree 
      
The care I receive in the clinic is just about 
perfect. 
     
      
I hardly ever see the same person when I 
come for my appointment. 
     
      
The person I see in clinic appears skilful at 
their job. 
     
      
The person I see in clinic does not always 
talk sense. 
     
      
Sometimes the person I see in clinic is too 
busy to spend enough time with me. 
     
      
When I attend the clinic I’m told everything I 
want to know about my arthritis. 
     
      
It’s hard to get an appointment if I need it 
quickly. 
     
      
I see the same person nearly every time I 
come to clinic. 
     
      
I’m usually kept waiting a long time in the 
waiting area. 
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Appendix 8: Patient support group survey 
 
 
KING’S COLLEGE HOSPITAL 
DEPARTMENT OF RHEUMATOLOGY 
 
 
ARE YOU INTERESTED IN A PATIENT SUPPORT GROUP? 
 
Some patients have expressed an interest in forming a patient support group, and as 
this would be a ‘new’ development we are interested in your views.  
A patient support group is organised and managed by patients.  Support could be 
given from staff to help set up the initial meeting, but the how the group develops 
would be totally dependant on what its members wanted. Staff could also be called 
upon to deliver short talks or demonstrations, but the main idea is that it is run by 
you, the patients. 
 
It would be helpful if you could take the time to answer the following questions, to 
give us an idea if there is a real need for such a group. 
 
Please tick the appropriate answers and thank you for your time. 
 
Do you think a patient support group is a good idea?  
YES  NO  
 
If there were to be a patient support group, would you attend?  
YES  NO  
 
IF YES:  
 
How often do you feel it should meet?  
Once a Month   Every 3 Months  Other (please 
specify)……... 
 
What time of day do you feel is the best time to hold a group?  
Morning   Afternoon   Evening  
 
Where do you feel the group should be held?  
King’s College Hospital   Elsewhere in the community   
 
Would you be interested in helping to set up and run such a group?   
YES  NO  
 
 
Once again, thank you for your time and views. 
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Appendix 9: SF-36 Questionnaire 
 
THE SHORT FORM 36 HEALTH SURVEY QUESTIONNAIRE (SF-36) 
 
The following questions ask for your views about your health, how you feel and how 
well you are able to do your usual activities. If you are unsure about how to answer 
any questions please give the best answer you can and make any of your own 
comments if you like. Do not spend too much time in answering as your immediate 
response is likely to be the most accurate. 
 
1. In general, would you say your health is: 



















2. Compared to one year ago, how would you rate your health in general now? 
 
(Please tick one box) 
 
Much better than one year ago  
 
 
Somewhat better now than one year ago 
 
 
About the same   
 
 
Somewhat worse now than one year ago  
 
 






3. Health and daily activities 
 
The following questions are about activities you might do during a typical day. Does 
your health limit you in these activities? If so, how much? 
 
(Please tick one box on each line) 










a) Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports 
   
b) Moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling or 
playing golf 
   
c) Lifting or carrying groceries    
 
d) Climbing several flights of stairs    
 
e) Climbing one flight of stairs    
 
f) Bending, kneeling or stooping    
 
g) Walking more than a mile    
 
h) Walking half a mile    
 
i) Walking 100 yards    
 
j) Bathing and dressing yourself    
 
 
4. During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of your physical health?  
 
(Answer Yes or No to each question) 
  Yes No  
a) Cut down on the amount of time you spent on 
work or other activities 
  
b) Accomplished less than you would like 
 
  
c) Were limited in the kind of work or other activities   
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5. During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems (such as 
feeling depressed or anxious)? 
 
(Answer Yes or No to each question) 
  Yes No  
a) Cut down on the amount of time you spent on 
work or other activities 
  
b) Accomplished less than you would like 
 
  





6. How much bodily pain have you had during the past 4 weeks? 
(Please tick one box) 
Not at all  
Slightly  
Moderately  
Quite a bit  
Extremely  
 
7. How much bodily pain have you had during the past 4 weeks? 
(Please tick one box) 
None  





Very Severe  
 
8. During the past 4 weeks how much did pain interfere with your normal work 
(including work both outside the home and housework)? 
(Please tick one box) 
Not at all  
A little bit   
 Moderately  
Quite a bit   




These questions are about how you feel and how things have been with you during 
the past month. (For each question, please indicate the one answer that comes 
closest to the way you have been feeling). 
9. How much time during the last month: 























a. Did you feel full of life? 
      
b. Have you been a very 
nervous person? 
      
c. Have you felt so down in the 
dumps that nothing could 
cheer you up? 
      
d. Have you felt calm and 
peaceful? 
      
e. Did you have a lot of 
energy? 
      
f. Have you felt downhearted 
and low? 
      
g. Did you feel worn out?       
h. Have you been a happy 
person? 
      
i. Did you feel tired?       
j. Has your health limited your 
social activities (like 
visiting friends or close 
relatives)? 
      
 
HEALTH IN GENERAL 
10. Please choose the answer that best describes how true or false each of the 
following statements is for you. 











a. I seem to get ill more 
easily than other 
people 
     
b. I am as healthy as 
anybody I know 
     
c. I expect my health to 
get worse 
    
 
 
d. My health is excellent      
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Appendix 10: HAQ Questionnaire 
 
HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) 
 
PATIENT INITIALS    DATE OF ASSESSMENT  
 
 
PATIENT STUDY NUMBER   
 
We are interested in learning how your illness affects your ability to function in daily 
life. 
Please feel free to add any comments at the end of this form. 
Please tick one response which best describes your usual abilities over the past week 
 
 










Are you able to: 
 
a. Dress yourself, including tying 
shoelaces and doing buttons? 
 



























Are you able to: 
 
a. Stand up from an armless  
straight chair? 
 























Are you able to: 
 
a. Cut your Meat? 
 
b. Lift a full cup or glass to your 
mouth? 
 
c. Open a new carton of milk 




































Are you able to: 
 
a. Walk outdoors on flat ground? 
 























Please tick any aids or devices that you usually use for any of these activities: 
Cane    Walking frame  Built-up or special utensils   
Crutches   Wheelchair   Special or built-up chair   
Devices used for dressing    Other (specify)………………………… 
(buttonhooks, zipper pull, shoe horn)  
 
Please tick any categories for which you usually need help from another person: 
Dressing and Grooming    Eating     
Rising      Walking    
 
Please tick the one response which best describes your usual abilities over the past 
week 












Are you able to: 
 
a. Wash and dry your entire body? 
 
b. Take a bath? 
 































Are you able to: 
 
a. Reach and get down a 5lb object 
(e.g. a bag of potatoes) from just above 
your head? 
 
































Are you able to: 
 
a. Open car doors? 
 
b. Open jars which have been 
previously opened? 
 



































Are you able to: 
 
a. Run errands and shop? 
 
b. Get in and out of a car? 
 
c. Do chores such as vacuuming, 































Please tick any aids or devices that you usually use for any of these activities: 
 
Raised toilet seat    Bath seat    Bath rail   
Long handled appliances for reach   Jar opener (for jars previously opened)   
 
 
Please tick any categories for which you usually need help from another person: 
 
Hygiene  Gripping and opening things  
Reach   Errands and housework  
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Appendix 12: MAF Questionnaire 
 
MULTIDIMENSIONAL ASSESSMENT OF FATIGUE (MAF) SCALE 
 
Instructions: These questions are about fatigue and the effect of fatigue on your 
activities. 
 
For each of the following questions, circle the number that most closely indicates 
how you have been feeling during the past week. 
 
For example, suppose you really like to sleep late in the mornings. You would 
probably circle the number closer to the "a great deal" end of the line. This is 
where I put it: 
 
Example: To what degree do you usually like to sleep late in the mornings? 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
1. To what degree have you experienced fatigue? 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
If no fatigue, stop here. 
 
 
2. How severe is the fatigue which you have been experiencing? 
 
 
1  2  3  4  5  6  7  8  9  10 
Mild  Severe 
 
 
3. To what degree has fatigue caused you distress? 
 
 
1  2  3  4  5  6  7  8  9  10 
No distress A great deal 




MULTIDIMENSIONAL ASSESSMENT OF FATIGUE (MAF) SCALE 
(Continued) 
 
Circle the number that most closely indicates to what degree fatigue has 
interfered with your ability to do the following activities in the past week. For 
activities you don't do, for reasons other than fatigue (e.g. you don't work 
because you are retired), check the box. 
 
In the past week, to what degree has fatigue interfered with your ability to: 
 
(NOTE: Check box to the left of each number if you don't do activity) 
 
 4. Do household chores 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 5. Cook 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 6. Bathe or wash 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 7. Dress 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 8. Work 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 9. Visit or socialize with friends or family 
 
 
1  2  3  4  5  6  7  8  9  10 





(NOTE: Check box to the left of each number if you don't do activity 
 
 10. Engage in sexual activity 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 11. Engage in leisure and recreational activities 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 12. Shop and do errands 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 13. Walk 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 14. Exercise, other than walking 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
15. Over the past week, how often have you been fatigued? 
 
4  Every day 
   
3  Most, but not all days 
   
2  Occasionally, but not most days 
   
1  Hardly any days 
 
16. To what degree has your fatigue changed during the past week? 
 
4  Increased 
   
3  Fatigue has gone up and down 
   
2  Stayed the same 
   





Appendix 13: MFSI Questionnaire 
 
The Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) 
 
Below is a list of statements that describe how people sometimes feel. Please read 
each item carefully, then circle the one number next to each item which best 
describes how true each statement has been for you in the past seven days. 
 
 Not at 
all   
A little Moderately Quite a 
bit 
Extremely 
      
1. I have trouble 
remembering things 
0 1 2 3 4 
2. My muscles ache 0 1 2 3 4 
3. I feel upset 0 1 2 3 4 
4. My legs feel weak 0 1 2 3 4 
5. I feel cheerful 0 1 2 3 4 
6. My head feels heavy 0 1 2 3 4 
7. I feel lively 0 1 2 3 4 
8. I feel nervous 0 1 2 3 4 
9. I feel relaxed 0 1 2 3 4 
10. I feel pooped 0 1 2 3 4 
11. I am confused 0 1 2 3 4 
12. I am worn out 0 1 2 3 4 
13. I feel sad 0 1 2 3 4 
14. I feel fatigued 0 1 2 3 4 
15. I have trouble paying 
attention 






 Not at 
all   
A 
little 
Moderately Quite a 
bit 
Extremely 
      
16. My arms feel weak 0 1 2 3 4 
17. I feel sluggish 0 1 2 3 4 
18. I feel run down 0 1 2 3 4 
19. I ache all over 0 1 2 3 4 
20. I am unable to concentrate 0 1 2 3 4 
21. I feel depressed 0 1 2 3 4 
22. I feel refreshed 0 1 2 3 4 
23. I feel tense 0 1 2 3 4 
24. I feel energetic 0 1 2 3 4 
25. I make more mistakes than 
usual 
0 1 2 3 4 
26. My body feels heavy all over 0 1 2 3 4 
27. I am forgetful 0 1 2 3 4 
28. I feel tired 0 1 2 3 4 
29. I feel calm 0 1 2 3 4 
30. I am distressed 0 1 2 3 4 
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Appendix 14: HADS Questionnaire 
 
Hospital Anxiety and Depression Scale (HADS) 
Instructions: Doctors are aware that emotions play an important part in most illnesses. If 
your doctor knows about these feelings he or she will be able to help you more. This 
questionnaire is designed to help your doctor know how you feel. Read each item and place a 
firm tick in the box opposite the reply which comes closest to how you have been feeling in 
the past week. Don’t take too long over your replies: your immediate reaction to each item 
will probably be more accurate than a long thought out response. 
 
1. I feel tense or ‘wound up’:   2. I feel as if I am slowed down:   
Most of the time   Nearly all of the time   
A lot of the time   Very often   
Time to time, occasionally   Sometimes   
Not at all   Not at all   
    
3. I still enjoy the things I used to 
enjoy:  
 4. I get a sort of frightened feeling 
like ‘butterflies in the stomach’:  
 
Definitely as much   Not at all   
Not quite so much   Occasionally   
Only a little   Quite often   
Not at all   Very often   
    
5. I get a sort of frightened feeling 
like something awful is about to 
happen:  
 6. I have lost interest in my 
appearance:  
 
Very definitely and quite badly   Definitely   
Yes, but not too badly   I don’t take as much care as I should   
A little, but it doesn’t worry me   I may not take quite as much care   
Not at all  
 
 I take just as much care as ever   
7. I can laugh and see the funny 
side of things:  
 8. I feel restless as if I have to be on 
the move:  
 
As much as I always could   Very much indeed   
Not quite so much now   Quite a lot   
Definitely not so much now   Not very much   
Not at all   Not at all   
    
9. Worrying thoughts go through 
my mind:  
 10. I look forward with enjoyment to 
things:  
 
A great deal of the time   A much as I ever did   
A lot of the time   Rather less than I used to   
From time to time but not too often   Definitely less than I used to   
Only occasionally  
 
 
 Hardly at all   
 305 
11. I feel cheerful:   12. I get sudden feelings of panic:   
Not at all   Very often indeed   
Not often   Quite often   
Sometimes   Not very often   
Most of the time   Not at all   
    
13. I can sit at ease and feel 
relaxed:  
 14. I can enjoy a good book or radio 
or TV programme:  
 
Definitely   Often   
Usually   Sometimes   
Not often   Not often   
Not at all   Very seldom   
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Appendix 15: Fatigue questionnaire and pain study consent form 
 
 




Principal Investigator: Dr L. Pollard  BSc MSc MRCP   
King's College Hospital 
Denmark Hill 
London 
SE5 9RS  
 
 
Title of Project:  Identifying the Optimal Multidimensional Tool to Measure 
Fatigue in Rheumatoid Arthritis and its Potentially Reversible Causes. 
 
Name of Researcher: Dr L. Pollard MSc, MRCP 
 
         Please initial box 
 
1. I confirm that I have read and understand the information sheet   
 dated September 23
rd
, 2005 (version 0.3) for the above study  
 and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am     
 free to withdraw at any time, without giving any reason, without 
 my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may     
 be looked at by responsible individuals from King’s College Hospital,  
 and/or from regulatory authorities where it is relevant to my taking 
  part in research. I give permission for these individuals to have  
 access to my records. 
 




_____________________ ________________ ______________ 
Name of Patient Date Signature 
 
_____________________ ________________ ______________ 
Researcher Date Signature 
 
 
 
 
 
